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Abstract 
This thesis is concerned with applying engineering principles to the use of 
polymeric nanoporous adsorbents for use in blood purification to obtain 
original knowledge. 
Styrene divinylbenzene copolymer nanoporous adsorbents offer a potential 
means to remove middle molecular (MM) sized molecules when in direct 
contact with blood. Three adsorbents produced from this material were 
selected based on their pore structures and characterised using nitrogen 
porosimetry (CW1, surface area accessible to MM's -20m2, pore cut off 
-11 nm, CW4, surface area accessible to MM's -35m2, pore cut off -11 nm, 
XAD4, surface area accessible to MM's -100m2, pore cut off -30nm). The 
effects of pore structure, particle size and mixing conditions were investigated 
to help understand how these fundamental parameters affect solute uptake 
characteristics. It was shown that the larger*pore cut off of the XAD4 material 
resulted in albumin accessing the internal pore structure (q* -. 95mg/g for 
albumin), whilst CW1 effectively excluded albumin (q* -2mg/g), CW4 showed 
some accessibility to its internal structure resulting in a albumin capacity of 
-51 mg/g. CW4 demonstrated the highest capacity for lysozyme (MM marker) 
with a q* of -570mg/g, with XAD4 having a q* of ~ 415mg/g and CW 1 q* 
equalling just - 60mg/g. External agitation had little effect on overall mass 
transfer resistance, whist particle size and pore structure both had substantial 
effects. The internal mass transfer resistance (quantified as' an effective 
diffusivity value) was an order of magnitude greater in CW 1 (-3.6x10,13) 
compared with XAD4 -32x10-13) due to its tighter pore size distribution. 
Finally, a novel approach of dynamically scaling down a commercial 
haemoperfusion column resulted in a means to access biocompatibility in 
realistic flow conditions was completed. It was demonstrated that one of the 
adsorbents (CW4) possessed a pore structure suitable for blood purification, 
due to its high capacity and relatively open pore structure. 
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Introduction 
This chapter offers an introduction to kidney function and failure. The current 
treatment modalities are discussed and their limitations identified. The solutes 
known to be retained at elevated concentrations in dialysis patients (due to 
their molecular size) are highlighted and some conditions related to their 
presence are identified. Therefore a case to augment dialysis by removing 
uraemic toxins by haemoperfusion emerges. Some current devices and 
adsorbent specifications are also included. The chapter is concluded by the 
identification of scientific objectives for the thesis. 
1.1 Introduction to the clinical need. 
Blood performs many essential functions within the human body. One such 
role is the transportation of waste products arising due to normal metabolic 
processes. The kidneys are the organs that filter the blood and are 
responsible for separating the waste products ready for excretion from the 
body via the urinary system. 
The biological kidneys consist of millions of nephrons which are the functional 
units of the organ. Ultrafiltration occurs in the blind end of the nephron - the 
Bowman's capsule (see Figure 1.1) 
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Figure 1.1 - Schematic of kidney filtration mechanism. 
The Glomerulus has the function of producing the ultrafiltrate of the plasma 
which enters the proximal tubule. The ultrafiltrate passes along the proximal 
tubule providing opportunities for water and essential molecules to regain the 
bloodstream. Molecular size is the predominant determinant to capillary 
retention or filtration controlled by diffusion. The collecting tube is connected 
to the urinary system enabling the retained waste molecules and excess water 
to be removed from the body. 
The efficiency of the kidneys function can be expressed as the glomerular 
filtration rate (GFR). GFR is expressed in terms of the volume of plasma 
which is cleared of creatinine per unit time. A useful marker to measure this is 
creatinine. Creatinine is a product of muscle metabolism and therefore as 
long as the patient remains at rest the plasma creatinine levels can be 
assumed to be constant. Although some creatinine can be excreted by the 
kidney, the assay used over estimates the value, and the two errors are said 
to cancel each other out. clearence is calculated by the following equation :- 
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Cx= 
UxV 
Px 
Where 
CX = The clearance of x (i. e. creatinine) 
UX= Urine concentration of x 
PX= Plasma concentration of x 
V= Volume of urine per unit of time 
GFR is often used as an indicator of kidney function. 
(Equation 1.1) 
1.1.1 Kidney failure - when it all goes wrong..... 
Kidney failure can be either chronic or acute in nature. The sudden and 
reversible loss of kidney function is termed acute renal failure. Acute renal 
failure can present itself for a number of reasons such as severe trauma, 
septic shock, or a multitude of underlying conditions. 
If acute renal failure occurs, physicians must ensure correct electrolyte and 
fluid balance is obtained and act to minimize the build up of nitrogenous waste 
to prevent further damage. Despite improvements in renal technologies, the 
mortality rates have remained constant, primarily due to the increased age of 
affected patients and the related increased presence of co-morbid conditions. 
Renal failure will present as the glomerular filtration rate (GFR) decreases. 
Typically this will occur over the course of days or weeks. Due to the 
reduction in GFR, the body's electrolyte balance changes and a build up of 
nitrogenous waste occurs due to the reduction of excretion. 
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The longer term progressive loss of renal function is termed chronic renal 
failure. Chronic renal failure requires long term treatment, usually for the 
remainder of the patient's life. If kidney function falls to 5-10% of normal, 
most patients will not survive for long without dialysis. The highest risk of 
death within this patient group is due to cardiovascular complications. In 
addition to dialysis itself, there are often a number of drugs which need to be 
administrated to complement the treatment and protect the patient from 
secondary complications such as anaemia. The failing kidneys are unable to 
increase appropriately the production of erythropoietin. The introduction of 
genetically engineered recombinant erythropoietin (EPO) has almost 
eliminated anaemia which was a major contributor to the malaise and poor 
health in renal failure patients (Eschbach et al, 1989). 
However, irrespective of the cause, kidney failure will require some type of 
dialysis to carry out the function of the kidney. This intervention will last until 
the natural kidney has regained its function, or in the case of chronic kidney 
failure, until a transplant organ becomes available. The actual type of 
treatment a patient will receive will depend upon patient specific parameters in 
addition to accepted national practices. 
There are two primary methods of renal replacement therapy (excluding 
transplant). Both methods rely on diffusion of toxins across a semi-permeable 
membrane. The semi-permeable membrane sits between the blood and a 
dialysate fluid. The composition of the fluid is such that it contains sodium 
and chloride at physiological concentrations to prevent their loss but provides 
a concentration gradient that favours removal of toxins. 
Haemodialysis is a renal replacement strategy where the blood is 
mechanically pumped from the body, before passing through the membrane 
(surrounded by flowing dialysate). The cleansed blood is then returned to the 
patient and sessions are usually conducted 3 times a week for several hours. 
Although it is possible to have haemodialysis treatments at home, they are 
usually conducted in treatment centres. 
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Peritoneal dialysis (PD) is where the peritoneal membrane (inside the patients 
abdomen) is used as the semi-permeable membrane. Dialysate fluid is added 
to the abdominal cavity via a catheter. The diffusion occurs through the 
peritoneum and the dialysate fluid is subsequently drained and exchanged for 
fresh fluid. PD dialysis requires good patient cooperation and commitment. 
Infections are a common occurrence with PD patients. 
With over a million people currently requiring ongoing dialysis treatment 
worldwide, typically 3 times per week, there is a huge demand for dialysis 
hardware. Lysaght (2002) estimated an increase in the need for patients 
requiring dialysis at 7% per year. In 2004 approximately 88% of those 
requiring dialysis were treated using haemodialysis, with the remainder on 
peritoneal dialysis (Grassman et al, 2005) 
1.1.2 Haemodialysis Treatment and its limitations - 
identifying the clinical need 
The molecules associated with dialysis treatments can be grouped according 
to their size. Low molecular weight molecules (<500Da), middle molecules 
(500 - 60000Da) and large molecules (>60000Da) see Table 1.1. These 
categories have been discussed in the literature over the years and the sizes 
stated here are as published by Winchester et al, (2006), which are slightly 
modified from an earlier classification of Vanholder et al, (2001). The small 
molecules are usually water soluble, or protein bound compounds. Dialysis 
membranes are generally effective in removing this group of molecules due to 
their physical size. However, the same cannot be said for the larger 
molecules. The middle molecular weight molecules (MM) are thought to be of 
peptidic origin (Winchester et al, 2001). 
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Haemodialysis is insufficient at removing uraemic solutes ranging from 500 to 
60000 Da which may act as uraemic toxin causing ill health in patients 
(Vanholder et al, 2001). Therefore it follows that an augmented treatment 
could be one that combines dialysis with a means of removing the middle 
molecular sized molecules. 
Table 1.1. Categorisation of molecular weight groups 
Group Size Removed by standard 
haemodialysis. 
Low molecular weight <500 Da Yes 
Middle molecular weight 500 - 60000 Da No 
Large molecular weight >60000 Da No 
Molecules of the middle molecular weight range have been shown to be 
present in uraemic blood (Kaplan et al, 2003). This study utilized sensitive 
protein microsequencing and mass spectrometry to chemically identify the 
uraemic peptides in the blood samples. Winchester et al, (2001) combined 
the more contemporary uraemic molecules with the traditional molecules 
identified in earlier papers. As Uremia is understood further, the identification 
of new molecules will continue. Recent discovery of molecules such as 
reactive oxygen spiecies (ROS), Advanced lipoxygenation end products 
(ALEs) and C-reactive protein (CRP) have been shown by Miyata et al, (1998) 
as remaining in dialyzed uraemic patients. 
Although dialysis is a successful treatment for kidney failure, its use, or more 
specifically, its extended use can lead to secondary complications affecting 
patient health. Due to the molecular cut off of the dialysis membrane the 
process is unable to remove larger molecules or any that exhibit larger 
molecule behaviour (i. e small protein bound molecules). Membranes often 
use molecular weight cut off as a means to express their pore structure. It is 
also possible to quote pore size as a means of estimating the size of 
molecules the membrane will retain. Table 1.2 tabulates some dialysis 
membrane pore sizes. 
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Table 1.2. Dialyser manufactures maximum pore size information. Adapted 
from (Hoenich N. A, 1996) 
Type Model Supplier Membrane Max pore 
size 
(microns) 
Parallel TPE Cobe polyvinylchloride 0.6 
plate 
Ps 4000 Cobe Cellulose 0.45 
acetate 
Hollow Plasmaflux Fresenius polypropylene 0.5 
fibre P2 
Hemaplex Didecco polypropylene 0.5 
BT 900 
The molecular cut off of the membranes is a useful parameter for identification 
of which molecules, it may be capable of removing. Although the data shown 
above is a maximum pore size, mean pore size distributions may be more 
useful for this evaluation. Table 1.3 shows the hydrated diameters of some of 
the molecules involved. It is worthy of note that although some molecules 
have greatly different molecular weights, their hydrated diameters are similar. 
Therefore, both values should be considered when selecting membrane pore 
size. Table 1.3 provides useful information as to what pore size distributions 
may be required in order to ensure targeted molecules are dialysed whilst 
larger molecules such as albumin remain in the patient. However, protein 
fouling of the pores occurs very quickly after contact, effectively reducing the 
molecular cut off of the membranes thus enabling only removal of small 
molecules. Most current dialysers have a molecular weight cut off of around 
50kDa before fouling effects occur. It is accepted that dialysis is an effective 
way of removing small molecules but it's efficacy at removing larger molecules 
or protein bound solutes (in the MM size range) is questionable due to the 
effective cut off of the fouled membranes being too small. 
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Table 1.3. Molecular weights and hydrated diameters of blood components. 
(adapted from (Henderson, 1996) 
Molecule Molecular Weight 
(Daltons) 
Hydrated Diameter 
(nanometers) 
Albumin 69,000 7.1 
Urea 60 0.5 
Dextrose 180 0.9 
-------------------- Sodium 23 1.0 
Lysozyme 14400 4.5 
Creatinine 113.12 4.5 
Beta2microglobulin 11800 3.4 
Therefore it is beginning to emerge that retention of MM molecules occurs in 
dialysis patients due to the effective pore cut off of dialysis membranes. 
Although dialysis offers an effective means of removing smaller molecular 
weight toxins and water, the retention of MM's could be causing health 
complications. Therefore a case for their removal via an additional strategy is 
being made. 
1.1.3 The Uraemic Syndrome 
Uraemic syndrome is the term associated with complications arising from the 
retention of solutes which are normally removed by the healthy kidney and not 
removed by current dialysis methods. The solutes which remain are often 
termed the "uraemic toxins" although the exact composition or effects of these 
molecules is not totally understood. These molecules are in the middle 
molecular size range. By controlling intake of precursors such as potassium 
and protein in a patient's diet, the onset of uraemic syndrome may be 
suppressed. However, the long term accumulation of the "uraemic molecules" 
can lead to a number of morbid conditions. 
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This increase in concentration of middle molecular weight molecules within 
the body is attributed to the deterioration of the patient's health (Vanholder et 
al, 1996). In addition to the increase of toxins, uraemic syndrome is often a 
result of a malfunctioning hormonal and enzymatic homeostasis. It has been 
surmised that the fluctuations of toxin levels is more important than the mean 
level. This is supported by clinical observations that have demonstrated that it 
is patients that are undergoing intermittent hemodialysis that demonstrate a 
less satisfactory condition than those which undergo continuous ambulatory 
peritoneal dialysis (CAPD) (Vanholder et al, 1992) 
The suppression of immune response in uraemia is often deemed counter 
intuitive. Although the circulating levels of cytokines and other molecules 
concerned with the expression of immune response are intrinsically high in 
uraemic patients, the immune response itself is often poor. Girndt et al, 2001 
highlighted the functionality of T and B cells in uraemic patients. It was 
suggested that greatly reduced activation of T and B cells were apparent 
despite a global increase in serum levels of other markers. The effect of 
uraemia on the immune response is critical to health. Clinical problems 
observed include tuberculosis, presence of immunologic disorders, increased 
incidence of cancer and inadequate production of antibodies. All these 
factors suggest an immune deficiency in uraemic patients. Again these issues 
are not purely due to the presence of toxic solutes but also due to issues 
relating to the dialysis process itself. Biocompatibility, contamination and 
infection relating to catheter access (Chatzinikolaou, et al, 2004) and Vitamin 
D deficiency are all examples of non toxic factors associated with the immune 
system response. 
Interestingly the detection of immune response change in uraemic patients is 
often subtle. The number of circulating white cells is often unchanged. 
Circulating phagocytes are also unaffected, but granulocytic and macrophagic 
quantities may differ (Ponassi et al, 1987). 
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Bacterial infection is said to be suppressed by actions carried out by 
neutrophils and monocytes (Lewis et at, 1987). The depression of phagocytic 
metabolism has been demonstrated once Creatinine is higher than 
6mg/100mL. Indeed, the dialysis treatment furthers this response although 
the cause may be related to bioincompatability of dialysis membranes and not 
the toxic effects of the uraemic syndrome (Vanholder et al, 1992). The 
precise reasons why uraemia causes depression of phagocytic function is not 
known. However many studies have highlighted potential causes and most 
interestingly a study by Haagweber et at, (1994) highlighted a peptidic 
structure that resembled part of the ß2-microglobulin molecule. 
The precise effects uraemic toxins have on patients' health is often difficult to 
evaluate due to the heterogeneous nature of the patient group. However, 
there is a body of evidence that supports the removal of these toxins. 
Quantification of uraemia is possible although due to the non-specific nature 
of the condition, confusion arises as to which markers are most relevant. 
Creatinine clearance is a common clinical measure used to assess the 
progression of kidney failure. Indeed, creatinine clearance was established by 
Bonomini et al, (1986) as a metric for deciding on treatment options, and a 
level of 5 ml / min was suggested as a limit before transplant would be 
required. Although creatinine clearance has been criticised by Lameire et al, 
(2005) and others it is still routinely quoted. 
Studies have shown correlations between time on dialysis and onset of 
dialysis related amyloidosis (DRA) (Vraetz et al, 1999 ). The retention of 
middle molecular weight toxins is suggested as being the cause for DRA in 
the dialysis patient population. This condition encompasses a wide range of 
symptoms such as osteolytic bone lesions and carpal tunnel syndrome. 
Direct links with the presence and inadequate clearance of specific uraemic 
molecules such as ß2-microglobulin have been associated with DRA. In 
addition, defective production of insulin like growth factor-1 has been linked by 
Ritz et al, (1992) with bone disease. 
-10- 
Chapter 1 Introduction 
End stage renal disease (ESRD) has been linked to the presence of middle 
molecular weight toxins and Winchester et al, 2002 highlight the use of 
sorbents in this field. 
Lindner et al, (1974) established a strong link between end stage renal 
disease (ESRD) and artheroscierotic cardiovascular disease (CVD). The 
HEMO study (Depner et al, 2004) furthers support for MM removal suggesting 
that greater clearances of small molecules didn't necessarily improve mortality 
rates. Therefore the case for further research into middle molecules and their 
effect on patient mortality is required and further promotes the need for their 
on line removal as a potential treatment strategy. 
Hence, it is known that the uraemic syndrome is a complex and multifactorial 
condition. However, the body of evidence suggests that reduction in uraemic 
toxins could cause an improvement in patient health. Although work has been 
undertaken identifying specific molecules and their associated symptoms, the 
case is still strong for an attempt to non specifically removing all known 
uraemic toxins based upon their molecular size. 
1.1.4 Identification of target molecules for the research 
In order to validate any potential device's efficacy at removing middle 
molecular weight toxins, a suitable marker molecule should be identified. The 
literature contains details of the toxins identified to date and a brief overview 
of the most commonly studied molecules is included below. 
P2 Microglobulin 
Successful removal of ß2-microglobulin with a commercial adsorbent column 
(Lixelle) demonstrated improved patient health (Hiyama et al, 2002). In 
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addition strong links with the removal of ß2-microglobulin on the effects of 
dialysis related amyloidosis (DRA) have been demonstrated (Kazama et al, 
2001). The augmented activation of ß2-microglbulin has been linked by 
Hakim et al, (2000) to the bioincompatability of dialysis membranes, and 
hence promotes the case for its removal. 
It has also been demonstrated that although plasma levels of 02-microglobulin 
don't correlate directly with the onset of DRA, high values are always present 
in dialysis patients (Gejyo et al, 1993). This fact therefore suggests that an 
elevated level of ß2-microglobulin leads to the onset of DRA. A long term 
study (Lornoy et al, 2000) backed up these observations and supports the 
removal of ß2-microglobulin. 
The Glycated form of ß2-microglobulin has also been implicated by Koda et at 
(1997) to deposit in amyloid fibrils producing bone cysts, severe carpul tunnel 
syndrome and crippling arthritis. 
Despite there being some evidence to suggest a survival advantage to 
reduced 02-microglobulin concentrations in dialysis patients, it is not 
effectively removed using cellulosic membranes and the reuse of PMMA 
membranes reduces its mass transfer (Westhuyzen, J et al, 1992). 
Transplant patients demonstrate a dramatic reduction in ß2-microglobulin 
concentrations post operation. 
Due to the overwhelming evidence supporting the need to remove 02- 
microglobulin, many papers have used it as a marker for middle molecule 
removal. 
02-microglobulin has been widely studied in literature and makes for a 
suitable comparison between new novel adsorbent materials and current 
products already reported in the literature. 
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Cytokines 
Introduction 
Another important and increasingly well documented group of molecules are 
the cytokines. The cytokines act as intracellular communicators within the 
immune system and between the immune system and other systems. Their 
function is highly specific and due to their hormone type activities they can 
effect both local and systemic events. They have been linked to the 
symptoms of a plethora of physiological events such as propagation of 
immune response, pathology of infection as well as malignant disease. Their 
relevance within the dialysis treatment is important due to their involvement in 
response to biomaterials as well as their insufficient removal by the dialysis 
treatment itself. A sub group of the cytokine family, the interleukins, have 
been studied in dialysis treatments by a number of groups. The pro 
inflammatory interleukins (IL's) have been linked to the pathogenesis of 
sepsis. Low concentrations of IL's are normal, and any rise is usually 
controlled in healthy individuals. However, in uraemic patients significantly 
higher levels of IL's have been identified. Cheung, (1990) demonstrated the 
role IL's have in the assessment of biocompatibility. In addition Pereira et al, 
(1995) demonstrated how cytokines are involved in a multitude of responses 
to the dialysis process, furthering the importance of their study. Other studies 
have shown a spontaneous production of IL-1 in dialysis patients (Lonnemann 
et al, 1990). 
Stenvinkel et al, (2005) highlighted that IL-10 (18 kDa) plays an important role 
as an anti-inflammatory immune regulating cytokine communications. IL-10 is 
commonly secreted following a release of pro-inflammatory factors and is 
therefore said to be responsible for the down regulation process observed. 
Although the precise mechanism is not known, the effect is to reduce the 
systemic inflammatory response. IL-10 is often released due to endotoxin 
production and / or complement activation due to the presence of bio- 
incompatible materials known to be used in renal replacement therapies. 
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Like many uraemic toxins, the presence of IL-6 (polypeptide, 20kDa) is 
attributed to multiple factors. IL-6 can be secreted by a multitude of different 
cells including monocytes and endothelial cells and is influenced by patient 
specific factors (age, medical history, genetics, comorbidity, oxidative stress, 
hypertension etc) and dialysis related factors (backfiltration, sterilisation 
issues, and bio-incompatible materials). Stenvinkel et al, (2002) discussed 
likely links with IL-6 and mortality and health in ESRD. The paper linked the 
inflammation state of ESRD and suggests that the known pro and anti 
inflammatory cytokines (IL-1, IL-10, CRP and their relevant receptors) are 
contributed to by the presence of IL-6. IL-6 is often elevated in uraemic 
patients although this is not always the case suggesting that there may be 
other factors involved. Existing strong links between C-reactive protein (C- 
RP) and outcome, as reported by Zimmermann et al, (1999) could be due to 
the association of IL-6 production and levels (Ridker et at, 2000). The cause 
of raised IL-6 serum levels are numerous, but have been reported to be linked 
to regenerated cellulose membranes in addition to co morbid conditions 
related to aging. 
IL-1 is a cytokine that has undergone much study in uraemia. IL-1 (17kDa) 
can be excreted by nearly all nucleated cells but is released primarily by 
mononuclear phagocytes. High concentrations of IL-1 can be assumed to be 
toxic. In addition, there are some links with IL-1 and hormonal responses, 
(Lonnemann et aI, 1990) which could also result in decreased patient health. 
In a later study, Lonnemann et al, (1999) also highlighted the clinical 
relevance of cytokine activity in dialysis patients. Due to the relatively low 
serum concentrations of IL-1 (max of 500pg/ml in sepsis, (Teraoka et al, 
2000)) the identification of such molecules is usually carried out by ELISA kits. 
The same study highlighted the limitations of some current hemoadsorbents 
suggesting there is still work to be done to further their removal. 
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AGEs 
Another emerging group of uraemic toxins are advanced glycation end 
products. When proteins are exposed to carbohydrates usually in the form of 
glucose they can form advanced glycation end products (AGEs). Like other 
uraemic toxins, AGEs begin to accumulate due to the reduction of renal 
excretion. Interestingly, in addition to high concentrations of AGEs being 
reported in renal failure, they are also found in diabetic patients. Vlassara et 
al, (1988) suggested AGEs role in a host of biological responses including the 
promoted release of cytokines. The latter due to the AGEs ability to activate 
monocytes and macrophages in addition to endothelial cells although this has 
only been proved in vitro (Bierhaus et al, 1998). This leads to clinically 
important physiological changes and contributes to the increase in oxidative 
stress, inflammation and abnormal cell proliferation. 
AGEs have also been linked to the modification of ß2-M which is known to be 
a predominant component of dialysis related amyloidosis (DRA). 
Many AGEs can be removed successfully by high flux membranes (MW < 
lOkDa). The removal when using a standard dialysis membrane was shown 
by Makita et al, (1994) as being less efficient. However, polysuiphone dialysis 
has been shown to reduce pentosidine (protein bound AGE, MW <5000Da) 
levels (Jadoul et al, 1999). 
Although AGEs have not been researched to the same extent as some of the 
more traditional MM markers, their involvement in propagation of many other 
important systems as described above makes them a potent and important 
group of toxins. A recent publication by Winchester et al, (2002) discusses 
the identification of ESRD as being an inflammatory state. Interestingly, along 
side the traditional markers of inflammation such as cytokines, AGEs are also 
connected with the inflammatory response. The inflammatory response has 
been used by many as an indication of biocompatibility of haemodialysis 
membranes. In addition, AGEs have been confirmed by Kazama et at, (2001) 
as having direct involvement with DRA alongside beta-2 microglobulin. There 
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is therefore increasing interest in including AGEs as markers for patient health 
and comparison of different treatments to reduce their concentrations. 
Lysozyme 
Although Lysozyme has been identified by Winchester et al, (2001) as one of 
the "new" uraemic toxins, its prevalence in literature is limited. However, it is 
an inexpensive robust protein that lends itself to preliminary studies looking at 
the fundamentals of the use of sorbents in blood purification. Lysozyme has a 
molecular weight of 14kDa (hen egg white lysozyme used in this study, has a 
MW of 14.4kDa), and an isoelectric point of 10.7. 
Albumin. 
Albumin is produced in the liver and is the most abundant protein in plasma 
(typically between 30 - 50g/L). It is a large protein with a molecular weight of 
67kDa. Albumin is a key protein linked to the regulation of osmotic pressure. 
Albumin is a vital protein and therefore should not be removed by any 
proposed haemoperfusion system. The use of any adsorbent based system 
is severely restricted by the fact that the albumin is present in blood at a 
concentration of 40g/I whereas the concentration of ß2-M and many MM toxins 
is three orders of magnitude smaller. Hence, if the solutes have an equal 
affinity for the surface, albumin would swamp the adsorbent surface resulting 
in inefficient adsorption. Albumin has an isoelectric point of 4.8. 
Marker molecule selection. 
Selection of a suitable MM marker is not intuitive due to the number of 
potential molecules available. This fact, combined with cost of sourcing high 
purity molecules required for adsorption studies further reduces the number of 
potential possibilities. In order to achieve the scientific objectives of this work, 
the robust protein lysozyme was been chosen to act as a surrogate middle 
molecular weight toxin. Albumin was selected to validate whether the pore 
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structure is capable of allowing access to this larger molecule as it is 
understood this could inhibit the adsorbents ability to remove middle 
molecular weight toxins. As a final clinical study, beta 2 microglobulin was 
studied as it is a commonly used marker in literature and has many direct links 
with disease and death. 
1.1.5 Novel / Current devices and their limitations 
Protein adsorption (also known as fouling) is well known in membrane 
separation processes. Middle molecules (specifically ß2- microglobulin) are 
known to be adsorbed to certain dialysis membranes (Winchester et at, 
2001). The capacity of this mechanism is low and doesn't remove other 
uraemic toxins which have possible links to patient mortality. In addition, it 
has also been reported that the reuse of dialysers significantly reduces the 
efficiency of ß2- microglobulin removal (Drueke et at, 2000). Odell et at, 
(1991) reported 23 - 37 percent reductions in plasma ß2 Microglobulin levels 
by using high flux membranes. This builds on evidence that high flux 
membranes can retard DRA progression. Much of these types of studies do 
however, fail to identify the molecules they are able to remove, and hence any 
specific correlations between molecules and patient response are not 
available. 
Although this suggests that high flux membranes offer a suitable treatment for 
middle molecule removal, capacity remains low and there use is not without 
potential problems. Davankov et al, (2000) highlighted a strong case for the 
use of both a traditional dialysis membrane in conjunction with an adsorbent 
based system that would ensure the removal of MM whist the membrane 
continues the function of removal of excess water and smaller toxins. This 
combination has the potential to be both an efficient remover of uraemic 
toxins, water and other waste products, whilst remaining clinically viable in 
terms of both economics and hardware compatibility. A number of products 
have been developed with varied success. 
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This thesis is concerned with the use of a haemoperfusion device used in 
series with current haemodialysis to augment the treatment of kidney failure. 
Hemoperfusion is defined as "the direct contact of blood from patients or 
animals with a sorbent system" (Winchester et al, 2002). This definition acts 
as a useful introduction into a plethora of varying technologies and 
techniques. 
The discussion of sorbents in uraemia can be split into two distinct areas, 
namely the adsorption of target middle molecules within the adsorbent particle 
and the biocompatibility response partly due to blood contact. This statement 
supports the views of Denti et al, (1980) whose early studies of carbon 
adsorbents led to a specification outline as follows: - 
Adsorbents should be :- 
" Free from particle fines 
" Resist attrition 
" High adsorption capacity - fast adsorption kinetics 
" Low micro particle generation 
" High blood compatibility 
" Reproducible 
" Low toxicity 
" Minimum elution of toxic ions 
" Low pyrogenicity 
" Smooth surface morphology 
Although much work has been completed on the use of sorbents in uraemia 
and related conditions, there are still few viable commercial products which 
utilize this technology. 
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1.1.6 Adsorbent technologies in Renal failure patients 
Davankov et al, (2000) discussed how hypercrosslinked networks form a 
special three dimensional polymer created in an excess of a 
thermodynamically suitable solvent. The resulting material (often polystyrene) 
had a homogeneous molecular structure with inherent low density and a 
suitably high accessibility to small molecules. The predominant limitation of 
such materials is their susceptibility to swelling. However, derivatives of this 
family of materials are being used successfully in industrial adsorption 
technologies as reported by Tsyurupa et al, (1995). The widespread 
application of these materials is due in part to the large surface areas 
produced (1000 - 1500m2 / g). This process does however often form a 
microporous structure with a pore distribution of 1 -2 nm which is not suitable 
for human protein adsorption. Purolite Ltd. were successful in the production 
of mesoporous materials with the addition of larger transport pores on the 
materials surface in the region of 80 - 90nm. This modification made it ideal 
for the removal of proteins. These materials have been shown to remove ß2- 
microglobulin by Davankov et al, (1997). This paper also suggested that a 
more suitable material may be one that possess mesopores in the region of 4- 
1 Onm which will result in a higher capacity for ß2-M adsorption. 
Mesoporus materials can be made by microphase separation during the 
formation of a polymeric network. One of the best documented materials 
containing mesopores by microphase separation is the copolymer of styrene 
and divinylbenzene (Belyakova et al, 1991). 
Winchester et al, (2001) reported on the successful removal of solutes with 
molecular masses of between 60 and 21500Da using activated carbon 
adsorbents in direct contact with blood. The group experimented with surface 
coating materials to improve their biocompatibility as this was highlighted as a 
major issue with carbon adsorbents. The same study demonstrated that 
surface coating tended to reduce the adsorption characteristics of larger 
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weight molecules (>350 Da). This material also demonstrated the ability to 
adsorb physiologically important solutes and thus created the need for further 
study to understand the effects of pore size distributions on adsorption of 
uraemic molecules. 
The clinical implications of the use of such devices has been studied. The 
study by Winchester et al, (1977) demonstrated a platelet loss of 30 % 
suggesting potential biocompatibility issues. Coagulation factors didn't 
change enough to be of significance, although the paper still recommended 
the pursuit of more biocompatible materials. These issues are discussed in 
chapter 4. 
1.1.7 Betasorb / cytosorb 
A material researched by Medasorb International, BetaSorbTM demonstrated 
ß2-M removal in the region of 92% in a uraemic dog (Winchester et al, 2001). 
A further study using the same material demonstrated ß2-M removal of 69% 
and 79% of ß2-M respectively with two dialysis patients. The biocompatibility 
was considered acceptable as there was no change in the platelet counts or 
leukocyte count over the 3 hour treatment. Further work indicated that the 
material possessed the ability to remove some cytokines and thus provided a 
strong case for further studies into the material's potential commercial use. 
Another material developed by Medasorb International, cytosorb TM is a 
polystyrene divinyl benzene copolymer with a polyvinylpyrrolidone coating to 
make it biocompatible. Kellum, (2004) reported experiments both ex vivo and 
in vivo using the cytosorb resin. The in vivo study looked at survival outcomes 
of animals undergoing severe septic shock against a control group. The 
results showed a large increase in survival (after 12 hours) for the group that 
was undergoing the cytosorb treatment. Ex vivo studies backed up this 
observation demonstrating rapid adsorption of tumor necrosis factor, 
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interleukin-6 and interleukin-10. No kinetic or precise capacity data is 
reported in these papers. 
This cytosorb device received approval for clinical study for the treatment of 
sepsis in October 2007. 
1.1.8 BioLogic DT/PF 
This DT filter based sorbent haemoabsorption system utilizes a2 litre sorbent 
suspension around a cellulosic or cuprophane plate dialyser to clear the 
dialysate of toxins. The suspension comprises of 140g of powdered charcoal 
(with surface area of 400m2/g). However, much of this surface area is within 
the micropore range (<2nm) and hence is not available for protein adsorption. 
The sorbent solution contains glucose, which is returned to the patient during 
the removal of toxins. 
In order to overcome issues relating to the removal of larger weight 
molecules, Biologic introduced a secondary filtration system downstream of 
their DT system. This second filter utilises direct contact between charcoal 
and the plasma, resulting in successful removal of both protein bound and 
larger molecular weight molecules. This system uses a cartridge with free 
space to allow the adsorbent particles to circulate and help uptake kinetics. 
The device suffered a set back due to financial problems but the technology 
has now been sold and research scientists are developing a new generation 
device which presently is still to arrive on the market. 
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1.1.9 Lixeile 
The Lixelle device, developed by the Kaneka Corporation, Osaka, Japan is a 
direct hemoperfusion adsorbent device capable of removing ß2-microglobulin 
from blood. The column contains cellulose beads with a mean diameter of 
4601im, which have covalently bound hexadecyl groups on their surface 
acting as ligands. This results in a surface that binds well with hydrophobic 
substances. The porous material is said to be of a size which should size 
exclude Albumin. Although the device is marketed towards the removal of ß2- 
microglobulin, Namatani et al (1998), demonstrated that the device is capable 
of removing peptides and proteins in the molecular weight ranges 4,000 - 
20,000Da. In addition, Tsuchida et al, (1998) demonstrated removal of 
cytokines IL-1 beta and IL-6. 
The device has been used in Japan for the treatment of patients who 
presented with symptoms of DRA and pain. The device was tolerated 
clinically and large improvements in patient health were reported. The review 
by Kutsuki (2005) demonstrated that both subjective parameters (joint pain, 
stiffness etc) as well as objective parameters (number of nocturnal 
awakenings, grasping power, pinch strength, motor nerve latency, area of 
bone cyst, thickness of synovia) were all significantly reduced or normalised 
completely against a control group. Gejyo et al, (2004) researched the effect 
of augmented dialysis using a polysulfone membrane and the lixelle device in 
series against a control group. The two year study showed that 50% of the 
lixelle group demonstrated improvements of subjective parameters within 3 
months of treatment. The control group (just dialysis) all tended to obtain 
worsening scores for the subjective parameters. In the patients treated by 
Lixelle, the ß2-microglobulin clearance was correlated with the changes in 
joint stiffness and soreness suggesting a direct link between 02-microglobulin 
and the symptoms of DRA. Abe et al, (2003) made similar observations. 
Homma et al (2003), showed that after only 5 months, cystic areas on 
humeral heads reduced significantly, and that they began to increase when 
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treatment was stopped. Further studies have shown that patients treated with 
Lixelle over a2 year period did not develop additional bone cysts, where as a 
control group continued to develop them. 
Clinical experience of Lixelle has also identified a number of potential issues. 
Main issues concerned temporary hypotension, decrease in hematocrit and 
hypovolemia. Most of these adverse effects were only seen in the Lixelle S- 
35 device and not during use of the the S-15 (S35 has a volume of 350ml, 
S15 just 150ml) suggesting the additional material or extra extracorpeal blood 
volume was to blame. Interestingly, the efficacy of both treatments measured 
by improving clinical symptoms were comparable. 
Despite promising clinical evidence, the lixelle system has failed to obtain 
widespread commercial success probably due to its cost. In Japan, its use is 
limited to 2 years and its high cost could be one of the predominant limiting 
factors for its use elsewhere. However, its clinical success furthers the 
evidence that removal of ß2-microglobulin is advantageous to patient health 
and survival. 
1.2 Conclusions. 
There is well documented evidence that middle molecules are present in 
elevated concentrations in patients with kidney failure. Although the uraemic 
milieu is not fully understood, there are a number of toxins which are well 
documented as being present and direct links with patient health and 
secondary conditions have been established. There is therefore good support 
for their removal. Although it has been reported in literature that some middle 
molecular weight toxins are removed by current membrane dialysers, their 
capacity for removal is known to be low. 
A small number of devices designed to remove either middle molecular weight 
toxins non specifically or target specific uraemic molecules have become 
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available. Documented limitations of current devices seem to be associated 
with either cost or biocompatibility issues. Arguably the most efficient of the 
current devices is the Betasorb system although little is reported on its 
physical properties in the literature. In addition to the removal strategy, little 
has been reported concerning the optimisation of the device in terms of pore 
size distributions, material size, material quantity, in column packing density 
and flow conditions. 
1.3 Scientific objectives. 
This work aims at taking a multidiscipline approach to study the fundamental 
parameters effecting MM uptake onto nanoporous polymeric adsorbents 
suitable for blood purification. By applying chemical engineering principles 
new knowledge of the structure-properties relationship in porous material in 
liquid phase adsorption may emerge. This has the potential to offer new 
insight into the design of a medical device suitable for extracorporeal blood 
purification. In addition, an original approach to the design of a scaled down 
haemoperfusion column based upon dimensions from an existing commercial 
device is to be completed, aimed at providing a means of evaluating 
biocompatibility data in realistic flow conditions instead of stagnant pools. 
1) Use physical characterisation techniques to demonstrate the suitable 
selection of a styrene divinylbenzene copolymer adsorbents capable of size 
excluding albumin whilst allowing access to Middle molecular weight size 
toxins. Comparison of these material with a similar styrene divinylbenzene 
copolymer adsorbent which possesses a pore structure capable of allowing 
access to albumin to identify the effects of this. 
2) To evaluate the adsorption of lysozyme (surrogate middle molecular 
weight marker) and albumin on each of the materials to develop an 
understanding of the effects of pore surface area and pore volume on uptake 
kinetics by obtaining effective diffusivities for each molecule on each material. 
Also, the influence of particle size and boundary layer reduction on uptake 
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kinetics is to be studied in order to inform future haemoperfusion column 
designs. The kinetic uptake experiments will also be used to obtain capacity 
data for both albumin and lysozyme on each of the adsorbent materials. 
3) To develop an understanding of the effects of a binary component system 
containing various concentrations of Albumin and lysozyme and measuring 
the uptake kinetics of lysozyme on a material that allows some access to 
albumin and one that effectively does not for direct comparison. 
4) A batch reactor experiment containing biologically relevant solutions 
should be prepared and the uptake kinetics of a clinically relevant marker 
such as B2-M measured to act as an initial indicator of uptake performance 
relative to other devices. 
5) It is important to consider the design of any proposed hemoperfusion 
column on its adsorption performance and any potential damage to blood 
cells. Therefore, evaluation of a mock commercial column using conventional 
dimensionless fluid dynamics parameters is to be completed and a scale 
down system for clinical development also investigated. The effects of 
packing, particle size and flow rate should be reported. In order to complete 
this work a suitable blood analogue will have to be developed and validated. 
6) Finally, an adsorption study using the scale down column should be 
undertaken to highlight the efficacy of the finalised column design parameters 
chosen. 
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Chapter 2 
Material Characterisation 
This chapter is concerned with the characterisation of nanoporous adsorbents 
to help their selection for blood purification. Desirable pore size distributions 
are proposed. Various methods of characterisation are discussed and data 
obtained for the selected Styrene divinylbenzene polymer adsorbents are 
reported. The characterisation process produces a detailed insight into the 
physical properties of various adsorbents and highlights their potential use as 
haemodsorbents. The effects of pore size distributions when particles of 
different sizes are produced is also explored. 
2.1 Introduction to method for physical 
characterisation of nanostructured adsorbents. 
Adsorbents in their various forms have been successfully utilised for the 
removal of molecules from liquid media. The surface area and pore 
distribution influences their capacity and adsorption rate as does the particle 
size of the adsorbent itself. The material the adsorbent is made from may 
also influence the adsorption performance and specificity. Surface 
modification such as the addition of functional groups may influence the 
effects on adsorption characteristics and are commonly used to tailor an 
adsorbent for a specific application. The result is a great variety of potential 
materials capable of specifically or non-specifically adsorbing molecules from 
solution. This chapter identifies methods of investigating porous media using 
both optical and nitrogen adsorption techniques to identify adsorbents for the 
removal of MM toxins from blood. 
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Due to the plethora of different MM molecules retained in dialysis patients it is 
clear that any suitable removal strategy should be non-specific in nature. 
However, the use of any adsorbent based system is severely restricted by the 
fact that the blood protein, human serum albumin (MW 69kDa) is present in 
blood at a concentration of 40g/l whereas the concentration of the MM's is at 
least three orders of magnitude smaller. For example concentrations of Beta-2 
microglobulin in dialysis patients is typically around 35mg/L (Winchester, 
2002). Hence, if the solutes have an equal affinity for the surface, albumin 
would swamp the adsorbent surface resulting in low adsorption of MM's. By 
tailoring an adsorbent that effectively size excludes albumin and large blood 
proteins, an attempt to prevent such an occurrence may be possible. 
A carefully selected method of characterising the adsorbents is required in 
order to compare various materials for their suitability at removing MM's 
efficiently whist size excluding albumin. Therefore, methods of identifying 
pore size, surface area and pore volume distributions will offer insight into 
potential capacity and kinetic uptake performance of MM's. Work by 
Davankov (2000) suggested a pore size of between 4 and 10nm would be 
capable of removing molecules in the region of 4-3OkDa whilst excluding 
albumin. 
In order to investigate the scientific objectives of this work, a number of 
adsorbents were selected on the basis of their physical characteristics. All the 
adsorbents were prepared from styrene divinylbenzene but changes in the 
synthesis condition (eg monomer, porogen ratio, cross link degree etc) result 
in subtle changes in the pore structure. Styrene divinylbenzene polymer 
adsorbents were selected because they are well characterised non-specific 
adsorbents which have been used for similar applications in the past, 
(Winchester (2001). XAD4, a commercial styrene divinylbenzene copolymer 
(Rohm & Haas) was purchased to compare with in-house materials which 
were synthesised to have a molecular size cut off capable of excluding human 
serum albumin (M). The in house materials were prepared at 
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Loughborough University by fellow researchers; the method for which was 
published by Webb, (2007). XAD4 contains larger transport pores accessible 
by albumin. A derivative of CW1 was also produced thought to have the 
same cut off, but with a greater surface area and pore volume (CW4). This 
material was produced by Webb and reported in the same paper highlighted 
above. 
The adsorbents studied consist of a mixture of monomers; styrene, 
divinylbenzene, ethyl-styrene and porogens; toluene and undecane. It is by 
manipulating the ratios of these ingredients which allows polymer scientists to 
produce differing pore structures. 
Traditional suspension polymerisation involves adding a continuous phase to 
a stirred reactor, with a stirrer speed set to a pre-determined value. This 
value is dependent on reactor and stirrer geometries which are used to control 
the particle size distribution. The monomer phase is added to the reactor and 
the reactor is sealed. The monomer phase forms droplets due to the stirrer 
agitation. Once the droplets have been formed, the reactor is quickly heated 
to 80°C and polymerisation begins to take place. The reactor is left in these 
conditions for a period of 24 hours. This method although suitable for large 
scale production, typically results in a wide particle size distribution due to non 
homogenous mixing conditions. 
Using a Micropore Technologies dispersion cell (see Figure 2.1) which utilises 
a patented membrane system it is possible to control the particle size 
distribution. The monomer is injected into the continuous phase through the 
membrane and the droplets are removed and their size controlled by the 
shear at the membrane surface created by the stirrer. Once the required 
quantity of monomer phase has been dispersed the dispersion is transferred 
to a conventional reactor, which is sealed before being heated to 80°C and 
the material allowed to polymerise for a period of 24 hours. 
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Figure 2.1. Schematic of micropore dispersion cell. 
The in house polystyrene divinylbenzene adsorbents were generated using 
the traditional suspension polymerisation technique. XAD4 is prepared in a 
similar manor albeit on an industrial scale. In addition, a Micropore 
Technologies stirred cell capable of generating the dispersion before 
polymerisation resulting in a tight particle size distribution is also discussed. 
The membrane can be selected to produce a specific particle size. 
2.1.1 Particle size analysis 
Laser diffraction particle size analysis is a well known technique for obtaining 
particle size distributions. The method relies on the principle that when a 
particle travels through a laser beam, light is scattered at an angle that is 
directly related to the size of the particle. An increase in particle size will 
result in a decrease in the observed scattered angle. In addition to this 
observation, the light intensity also diminishes in relation to particle size; 
larger particles scattering light at low angles and high intensity where small 
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particles scatter the light at larger angles but reduced intensity. Therefore 
laser diffraction particle size analysers usually consist of (i) a light source (the 
laser) (ii) a means of presenting the sample to the light source (a recirculating 
system ensuring homogenous mixing of the sample in water) and (iii) a series 
of detectors capable of measuring the light and feeding this back to the 
software to obtain the scattering profile and light intensities. The range of 
angles the instrument can measure dictates the particle size range that can be 
detected. A Malvern Mastersizer 2000 was used in this work. The instrument 
is capable of measuring particle sizes in the range of 2- 2000/im. From the 
light scattering data obtained, the software uses a mathematical model to 
convert the raw data into a size distribution. This model assumes all particles 
are spherical, homogenous and the optical properties of the medium are well 
known. The particle population in the examination cell must be sufficiently 
dilute that the light scattering off one particle can be obtained before the next 
particle scatters the light. 
Once the hardware has obtained a particle size distribution, a single value can 
be obtained to describe the entire population; the Sauter mean squared value. 
In order to characterise the particle size of the adsorbents used, first the 
shape of the particles should be considered. The sphere is a readily 
understood geometric shape which can be characterised by one dimension; 
its diameter. In order to allow for particle shape Wadell's sphericity equation 
was used: - 
surface area of sphere with equal volume Equation 2.1 
surface area of particle 
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Table 2.1. common particle shape descriptions - adapted from Holdich (1996) 
Descriptor Wadell's Sphericity Example 
--------- Spherical 1.000 Glass bead 
Rounded 0.82 Atomised drops 
Cubic 0.806 Sugar 
Angular 0.66 Crushed minerals 
Flaky 0.54 Talc 
Platelet 0.22 graphite 
There are a number of ways to describe the particle size distribution. A 
common approach is to categorise the distribution into different size grades 
from the minimum size to the maximum size and then identify how many 
particles within the distribution fit into each of these grades (or sometimes 
referred to as fractions). The cumulative number of particles below a size can 
be plotted against particle size. The resulting plot will show the number of 
particles within each of the grades. A histogram (instead of a cumulative 
distribution) is also commonly used. It is often useful to express the mass of 
particles within each grade. This conversion is possible using the following 
equation 
Mass of a single particle K, d3p,; (Equation 2.2) 
Where: 
K, = volume shape factor (rr/6 for spheres) 
d= particle diameter. 
ps = density of particle. 
In order to obtain the mass of the grade the above equation is multiplied by 
the number of particles in the grade or fraction 
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Mass of grade or fraction = K d3psf (Equation 2.3) 
From the latter equation, a mass fraction can be calculated. This value is the 
mass of the fraction divided by the mass of the entire distribution. 
Mass fraction (M; ) = 
K"d'3psf' 
Ekvd, 3Psf, 
(Equation 2.4) 
Which simplifies to = M; = 
d'3ý 
_ 
(Equation 2.5) 
Ed; f 
The above equation assumes that shape coefficients and density are constant 
throughout the distribution. The subscript "i" is the midpoint of each fraction. 
On review of this equation it can be seen that the resulting mass based 
distribution will be more biased towards the larger particles than a number 
based system. The terms volume fraction and mass fraction can be used 
interchangeably since the density cancels. 
As mentioned earlier, the use of histograms instead of a cumulative total is 
commonly used and offers a good means for comparison between different 
materials. Hence, particle size distribution data has been presented as 
volume percentage in each size grade. 
Although the distribution curves described above are useful for in depth 
comparison of different samples, this thesis is often dealing with very similar 
samples (which should have similar distribution profiles) but the mean particle 
size differs. Therefore the identification of an "average" particle size for a tight 
polydispersed sample would be advantageous. 
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The surface area of a single sphere is given by rrd2 and its volume, Trd3/6. 
therefore it is possible to express a term for the specific surface area per unit 
volume as follows (and is referred to as the specific surface) : 
6 
sv =-- 
d 
(Equation 2.6) 
Therefore the specific surface area of a distribution can also be obtained thus: 
Ld; 
2 f; 6Ti£d r2 . 
fr 
sv =_( (Equation 2.7) 
%ti6(Y-dr3fr) ýlýdi3Jiý 
The above equations can also be converted to mass terms by substituting in 
the mass fraction equation given above. Once rearranged the following is 
obtained: - 
Sv=6m' 
d; 
(Equation 2.8) 
This allows the use of another equivalent spherical diameter to be derived that 
is suitable for use over the entire distribution. This value is essentially a 
spherical particle diameter that has the same specific surface as that of the 
entire distribution. It is called the Sauter mean diameter and is commonly 
used in particle technology when doing fluid flow calculations. It is given by 
6 
x$v_ 
sv 
(Equation 2.9) 
The Sauter mean is idea for use in kinetic modelling as it represents the 
average size of particle in the distribution based upon volume. 
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2.1.2 Pore size characterisation 
Material characterisation 
The International Union of Pure and Applied Chemistry (IUPAC) recommend 
the following classifications for pore sizes. See Table 2.2 
Table 2.2. IUPAC classification of pore sizes 
Name Pore size 
Micropores <2nm 
Mesopores 2nm - 50nm 
Macropores >50nm 
Techniques such as scanning electron microscopy are limited in their ability to 
characterise materials with length scales (eg pore size) below around 3nm. 
Nitrogen gas adsorption has become a standard technique to evaluate the 
pore structure of nanoporous materials. 
The method of nitrogen adsorption utilises a model to calculate pore size 
distributions and surface area values. When a clean porous material is 
allowed to contact the probe gas (i. e. nitrogen) the gas will be attracted to the 
surface of the material in order to satisfy the imbalance of surface atom 
forces. The increased concentration of gas molecules at the material surface 
is referred to as adsorption. The movement of molecules away from the 
surface and into the bulk is termed desorption. The length of time a gas 
molecule remains on the surface of the solid material will depend upon many 
factors including the type of solid / gas molecule and the temperature of the 
solid surface. When the molecules collide more often it is due to either an 
increase in population or due to an increase of speed (due to an increase in 
gas temperature) and results in a pressure increase. Therefore it follows that 
if the concentration of gas molecules in the bulk decreases (due to an 
increase of concentration on the solid material) then a pressure decrease will 
be observed. By obtaining this pressure decrease in conjunction with the 
-34- 
Chapter 2 Material characterisation 
temperature and the volume of the container it is possible to determine the 
number of molecules adsorbed onto the material. With this value, it is 
possible to calculate the surface area and pore volume of the material. 
From the experimental data obtained (equilibrium pressure, relative pressure 
at room temperature) the volume of nitrogen adsorbed at each relative 
pressure can be calculated. When the adsorbed volume is plotted against the 
relative pressure of adsorbate the adsorption isotherm is produced. 
Adsorption Isotherms. 
There are five common types of adsorption isotherm. Type I isotherms are 
often referred to as Langmuir type and are obtained when adsorption is 
restricted to a monolayer. Type I isotherms are usually related to physical 
adsorption onto solids with extremely small pores. Type II isotherms usually 
represent multilayer physical adsorption on non porous solids or materials 
having relatively large pores. The type of hysteresis observed in the 
isotherms also offers insight into the material being analysed. deBoer (1958) 
suggested 5 different hysteresis loops, 3 of which were able to describe 
mesoporous materials. The IUPAC classification was developed in 1985 and it 
is based upon the work of deBoer and later Seaton (1991) who presented a 
technique to determine the connectivity of porous materials based upon the 
hysteresis observed during nitrogen adsorption. These models were 
developed and improved by Seaton and Liu (1992) to allow the prediction of 
effective diffusivities using effective medium theory. 
The main limitation of adsorption porosimetry is that a model is used to obtain 
pore size distributions and surface areas from the isotherm data. Therefore, 
the results are sensitive to the type of model used and hence a brief overview 
of suitable models is included here. Both surface area and pore volumes can 
be derived from the isotherm data. 
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Langmuir Theory. 
Langmuir (1916) first proposed a theory for mechanism of gas molecules 
adsorbing onto simple surfaces. The theory stated that when gas molecules 
hit a solid surface they do not rebound elastically and instead are held to the 
surface (adsorbed) by a force similar to that holding atoms. The amount of 
molecules adsorbed is a product of the strength of the attractive forces 
resulting in monolayer coverage of the surface if the strength of the attractive 
forces is sufficient. At high gas pressures, Langmuir demonstrated that the 
surfaces tend to become saturated with the adsorbed gas resulting in a 
monolayer coverage. Others who were working on porous materials used 
saturated vapours so that the condensation of liquid occurred in the capillary 
spaces. 
BET Theory 
Brunauer, Emmett and Teller (1938) continued the work started by deBoer 
and published isotherm equations for multilayer adsorption. 
It was thought that multilayer adsorption was a function of induced dipole 
interactions caused by the polarisation of the adsorbed layers. 
The Brunauer group however, suggested that the forces required for 
multilayer adsorption were the same as those that are present during 
condensation. The resulting model, referred to as the BET successfully 
explained most van der Waals adsorption isotherms of molecules including 
nitrogen onto various materials. However, the BET model has not been 
without its critics and there are a number of papers published using slightly 
modified techniques. Halsey (1948) questioned the theory that a single 
molecule could adsorb a second one and subsequent layers to arrive at 
multilayer adsorption. However, despite others arriving at their own models, 
-36- 
Chapter 2 Material characterisation 
the BET is still the most widely used and comparison of similar materials is 
possible and common practice. 
Calculation of BET surface area 
Sm = 
n"samNA (Equation 2.10) 
m 
Where: NA= Avogadro's number (6.023x1023 molecules / mol) 
m= mass of sample (g) 
srr, = specific surface area per unit mass (m2/g) 
nsm = uptake of gas corresponding to monomolecular coverage 
of the solid surface. 
am = average area occupied by each molecule (16.2A2 for 
nitrogen). 
Therefore for nitrogen, 
Sm =9. /6X104 
!. 
m 
(Equation 2.11) 
The monolayer quantity, nsm is calculated by the adsorption quantity of it" at a 
series of pressures and interpreting the data using the BET equation in the 
following form : 
x_1+ (c -1)x 
n3(1-x) nfmC nsmC 
(Equation 2.12) 
Where C is a constant. The plot of x/ ns (1-x) against x will produce a straight 
line with a gradient of (c-1)/ ns,  C and an intercept of 1/ n', C. From this plot 
it is possible to extract values of nf, and C. 
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Pore size distributions. 
Models first became available to calculate pore volumes in 1951 when Barrett 
et al published their paper on nitrogen adsorption. This model was limited to 
pores above 15 angstrom as below this the model was inaccurate. deBoer 
published a number of papers from 1964 regarding the t-curve method for 
identification of pore surface area in the micropore region. He used the 
density of nitrogen in the adsorbed layer to be the same as that of liquid 
nitrogen. By plotting the adsorbed nitrogen against the calculated thickness, t 
enables an insight into the micropore region. Non porous materials will exhibit 
a linear t-plot going through the origin. However, t-plots for porous materials 
exhibited a curve due to the filling of the micropores with the nitrogen. It was 
deduced that the linear portion of the t-plot was a measure of the specific 
surface area of the adsorbent. This work was developed further by Mikhail et 
al, (1968) who determined the gradient at each point on the t-plot which 
enabled them to calculate the surface area required to allow access to the 
nitrogen molecules at a specific pressure. This enabled surface areas and 
volumes of microporous materials to be obtained. 
Although other approaches followed since the earlier work by deBoer etc it 
wasn't until the 80's when some important models were developed. Horvath 
et al, 1983 developed a model (HK) for the calculation of the effective pore 
size distribution of molecular sieve carbons. Their approach was based upon 
that of Everett et al, 1976 who's work concentrated on a slit potential model. 
Although this technique is still in use today, it has been criticised for its 
accuracy in larger pores. 
A newer technique derived from the HK model is called the density functionel 
theory (DFT). It is essentially the same as the HK model but it calculates the 
density of fluid near the walls of micropores where the HK model assumes it 
to be a constant. As with the HK model, it assumes slit pores with graphite 
interaction energies. The DFT model is accepted for pore sizes upto 4000 
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angstrom. However, the DFT model still assumes slit shaped pores with 
graphite interaction energies. Despite these limitations the DFT model is in 
common use and will be used for these studies in conjunction with the BET. 
2.2 Experimental section 
2.2.1 Material preparation. 
Prior to characterisation, the adsorbent is washed using a Soxhlet extraction 
system using toluene as the solvent for 8 hours. Once the sample was 
removed from the Soxhlet it was dried in a vacuum oven to remove the 
toluene. If the material was made / purchased from a stirred cell 
manufacturing method, the dry resin was then sieved in order to obtain size 
fractions with a much tighter distribution. The size fractions obtained were 
300-500 pm, 500 pm - 710 pm and 710-850 pm in addition to samples 
obtained by dry crushing the material. Any material produced using the 
membrane emulsification method did not require sieving as the method 
produced particles with a significantly tighter size distribution. The dry resin 
was wetted using acetone followed by displacement of acetone with water 
using 20 bed volumes of distilled water (flow rate approximately 10 bed 
volumes per hour). The adsorbent was subsequently stored in water. For 
adsorption work, wet adsorbent was centrifuged immediately prior to use 
(3000rpm, 5 mins) to remove any adherent water from the adsorbents 
particles. The centrifuged adsorbent was weighed using a6 digit balance in 
the quantity required for each experiment. In order to obtain the correct dry 
mass of adsorbent, the moisture content of the centrifuged resin was 
previously evaluated so a correction could be made for each material to arrive 
at the correct dry mass. 
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2.2.2 Optical photographs / SEMs 
The use of optical photographs demonstrate the spherical nature of the 
adsorbents and also give a visual demonstration of the range of particle sizes 
obtained from the suspension polymerisation method. Scanning electron 
micrographs utilise a high energy beam of electrons and measures the 
interaction they have with the surface of the sample that has been covered in 
gold. The energy exchange between the electron beam and the sample 
results in the emission of electrons which in turn can be detected and 
subsequently converted into an image. SEM's were obtained to demonstrate 
the internal pore structure of the adsorbents. A Jeol 1000X scanning electron 
microscope was used to obtain the images shown here. 
2.2.3 Particle size distribution analysis 
A Lasentec S400A instrument made by Malvern was used to analyse 
equivalent spherical diameter by calculation of area by light scattering 
properties. This type of instrument is capable of obtaining a full particle 
distribution for particle ranges of interest in this thesis. Each of the size 
fractions was pre wetted in water before being measured. The Sauter mean 
value, median and mode were obtained. Additionally, a measure of span is 
also reported, defined as 
do. 9 - do. i = Spatz do. 5 
(Equation 2.13) 
Span values lower than 0.5 are considered as approximately monosized. 
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2.2.4 Polymer density. 
The polymer density is simply the ratio of polymer mass to volume. The mass 
of each of the samples was easily measured using a6 digit laboratory 
balance. The volume occupied by the adsorbent was obtained using a helium 
pycnometer. The pycnometer works by detecting the pressure changes 
resulting from displacement of gas by the polymer. The instrument obtains 
the skeletal volume of the porous adsorbent and its absolute density is 
obtained by knowing the mass of the adsorbent in the cell. Helium was used 
as the displacement gas as it is a small probe molecule and can diffuse into 
small micropores. The accuracy of the instrument is good providing the 
sampling gas is free from moisture. The sample must also not contain volatile 
substances so the samples were first vacuum dried in an oven prior to helium 
pycnometry measurement. 5 measurements of each material were made and 
the values reported in represent the mean average of those readings. 
2.2.5 Surface area and pore size distributions. 
Surface area and pore size distributions were obtained using a Micromeritics 
ASAP 2000 automatic analyser using high purity nitrogen as the probe 
molecule. Samples of each material and each size fraction were obtained, 
cleaned and dried in a vacuum oven prior to their study. The samples were 
prepared by degassing for a minimum of 24h in the degas port of the 
machine. The mass of adsorbent was carefully measured by subtracting the 
weight of the empty sample tube from that of the degassed tube including the 
sample. 
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2.2.6 Surface area and pore structure comparison. 
The three materials, XAD4, CW 1 and CW4 were characterised in order to 
evaluate their pore size distributions, pore size cut off, total pore volume and 
surface area using both the DFT and BET models. In order to demonstrate 
the effect pore cut off would have on potential uptake for the marker 
molecules used in this work, the pore structures are expressed in terms of 
surface area accessible to lysozyme and albumin based on pore sizes having 
a cut off of 6nm for Lysozyme and 14nm for albumin respectively. These 
values were obtained using size exclusion chromatography in previous 
studies. 
2.2.7 Effect of particle size on pore structure. 
Each material was fractionated using mechanical sieves so that discrete size 
fractions could be characterised to identify if samples within a particular 
particle size displayed differences in pore structures. In addition, adsorbents 
synthesised using the membrane emulsification process were evaluated to 
see if this variation in manufacturing technique had any effect on pore size 
distributions for the same material. This is of importance when considering 
the design a haemoperfusion column as one of the parameters which may be 
changed is the particle size. However, in order to ascertain how changing this 
parameter may affect the device's performance it is important to know if any 
other variables are changing such as the pore structure itself. In addition 
crushed samples were produced for kinetic studies and it was deemed 
important to characterise the effect of this practice on the resulting pore 
structure. 
-42- 
Chapter 2 M<ituiil ii characttitia, tliuýti 
2.3 Results and discussion 
2.3.1 Optical photographs / SEM 
The optical photographs shown in Figure 2.2 demonstrate the spherical nature 
of the particles produced using the suspension polymerisation method. The 
image on the left of the figure show that large particles were produced using a 
slow stirrer speed, and that smaller particles were obtained using a higher 
stirrer rate. The photograph on the right shows evidence of smaller particles 
(fines) caused by areas of high shear within the reactor. 
Figure 2.2. Optical pl)otogr[1pl1s of CW t p, irticles. 
Samples for SEM investigation consisted of both whole particles and crushed 
samples of XAD4, CW 1 and CW4. The samples were taken from bulk (not 
fractionated and not sieved after crushing). Figure 2.3 shows a crushed 
sample of XAD4, demonstrating the amount of fines that result from this 
process. Figure 2.4 shows the surface of a non crushed XAD4 particle. The 
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surface appears to have irregularities that could indicate the presence of 
porosity, and were probed further at higher magnification. Figure 2.5 shows a 
high magnification image of a fracture face of XAD4, clearly showing porosity. 
The image shows evidence of nodules (25 - 100nm) and a cauliflower like 
structure with mesopores between the nodules. 
The SEM image of CW1 shown in Figure 2.6 again shows the crushed non 
spherical material although less fines seem to be produced here than with the 
XAD4 sample. Evidence of potential porosity is again present in Figure 2.7. 
The porosity is visible along the fracture face shown in Figure 2.8. 
The fractured particle of CW4 shown in Figure 2.9 shows the presence of 
porosity, clearly visible along the fracture faces. Figure 2.10 is a magnified 
image of a fracture face of CW4 showing even distribution of the nodules 
which make up the structure. 
EHT= 5 00 kV Signal A- lnleii; 
WD =5 mm Photo No = 9802 
Figure 2.3. SEM of crushed fragments of XAD4. 
ýý. <` 
ýý - 
r 
ýy 
, ý. 
ý..: 
, 
v ,, 
ý 
-44- 
Chapter 2 Material characterisation 
" ,, *ý 
Ifs ^1idý` 
_"L. 
'^. °'`_F 
4., Ik 
', e, I W_ 
w ßäP"" - 4, tf .' 
Id 
, 
4 w. 
fY 
4 
ý6 Ir j7 'k- 
f. ,`pr 
let 
200nm EHT = 5.00 kV Signal A= InLens 
WD =6 mm Photo No = 9803 
Figure 2.5. SEM of fracture face of XAD4 showing porosity. 
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Figure 2.7. SEM of CW1 surface structure (non fracture face). 
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2.3.2 Particle size distributions. 
Table 2.3 tabulates the particle size fractions obtained from the Malvern 
instrument. The mean diameter refers to the Sauter mean value. The sieved 
fractions resulted in reasonably tight distributions as characterised by low 
span values. Although effort was made to sieve the crushed fraction to 
remove fines, it appears some remained in the XAD4 fraction resulting in a 
high span value. The majority of the size fractions exhibit a reasonably wide 
range of particle sizes despite being sieved. The larger size fractions have a 
tendency to exhibit tighter distributions, as the sieves are more effective at 
removing the smaller particles. The smaller sized sieves have a tendency to 
clog easily with fines thereby preventing the passage of smaller particles. 
Although care was taken to sieve only small quantities at a time, it is clear this 
process has limitations. 
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Figure 2.10. SEM of pore structure of CW4 taken along a fracture face. 
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Figure 2.11. Plot of particle size distributions for all adsorbents. Plotted as a 
percentage of distribution against size. 
Table 2.3. Average particle sizes for adsorbents used in kinetics experiments. 
ID / Fraction 
Particle Diameter (Nm) Span 
CW 1 crushed 
Mean 
197 
Median 
236 
Mode 
207 0.9 
CW 1 120* 120 112 109 0.3 
CW 1 300-500p 430 449 380 0.6 
CW 1 500-710 p 513 559 516 0.7 
CW 1 710-850 p 780 820 816 0.2 
CW4 20-50 p 28 38 44.5 1.4 
CW4 40-70 p 49 66 71.5 1.4 
XAD4 crushed 163 268 279 3 
XAD4 300-500p 400 368 380 0.8 
XAD4 500-710p 478 433 516 0.8 
XAD4710-8501 716 693 700 0.5 
* made by micropore membrane 
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The CW4 fractions were not sieved prior to use due to the small particle sizes 
and the span values were poor. The heterogeneous turbulence in the 
polymerisation reactor is likely to have caused the distribution of particle sizes. 
The CW 1 sample made using the micropore membrane exhibits a low span 
value without the requirement to sieve the material. This demonstrates a 
commercially viable way of producing materials in bulk with a tight particle 
size distribution without the need of any post processing. 
2.3.3 Surface area and pore size distributions 
All the materials used in the study exhibit type 4 nitrogen adsorption isotherms 
(using the IUPAC classification, see Appendix 1). Type 4 isotherms are 
typical of mesoporous materials and are characterised by an initial monolayer 
coverage up to point B where monolayer to multilayer coverage is taking 
place. The limiting uptake at higher P/Po suggest total pore filling. The 
hysterisis observed is evidence of pore condensation. 
The hysteresis observed in the isotherms offers insight into the material 
mesoprous structure. The XAD4 samples demonstrate a H2 hysteresis 
according to the IUPAC classification (see Appendix 1). This type of 
hysteresis is typical of a porous material containing small pores usually 
caused by agglomerates of spherical form and similar in size. The high 
magnification scanning electron micrographs support presence of such a 
structure. The hysteresis is more apparent for nitrogen adsorption isotherms 
of CW1 and CW4 samples. This is most likely due to the lower cut off of 
mesopores in these materials compared with XAD4 (see Figure 2.12- Figure 
2.18). 
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XAD4 demonstrated a higher capacity for nitrogen adsorption that CW4 which 
in turn was higher than CW1. The increased adsorption volume is due to the 
higher total porosity of XAD4 due to large macropores. 
2.3.4 Adsorption / desorption Isotherms. 
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Figure 2.12. Adsorption /desorption isotherm for crushed fraction of XAD4 
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Figure 2.13. Adsorption / desorption isotherm for 300 - 500u fraction of 
XAD4 
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Figure 2.14. Adsorption / desorption isotherms for 500 -710u fraction of 
XAD4 
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Figure 2.15. Adsorption / desorption isotherms for 710- 850u fraction of 
XAD4 
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Figure 2.16. Adsorption /desorption isotherm for mixed fraction of CW1. 
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Figure 2.17. Adsorption/ desorption isotherms for 20-50u fraction of CW4. 
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Figure 2.18. Adsorption/desorption isotherm for 40-70u fraction of CW4. 
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2.3.5 Comparison of materials. 
The BET model doesn't take into account the possibility of micropore filling or 
penetration, therefore it could falsify the results. 
Using the DFT model it is possible to obtain plots of surface area and pore 
volume based upon the experimental data obtained from the nitrogen 
adsorption isotherms. Incremental pore volumes and pore surface areas were 
obtained in addition to cumulative pore volumes. The Incremental values are 
obtained by calculating the quantity of area or volume at a particular pore 
width. The cumulative vales are obtained by summing the (area or volume) 
values for each pore width together. The sharp peaks in some of the data are 
likely to be an artefact of the model and not actual pore structure. When the 
plots of incremental surface area against pore width are overlaid as in Figure 
2.19 the differences in pore structure become apparent. CW1 and CW4 have 
virtually identical pore cut off of around 11 nm. XAD4 however, exhibits a 
considerably higher cut off of around 30nm. Figure 2.20, Figure 2.21 and 
Table 2.4 highlight the fact that XAD4 has considerably more pore volume 
than both CW4 and CW1. CW4 contains more pore volume and surface area 
than CW1. By normalising the cumulative pore volume data as in Figure 2.22 
it can be shown that CW1 and CW4 have much of their pore structure in the 
mesopores region where as XAD4 contains a large quantity of larger 
mesopores as well as significant microporosity. Although CW 1 and CW4 
have the same cut off, CW4 contains a greater pore volume and surface area 
in the mesopore region compared to CW1. The surface area and pore 
volume in this region is still less than that found in XAD4 however. The pore 
structure data suggests that both CW 1 and CW4 should size exclude albumin 
whilst allowing access to MM's. XAD4 in contrast may allow access to human 
serum albumin due to the larger mesopores. Table 2.4 provides guidance on 
the potential amount of surface area accessible to the two bio markers on 
each of the materials based on DFT data. The characterisation of these 
-55- 
Chapter 2 Material characterisation 
materials suggest that CW1 & CW4 posses suitable pore structure for removal 
of MMs and are were therefore chosen to evaluate MM adsorption. XAD4 
with its more open pore mesopore structure was selected to compare with 
CW1 & CW4 and see whether albumin could result in competition of binding 
sites for MMs. 
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Figure 2.19. Comparison of pore structure of materials CW1, CW4 and XAD4 
with respect to incremental surface area against pore width. 
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Figure 2.20. Comparison of pore structure of materials CW1, CW4 and XAD4 
with respect to incremental pore volume against pore width. 
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Figure 2.21. Comparison of pore structure of materials CW1, CW4 and XAD4 
with respect to incremental pore volume against pore width. 
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Figure 2.22. Comparison of pore structure of materials CW1, CW4 and XAD4 
with respect to normalised cumulative pore volume against pore width. 
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2.3.6 Effect of particle size on pore structure. 
Although the pore structure of the materials appears well suited for use as a 
selective adsorbent for blood purification, it was important to ensure synthesis 
of adsorbents under identical conditions except for particle size doesn't have a 
great impact in the resulting pore structure. Figure 2.23 shows that there is 
little effect on pore structure with regard to different particle size fraction. The 
BET data for each of the size fractions of XAD4 (see Table 2.4) provides 
evidence that there is little difference in the surface areas when the particle 
size of the adsorbent is changed. The pore volume is reduced slightly in the 
crushed sample of XAD4 based on the DFT modelling data. This is most 
likely to be due to the fact the particles will fracture along the largest pores as 
these are likely to exhibit the lowest mechanical strength. The result is a 
relative reduction in pore volume especially in the larger pore region (10- 
50nm). Figure 2.23 shows a plot of incremental pore volume against pore 
width for all size fractions of XAD4 obtained by using the DFT model. The 
data from the different size fractions overlay with the exception of the crushed 
sample which has as stated previously a slightly lower pore volume. This 
observation is better illustrated by Figure 2.24 where cumulative pore volume 
is plotted against pore width. In addition Figure 2.25 where the same data is 
normalised against pore volume it becomes apparent that the pore volume 
distributions for all of the XAD4 size fractions are similar but the crushed 
fraction has a slight reduction in volume in the larger pores. This provides 
supporting evidence that the larger pores have been lost in the crushing 
process. Figure 2.26 demonstrates that there is a negligible difference in 
pore surface area in the crushed sample of XAD4 compared to the sieved 
whole particles. This suggests that the particles have fractured along the 
larger pores and hence although some pore volume is lost the surface area 
remains constant. Therefore, it is assumed crushed particles will have similar 
adsorption characteristics to whole particles. 
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In addition, the CW1 material made using the dispersion cell method 
demonstrated similar pore structure in the mesopore region. Therefore, it 
appears that the membrane emulsification process and the emulsion 
generation using a commercial stirred reactor does not effect the mesopore 
structure of the material. Thus control of 'particle size may be affected by the 
use of membrane emulsification techniques without influencing the pore 
structure development. 
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Figure 2.23. plot of incremental pore volume against pore width for different 
size fractions of XAD4. 
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Figure 2.24. plot of cumulative pore volume against pore width for different 
size fractions of XAD4 
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Figure 2.25. Plot of normalised cumulative pore volume against pore width for 
various size fractions of XAD4. 
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Figure 2.26. Plot of incremental surface area against pore width for different 
size fractions of XAD4. 
2.4 Conclusions 
Using a combination of physical characterisation techniques, data on the 
particle size, pore size and surface area for 3 different styrene divinylbenzene 
copolymer adsorbents have been obtained. The data suggests that both CW1 
and CW4 should be capable of removing MM toxins whilst size excluding 
albumin. The commercial material, XAD4 may allow human serum albumin 
into some of its internal pore structure although it does posses the largest 
quantity of surface area available to MM's. CW1 has the lowest surface area 
available for MM removal with CW4 having around 50% more surface area 
whilst maintaining the same cut off (11 nm). The materials were therefore 
selected for further adsorption studies to see whether the exclusion of human 
serum albumin may be demonstrated. In addition, the differing pore 
structures between CW1 and CW4 may highlight the effects of pore structure 
and surface areas on kinetics and uptake capacity. The use of a micropore 
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technologies dispersion cell has shown a commercially viable method of 
producing monosized particles with little effect on the mesopore structure. 
The traditional suspension polymerisation technique has been shown to 
produce wide particle size distributions that would require fractionating in 
order to increase the bed porosity in any proposed fixed bed type 
haemoperfusion device to prevent high pressure drop during treatment. The 
particle size has been shown to have little effect on pore structure. 
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Chapter 3 
Protein adsorption studies 
This chapter introduces the principles off mass transfer and how their 
understanding has the potential to inform the engineering of a suitable blood 
purification device. The resistance to mass transfer of simple single solute 
systems is explored on 3 adsorbent materials (characterised in chapter 2). 
Binary systems containing both lysozyme and albumin were studied in 
addition to a more complicated concentrated biological fluid (PD fluid) 
containing a plethora of MM's and albumin at physiological concentrations. 
From these experiments a clearer understanding of the fundamental key 
parameters in uptake of MMs from blood emerge. 
3.1 Introduction to mass transfer theory 
Adsorbents are commonly used for purification applications. A solid material 
is used to separate soluble solutes from solution. The process relies on 
interaction of the solute molecules contained within the solution to the 
adsorbent material surface due to shot range Van der Waals forces that arise 
as a solute approaches an adsorbent surface. It is possible that the 
molecules could adhere to the material surface due to chemisorption, which is 
where a chemical bond is formed between the adsorbent and solute. 
Adsorbents offer a suitable means of separating solutes from dilute solutions 
e. g. organic pollutants including herbicides and pesticides from water 
(Daignault et al (1988), Tsyurupa et at (1995). It is possible to alter the 
adsorption characteristics of the adsorbent by controlling the physicochemical 
properties . Adsorbents can be made to be highly specific in their adsorption 
of target molecules. For example, incorporation of surface functional groups 
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that form complexes between solutes in solution could significantly enhance 
the solute affinity for the adsorbent. 
Identifying the key parameters influencing protein adsorption along with the 
role of the pore structure in terms of size exclusion may allow the design of an 
adsorbent suitable for the removal of middle molecules. 
The adsorption process may be viewed as three distinct steps in series. 
External transport: The transport of molecules to the surface of the 
adsorbent from the bulk solution. This process may be influenced by external 
mass transfer effects e. g. mixing. 
Internal transport: The transport of molecules within tortuous channels 
(pores) of the adsorbent material eg via mesopores and macropores. 
Sorption: The physical attachment of molecules to the surface within the 
adsorbent bead. 
The diffusion transport processes described above can be modelled using 
Fick's first law of diffusion :- 
J= -D 
dc 
dx 
(Equation 3.1) 
The interaction of proteins at the adsorbent/solution interface depends on 
both the surface characteristics of the adsorbent and the solute chemistry 
influenced by the intimate solution environment (e. g. pH, ionic strength etc). 
The surface characteristics include surface charge, surface energies, surface 
hydrophobic properties and the presence of surface functional groups. 
Ramsden (1997) suggested that non-specific hydrophobic interactions are 
likely to be the primary mechanism for protein adsorption onto polymer 
surfaces. It is well documented in the literature (Malik et al, 2008) that 
activated carbon materials exhibit larger adsorption capacity for proteins than 
their polymer counterparts suggesting that perhaps the increase in 
hydrophobicity results in this increased uptake. 
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The mechanisms of adsorption of lysozyme and albumin onto polymer 
surfaces used in this work have not been studied in detail. Suggestions for 
how this may be done are included in chapter 5. The focus of the work 
presented here is the investigation of how the adsorbent pore structure affects 
the adsorption performance in terms of mass transport and protein size 
exclusion. The adsorbents studied are all copolymers of polystyrene-co- 
divinylbezene. These are known to be hydrophobic in nature, therefore 
protein-surface interactions with the adsorbent are thought to occur primarily 
due to hydrophobic interactions. 
Equilibrium and the adsorption isotherm 
The equilibrium adsorption isotherm relates the equilibrium partitioning of the 
solute between the solid/liquid phases. An adsorption isotherm may be 
obtained by undertaking batch adsorption experiments under controlled 
conditions (e. g. temperature). By contacting equal amounts of adsorbent with 
solute solution having a different initial solute concentration, the solute uptake 
(at equilibrium) may be plotted as a function of the equilibrium solute solution 
concentration. Usually, in physical adsorption processes, the equilibrium 
condition is one that is dynamic in nature. The rate of solute adsorption 
equals the rate of solute desorption. 
Protein adsorption has however, been found to be concentration independent 
(Ramsden, 1997 and 2002), resulting in a rectangular adsorption isotherm 
(see Figure 3.1 below). Therefore if a site is vacant and there are solute 
molecules in solution available to fill the site, then the site shall eventually be 
filled. The filling will continue until the surface is saturated. Literature 
suggests that proteins are able to form a monolayer on the polymer surface 
(Ramsden, 2002) 
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Figure 3.1. Schematic diagram showing form of an irreversible isotherm. 
3.1.1 Kinetics of adsorption 
The rate of adsorption can be said to be governed by two main factors. The 
rate at which the molecules arrive at the adsorption surface (within the 
adsorbent particle) and the rate at which molecules at the surface undergo 
adsorption (e. g. if there is a barrier to adsorption so that the frequency of 
adsorption attempts is not the same as the rate of adsorption). 
Understanding of the underlying mass transport mechanism is important in 
order to optimise both the adsorbent material and the design of the blood 
purification system. As discussed previously, the transport mechanism may 
be split into three distinct steps. 
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External Transport. 
Diffusion of the solute occurs across a stagnant liquid film adherent to the 
external surface of the particle. The thickness of the liquid film (the stagnant 
boundary layer) is influenced by the degree of external agitation (empirical 
correlations are available that relate the dimensionless Sherwood number 
(Sh) as a function of Reynold's number (Re), Schmidt number (Sc) and power 
number (Po)). External agitation (e. g. using a stirrer and baffles) affects the 
film thickness (shown schematically in Figure 3.2) 
Boundary Layer 
Adsorbent bead 
Figure 3.2. Schematic diagram showing stagnant film boundary layer around 
the adsorbent bead. 
Transport within the particle 
It is suitable to think of a pore as a capillary and a pore size distribution in 
terms of a number of capillaries of various sizes (see Figure 3.3). Generally, 
adsorbents containing larger pore sizes will have a smaller surface area. 
Typically, microporous adsorbents (pore sizes less than 2nm) have surface 
areas in excess of several hundred square meters per gram of adsorbent. 
Adsorbents with small mesopores (2-10 nm) could result in the solute (MMW 
protein) interacting with the surface more often, thus causing a hindrance to 
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diffusion. This happens when the solute mean free path (distance the solute 
travels before it encounters another solute molecule and collides with it) is 
longer that the pore width. Therefore an adsorbent with large transport pores 
(10-50 nm) is likely to exhibit faster adsorption kinetics. However, the size of 
pores for blood purification is potentially limited due to the requirement to size 
exclude larger proteins (see Figure 3.3). For the molecule to be able to 
access the adsorbent internal surface, the transport pores must be large 
enough to allow the solute to enter into the adsorbent pore structure. 
Tortuous 
MMW solutes capillaries are 
easily diffuse accessible to 
inside the MMW proteins 
porous bead 
Ito 
Larger proteins e. g. 
/albumin cannot 
penetrate within the 
bead 
Figure 3.3. Schematic diagram of a size selective adsorbent bead, with a 
nanoporous structure suitable for size exclusion of HSA whilst permitting 
smaller proteins e. g. lysozyme, to diffuse within. 
Adsorption on the pore wall 
Within the confines of the pore, the solute experiences Van der Waals forces 
with the likelihood of being retained at the surface (phenomenon known as 
adsorption). 
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Protein adsorption studies 
The process of adsorption described above may be reversible. The adsorbed 
molecule may leave the surface and hence be desorbed. The phenomenon 
of desorption is less likely in protein adsorption due to the protein unfolding 
and attaching at multiple sites on the surface. The accompanying increase in 
system entropy and the exothermic nature of the adsorption process results in 
a significant decrease in the system free energy. If desorption does occur, it is 
possible for the molecule to leave the pore and subsequently pass through 
the film boundary layer at the particle surface and return to the bulk solution. 
(see Figure 3.4) However from simple solutions such as a single protein in 
buffer, it is often thought that once the protein adsorbs, the process is 
irreversible. 
--- Fier. mnlecide 
Adsorption onto pore wall Desorption from pore wall 
Figure 3.4. Schematic of adsorption / desorption of molecules at the solid l 
liquid interface. 
Although literature suggests that protein adsorption onto polymer surfaces is 
often irreversible, Vroman (1962) suggested that in complex solutions there is 
a hierarchy of protein adsorption onto a material surface, this phenomenon is 
known as the "Woman effect". Some proteins have the ability to dislodge a 
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preadsorbed protein if the affinity of the adsorbing protein for the surface is 
greater than that of the protein previously adsorbed at the surface. This is of 
particular interest for a blood purification device because if albumin is able to 
access the internal surface area within the adsorbent bead containing 
previously adsorbed MM's there could be an exchange between the faster 
diffusing smaller proteins eg MM's by albumin taking place due to its presence 
at the top of the hierarchy. 
Experimental Methodology 
Batch adsorption experiments carried out in an agitated tank offer a means to 
characterise the kinetic performance of the selected adsorbents at removing 
MM's. By measuring the time dependent reduction in solution concentration 
of a single marker protein (lysozyme, >99.9% purity, and human serum 
albumin, -99% purity, both purchased from Sigma-Aldrich, UK. ) in the bulk 
solution and applying a mass balance, the adsorption kinetics of each 
adsorbent may be studied. 
All experiments utilised the methodology detailed below. Adsorbents XAD4, 
CW1 and CW4 with different mean particle sizes and various rates of agitation 
were studied. This enabled evaluation of the mass transfer resistance to MM 
adsorption within the nanoporous adsorbents. In addition binary solute 
systems containing both lysozyme and albumin in Hepes buffer solution were 
used. This was to evaluate if albumin access to the internal pore area of any 
proposed adsorbent bead may result in blocking of the pores and / or reduce 
the capacity for MM removal. Finally a clinically relevant multi-component 
system (concentrated peritoneal dialysis fluid) was used to study competitive 
adsorption effects. A matrix of the adsorption experimental work undertaken 
is presented in Table 3.3. 
Protein solution preparation 
A 0.1 M Hepes buffer solution containing 100 mM NaCl (pH7.4) was used to 
prepare all protein solutions. A known weight of protein was carefully 
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dissolved in the solution. Care was taken during dissolution to prevent 
foaming of solution by gently agitating the protein solution. 
Batch adsorption experiments using the stirred tank reactor 
A1 litre round bottomed glass reactor flask was placed in a temperature 
controlled water bath (temperature controlled at 37°C). A PTFE paddle (4 
blades) connected via a variable rotational speed overhead stirrer (60- 
1500rpm) provided controlled agitation to study the influence of mixing. The 
speed of the stirrer was measured using a tachometer prior to each 
experiment. The PTFE paddle stirrer geometry was selected after it was 
noted that some geometries were capable of mechanically damaging the 
adsorbent at high agitation rates resulting in production of fines. The stirrer 
used in the study was selected following initial studies showing that agitation 
of the adsorbent beads caused no change to the particle size distribution of 
the sample after 24hours agitation at the maximum agitation rate (826rpm). 4 
stainless steel baffles (at right angles) were added to the reactor to reduce 
vortex formation and the subsequent entrapment of air. A sampling syringe 
equipped with an in-line filter was added to the system to aid sample 
collection. The reactor was filled with 500ml of buffered protein solution 12 
hours prior to the addition of any adsorbent to ensure that any non-specific 
adsorption on the vessel walls was complete and no further change in solution 
concentration took place. Once the system was at equilibrium, a1 mI solution 
sample was withdrawn to measure the initial protein concentration (C; n; t, a, ) 
prior to addition to the reactor of a known weight of pro-wetted adsorbent 
sample. A stop watch was started to follow the adsorption kinetics. The 
adsorbent was pre wetted in ultra-pure water and centrifuged to remove all 
external particle moisture apart from that contained within the pore structure. 
This process ensured access of solution within the beads once they were 
added to the protein solution. Subsequent samples were then taken at time 
varying time intervals (typically after 1,2,5,10,20,30,45,60,90,120,150, 
180,210,240,300,360,420,1440 min). Solution samples were withdrawn 
using the syringe and in-line filter assembly to prevent removal of particles 
during sample collection. Each solution sample was filtered through a 0.45pm 
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filter and stored in a refrigerator until all samples for the experiment had been 
collected. Samples were taken out of the refrigerator and brought to room 
temperature prior to analysis using the HPLC method described below. 
Methodology for protein detection 
The separation of biological macromolecules such as proteins from aqueous 
solution is achieved by injecting a small quantity of the sample onto a 
chromatography column. Mobile phase is pumped through the column 
containing the stationary phase. The separation occurs within the column 
based on different affinities of the solutes with the column stationary phase. 
The solution. coming out of the column passes through a cell equipped with a 
detector e. g. a UV detector. The resulting chromatogram contains peaks 
corresponding to the elution of various analytes. The area under the peak 
may be used to calculate the concentration of the analyte by relating the area 
via a calibration curve obtained using pure samples of known concentrations. 
Initially, a size exclusion column, Aquagel OH-30 purchased from Polymer 
Laboratories (UK), was used to quantify albumin from buffer solution. 
Quantification of Lysozyme by SEC resulted in poor resolution hence, reverse 
phase HPLC was used for the separation and detection of both lysozyme and 
albumin. A linear solvent gradient starting with 2% A (ultrapure water 
containing 0.01 % trifluoroacetic acid (TFA)) and 98% B (acetonitrile containing 
0.01 % TFA) and linearly changing the composition to 80% A and 20% B over 
60 minutes was found to offer the best binary protein separation and peak 
resolution over a reasonable analysis time (-1 hr). 0.01% trifluoroacetic acid 
was added to both phases to introduce a source of protons. Mobile phase 
flow rate was selected to give the best peak shape, and the column 
temperature was set to 35'C. A wavelength scan of single protein in buffer 
solution (limit of detection of lysozyme was 2 mg/I and HSA 3 mg/I) was used 
to decide the detection wavelength (X). 
The following is a summary of the HPLC method used for the work. 
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Column type: Supelco C18 reverse phase column 
Mobile phase flow rate :1 ml/min 
Solvent A: Ultrapure water containing 0.01 % TFA 
Solvent B: Acetonitrile containing 0.01 % TFA 
Gradient profile : 98% A and 2% B to 20% A and 80% B, over 60mins, 
followed by a step change back to 98% A and 2% B with an equilibration time 
of 1 Omins before the next sample was injected into the column. 
Injection volume : depending on concentration (20 -100µI) 
Column temp : 35'C. 
Detection wavelength, 230nm for Albumin, 280nm for Lysozyme. 
Figure 3.5 shows results of a typical calibration obtained by making serial 
dilutions from a concentrated stock solution containing 1 g/l of human serum 
albumin in '10 mM Hopes buffer. Each sample was injected 5 times and the 
mean and standard deviation (error bars) values were evaluated (these are 
included in Figure 3.5). 
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Figure 3.5. Calibration data for human serum albumin measured on a 
reverse phase C18 column; detection wavelength 230nm, limit of detection 
3mg/l.. 
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Figure 3.6 presents sample calibration data for lysozyme in 0.1 M Hepes buffer 
solution obtained in the same way as described previously for albumin. 
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Figure 3.6. Calibration curve for Lysozyme measured on a C18 column at 
280nm, limit of detection 2mg/1.. 
3.1.2 Detection of Beta2-microglobulin and 
Albumin from concentrated peritoneal dialysis fluid. 
Although HPLC offers a good method for quantifying marker proteins from 
simple synthetic protein solutions, it is not possible to measure single solutes 
from a highly complex biological fluid such as peritoneal dialysis fluid 
containing many unknown solute species. 
There are a multitude of highly selective enzyme based immunoassay 
techniques available. Although some generic principles run through all the 
techniques the precise protocols for each immunoassay may be slightly 
different. 
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A two site sandwich immunoassay was used for the detection of human 
serum albumin and ß2-microglobulin from concentrated peritoneal dialysis 
fluid. The basic method is to immobilise a capture antibody on to a solid 
phase (usually the microplate wall) and then allow the sample solution to 
come into contact with the immobilised antibody. The equilibrium portioning of 
protein in solution and immobilised antibody is governed by the mass action 
law. After equilibration, a second antibody is attached to the bound target 
molecule and subsequently a molecule is attached to this which is capable of 
having an enzymatic effect on the substrate solution (a colour change) which 
is added in the next step. The colour intensity created is related to the 
quantity of the bound target molecule which is measured. Due to the fact two 
antibodies are used to bind to a single molecule the sandwich type assay is 
extremely specific. A more detailed explanation of the procedure is given in 
Figure 3.7 below. 
The following is a generic overview of the sandwich ELISA technique (to be 
read in conjunction with Figure 3.7). 
A capture antibody (in red) was added to each of the wells and incubated for a 
period of time depending on the capture antibody used (20 min - overnight) 
(1). This time allowed non-specific adsorption of the capture antibody on to 
the surface of the microplate walls. 
The capture antibody solution was removed and the microplates wells were 
rinsed with a washing buffer. This process removed any unbound capture 
antibody solution but did not remove the immobilised capture antibody 
molecules adsorbed (bound) to the microplate wall (2). 
A blocking solution (shown in orange (3)) was added to the microplate wells. 
The role of a blocking agent present in this solution was to non-specifically 
adsorb to the remaining wall area i. e. sites not already taken-up by the 
capture antibody molecules, This is an important step that ensures that the 
molecules from subsequent steps do not adsorb onto the microplate surface 
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and thus affect results. The system was then left for a period of time to allow 
adsorption to take place and equilibrate. 
The blocking solution was removed and the microplate wells were rinsed with 
a washing buffer. Again, this ensured the bulk solution was removed 
(unbound molecules), whilst not removing the molecules adsorbed to plate 
surface (4). 
This step involved the addition of the standard (known concentration of protein 
in buffer solution) or the sample (containing the analyte i. e. unknown 
concentration of protein in buffer solution) followed by an incubation period 
(5). The protein attaches specifically to the antibody previously adsorbed to 
the plate surface. 
Another wash step was carried out to remove the bulk solution from the 
microplate wells (6). 
The next step in the process was the introduction of a detection antibody in 
buffer solution (shown in green in frame (7)). The antibody binds to the target 
molecule thus forming a sandwich. The binding process is extremely specific; 
precise details of cross reactivity may be found in the data sheets provided by 
the manufacturer of the ELISA kit. 
A wash phase ensured the removal of all unbound molecules(8). 
A solution containing the enzyme Horseradish peroxidase (HRP) (shown in 
black in frame 9) was added to the microplate wells. The incubation time 
required for HRP to bind to the detection antibody is dependent on the age of 
the kit, the molecules being studied and atmospheric conditions. HRP 
enzyme or conjugates are of little value on their own; its presence is made 
visible using a substrate that when oxidized by HRP using hydrogen peroxide 
as the oxidizing agent, yields a characteristic colour change that is detectable 
by a spectrophotometer. Some ELISA kits use a HRP conjugate system that 
includes the detection antibody hereby eliminating the previous 2 steps. 
A wash step was used to remove all unbound molecules (10). 
The next step was to add the substrate solution which is clear when added, 
but upon oxidation by HRP forms a coloured product (11). Due to the high 
turnover rate of HRP strong signals in a relatively short time are made 
possible. The colour intensity produced is in theory directly proportional to the 
amount of analyte bound to the microplate well. 
-78- 
Chapter 3 Protein adsorption studies 
The reaction which occurs in step 8 can be "stopped" by adding a weak acidic 
solution (12). The intensity of the colour produced was then read at an 
appropriate wavelength (450nm for HRP systems) 
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Figure 3.7. Schematic diagram illustrating the various steps used to perform a 
sandwich ELISA. 
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ELISA method for the detection of Human Serum Albumin 
Although ELISA's offer a suitable means of quantifying specific molecules 
they often require a degree of method development to maximise sensitivity. 
The albumin ELISA kit was purchased from R&D systems, UK. Initially, the kit 
instructions suggested a capture antibody concentration of 1: 50,000 but when 
the kit was used at this concentration, saturation of the spectrophotometer 
detector occurred By diluting the capture antibody concentration to 
1: 150,000 the sensitivity of the assay to discern albumin concentrations over a 
wider concentration range was improved, the signal intensity however was 
weak. Increasing the incubation time from 20 min to 25 min, amplified the 
signal (results are presented in Figure 3.8). Samples from adsorption 
experiments were diluted if the albumin concentration in the samples was 
greater than the detection range of the ELISA kit. 
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Figure 3.8 Results of albumin ELISA method development showing effects of 
varying capture antibody concentration and incubation time. 
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ELISA method for the detection of Beta2-Microglobulin 
Beta2-microglobulin ELISA kits were purchased from BioSupply UK and 
required no optimisation prior to use. The kit included antibody precoated 
wells. All solution samples were diluted to ensure the concentration was 
within the detectable range of the kit (measurable concentration range 0.2 - 12 
Ng/I). 
3.1.3 Mass transfer limitations on protein 
adsorption dynamics: Influence of film boundary 
layer. 
The effect of turbulence in the bulk of the fluid (influenced by the stirrer 
agitation rate) and the effect this has on the reduction of the stagnant film 
boundary layer surrounding the adsorbent particle was studied. This was 
accomplished by studying the adsorption kinetics of a single protein (lysozyme 
or albumin) in buffer solution on a fixed particle size fraction of adsorbent 
material. A number of experiments were carried out under identical conditions 
(15g of adsorbent contacting 0.51 of single protein Hepes buffered solution) 
except for each experiment a different stirrer speed was used. As the 
agitation rate was increased, it was possible to study the effect of external 
mixing conditions on the mass transfer coefficient. If the external film 
boundary layer surrounding the particle has an appreciable affect on mass 
transfer of MM's its effect on the uptake kinetics would become apparent as a 
consequence of the controlled experimental conditions., The bulk solution 
concentration change during adsorption experiments was followed for a time 
period of 24 h. A low agitation rate (lowest stirrer speed required to just 
suspend particles) of 84 rpm, an intermediate agitation rate of 700rpm and a 
high agitation rate of 826 rpm (highest stirrer speed possible whilst avoiding 
vortex formation) were selected for the study. Particle size fractions between 
500-710 µm of XAD4 and CW1 copolymer samples were prepared (by sieving 
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the appropriate size fraction from a bulk sample) for the adsorption of the 
single protein lysozyme from OA M Hepes buffer solution. A 710-850 Nm 
fraction was used for the adsorption of albumin on XAD4.15g of dry 
adsorbent was contacted with 0.51 of protein solution ((commercial blood 
purification columns typically contain between 150 g and 300 g of adsorbent 
material to treat 5L of blood). Thus for the batch adsorption experiments a 
similar solid / liquid ratio was initially used. Physiological concentration of 
lysozyme (surrogate MM marker) was used for this study. In addition albumin 
at 200 mg/I was used to ensure the resulting change in concentration could be 
detected. 
3.1.4 Intraparticle mass transfer effects on 
protein adsorption dynamics: influence of particle 
size. 
Using the same copolymer adsorbent, but sieving the sample to obtain tight 
particle size fractions allowed the effect of particle size on the uptake kinetics 
of both albumin (initial concentration 200mg/I) and lysozyme (initial 
concentration 100mg/I) to be studied. , 
Experiments were performed using a 
single solute dissolved in O. 1 M Hepes buffer solution. For all experiments, the 
mass of adsorbent (15g), the initial concentration of protein and the stirrer 
speed (826 rpm) were kept constant. The stirrer speed was set to the highest 
value as this reduces external mass transfer resistance to solute diffusion. A 
reduction in the adsorbent particle size affects the diffusion path length. If 
intraparticle diffusion is the rate limiting step for the adsorption of the protein 
within the adsorbent bead then reducing the particle size should have a 
marked effect on the adsorption kinetics. As the diffusion path length is 
related to the radius of the particle whilst the time for diffusion is proportional 
to r2, the time for the solute to diffuse from outside the particle to the centre of 
the particle is four times less when the particle size is halved. 
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Particle sizes fractions of the adsorbent copolymer XAD4 were prepared as 
follows, a crushed sample (particle size < 300 µm), 500-710 , um and 710-850 
pm. CW1 fractions studied were 300-500 Nm, 500-710 pm, and 710-850 pm. 
3.1.5 Adsorption dynamics in a binary solute 
system 
Single solute adsorption experiments permit analysis of the effect of the 
adsorbent pore structure on the rate of adsorption of MM's under controlled 
conditions. Also, the maximum adsorption capacity of the solute may be 
evaluated and correlated with the available adsorbent area. However, blood 
is a highly complex mixture of molecules and the presence of other molecules 
may affect the uptake of specific solutes that are marker MM's (e. g. P2-M) due 
to competitive adsorption effects. Albumin is present in blood at 
concentrations around 40g/I and is the most prevalent blood protein. Its 
presence at concentrations several orders of magnitude greater; ß2-M (renal 
blood concentration typically - 35 mg/I), may potentially result in swamping of 
the adsorbent surface resulting in a marked reduction in the uptake capacity 
of the adsorbent for the target MMs. 
In order to study these effects, solutions containing 100 mg/I of lysozyme and 
either no albumin or 200mg/I albumin or 1000 mg/I of albumin (approximately 
equal number of albumin molecules to lysozyme) were prepared in OA M 
Hepes buffer. Adsorption experiments using the binary solute system were 
conducted using CW1 and XAD4. CW1 was synthesised with a tailored 
mesopore structure with the aim to size exclude proteins such as albumin. 
The DFT data presented in chapter 2 suggests CW1 possesses less that 1 
m2/g of accessible surface area for albumin based upon size exclusion 
chromatography. XAD4 has larger mesopores and so may allow albumin 
molecules access to surface area within the adsorbent bead (-. 40 m2/g). 15 g 
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of the 500-710 µm fractions of each of the adsorbents were added to the 
reactor and experiments were carried out under the conditions described 
above. 
3.1.6 Multicomponent protein adsorption 
dynamics from concentrated peritoneal dialysis fluid 
Single solute adsorption experiments provide useful data for the 
characterisation of the adsorption potential (capacity and kinetics) of 
adsorbents for use in a haemoperfusion device. The introduction of a binary 
system is a controlled step-up in complexity offering insight into the effects of 
competitive adsorption. Blood is an extremely complicated fluid which 
contains a plethora of molecules (unknown composition) and it is difficult to 
know how their presence will affect the adsorption uptake of MM's in any 
potential adsorption device. In vitro experiments using biological fluids (e. g. 
readily available waste peritoneal dialysis fluid) is an economical and 
accessible means to measure the uptake of clinically relevant molecules on 
any proposed adsorbent material. 
Although blood would naturally be the fluid of choice, its use in vitro presents 
a number of experimental difficulties. Obtaining sufficient volumes of blood 
(0.51 per adsorption experiment) is costly. Associated problems such as 
addition of blood anticoagulants, changes in blood composition arising from 
stressing blood cells outside the body for long periods of time (several hours 
in a stirred tank) pose formidable challenges to the experimentalist. . 
However, peritoneal dialysis (PD) fluid offers ready access to a highly 
complex multicomponent mixture of uraemic toxins and human serum albumin 
but is inherently easier to use in vitro. Adsorption studies using PD fluid was 
considered a suitable precursor to future adsorption experiments with whole 
blood. 
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As previously stated (Chapter 1), beta2-microglobulin (ß2-M) is a clinical 
marker often reported in scientific literature, its elevated blood concentration 
(typically - 35 mg/I) in patients on long term renal dialysis is often correlated 
with their poor health. Therefore, adsorption performance of the novel 
mesoporous copolymers in terms of effectiveness in reducing ß2-M 
concentration in PD fluid was considered worthy of study. 
The concentration of ß2-M in peritoneal dialysis fluid was unknown but 
expected to be below the expected serum level of - 35mg/I in renal dialysis 
patients. Therefore a pilot study was undertaken to sample typical peritoneal 
dialysis fluid ß2-M concentrations and develop a methodology for 
concentrating the solute from the fluid to increase the ß2-M concentration to- 
35 mg/I. 
The concentration of 02-M in PD fluid was measured using ELISA (method 
outlined above) in its "as received" state and following a series of 
concentrations obtained using an ultrafiltration stirred cell device (see Figure 
3.9 showing a schematic diagram of the stirred cell apparatus). Pressure in 
the cell was provided by a regulated nitrogen gas supply (A), since the use of 
compressed air could induce undesirable pH shifts. The magnetic stirrer (B) 
provided agitation within the cell and reduced concentration polarisation 
effects enhancing the filtration rate. The nitrogen supply was connected to a 
ball valve (C) and a pressure regulator (D) as well as a pressure gauge (E) in 
order to allow for controlled pressure adjustments. Retentate samples were 
taken after the volume of feed had been reduced to -6% of the original 
volume thereby achieving a concentration of ß2-M by a factor of 16. 
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Figure 3.9. Stirred cell ultrafiltration apparatus used to concentrate peritoneal 
dialysis fluid. 
Preliminary trials used a 48mm diameter 5kDa Microdyne-Nadir ultrafiltation 
membrane. Initial measured concentration of ß2-M was just below 2mg/I and 
by concentrating by a factor of 16, a final concentration of approximately 
29mg/I was achieved (see Table 3.1) 
Table 3.1 Concentration of PD fluid using a 48mm diameter 5kDa 
ultrafiltration membrane. 
Membrane Concentration B2-M Albumin 
cut off factor concentration concentration (g/I) 
(mg/I) 
5kDa 
------------ 
0 1.8 <2 
5kDa 2 3.6 rid 
5kDa 4 7.5 nýi 
5kDa 8 14.5 nci 
5kDa 16 28.9 26 
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Complete retention of ß2-M by the 5kDa membrane was observed. However, 
due primarily to the small surface area available for filtration, the time required 
to achieve 16x concentration was not practical as 0.5L of concentrated fluid 
was required for each adsorption experiment. The use of a hollow fibre 
polysulfone haemodialysis membrane module (Fresenius F60) was tested due 
to the considerably larger surface area (-1.25 m2 per module). However, the 
large molecular weight cut-off of the dialyser (typically -50kDa) meant the 
required concentration factor was not achievable using this device. The work 
indicated the potential of such a system as the filtration rate was significantly 
higher. Therefore, a hollow fibre device incorporating membranes with a 
smaller molecular weight cut off (MWCO - 10kDa) was secured from 
Microdyne-Nadir GmbH (Germany) and used to concentrate ß2-M from PD 
fluid Prior to purchasing the 10kDa hollow fibre module, preliminary 
concentration experiments were conducted to verify that UF membranes with 
a MWCO of 10kDa were capable of concentrating ß2-M in PD fluid to the 
desired amount (-40 mg/I). Table 3.2 tabulates the results of the experiments 
using a different patient PD sample with a 10kDa cut-off flat sheet Microdyne- 
Nadir membrane in the stirred cell. The results showed that concentration of 
ß2-M was possible whilst maintaining an acceptable filtration flux. 
Table 3.2. Concentration of PD fluid attempt using Microdyne-Nadir 10kDa 
MWCO hollow fibre membrane module. 
Membrane 
Cut Off 
10kDa 
Concentration 
Factor 
0 
B2-M 
Concentration 
(mg/I) 
2.5 
Albumin 
Concentration (g/I) 
<-2 
10kDa 2 5.4 na 
10kDa 4 10.6 na 
10kDa 8 20 na 
10kDa 16 40.3 25 
The 10kDa hollow fibre membrane unit was used to concentrate the PD fluid 
using the experimental Ultrafiltration rig shown in Figure 3.10. Based on the 
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------------ 
pilot studies typical initial concentrations of ß2-M in PD fluid were of the order 
of -2 mg/I. Therefore, starting with an initial pooled volume of 10L of PD fluid 
volume reduction to 0.5L resulted in ßi2-M concentration of 40mg/I . 
Retentate 
Hollow fibre 
dialyser 
Peristaltic 
F pump 
Feed Permeate 
solution tank 
Figure 3.10 Schematic diagram of experimental hollow fibre ultra filtration rig 
used for concentrating the peritoneal dialysis fluid. 
Once the peritoneal dialysis fluid had been concentrated, the solution was 
added to the stirred tank batch reactor and the adsorption experiment 
conducted following the methodology described earlier. 0.5g of adsorbent 
XAD4 was contacted with 0.51 of concentrated PD fluid and 0.5g of CW4 was 
contacted with 0.51 of concentrated PD. Adsorption experiments were carried 
out under identical conditions. Solution samples were withdrawn from the 
batch reactor over a period of 7h and the samples were analysed using the 
ELISA method (described previously). 
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3.1.7 Modelling batch adsorption dynamics - 
irreversible adsorption 
Characterising adsorbents in terms of adsorption capacity and adsorption 
kinetics is possible experimentally using a batch stirred tank reactor. The time 
" to equilibrate/saturate the adsorbent with protein diffusing from the bulk 
solution to the interior of the adsorbent particle depends on the particle size of 
the adsorbent beads and the effective diffusivity of the protein in the interior 
of the adsorbent. A small number of experiments under carefully controlled 
conditions coupled with use of a mathematical model incorporating the 
necessary physics of the process allows parameter estimation of the effective 
diffusivity for the adsorbent-protein system. Subsequently, having 
experimentally validated the predictive capability of each adsorbent, the model 
may be used as tool to inform the design of a haemoperfusion device. This 
approach has a number of merits both in terms of cost and time spent 
investigating a large combination of experimental parameters. Modelling 
offers insight into the effect of the physical properties of the adsorbent and 
helps in highlighting the rate liming parameters. By quantifying the effects of 
pore structure (eg, tortuosity & porosity), particle size and boundary layer 
reduction in terms of an effective diffusivity, comparison and selection of 
different adsorbents may be made more rationally. 
The case of an irreversible adsorption isotherm has been modelled previously 
by Suzuki et al, (1973) and was used by the researchers to estimate the 
intraparticle diffusivities of organic solutes within carbon adsorbents. A 
detailed account of the model development is provided in the following 
section. For the development of the model the following assumptions were 
made :- 
" Adsorption was considered permanent and irreversible. 
" Rectangular isotherm; strong adsorption, limited by capacity. 
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" The particles were considered homogeneous. 
" Any accumulation of solute within the liquid phase within the particle 
was considered negligible. 
These assumptions result in a case where the adsorption process was 
considered to be taking place only at the adsorption front (r = ri), (see Figure 
3.11) where the concentration of the liquid phase was said to be zero. Within 
the shell (ri <rs R) the adsorbent was considered to be saturated by the 
solute. The rate at which the adsorption front moved towards the centre of the 
particle was considered to be dictated by the rate of adsorption of diffusion of 
the solute in the liquid phase through the shell. Experimental design 
undertaken during this study was such that the final concentration (C; n}) was 
reasonably different from zero to ensure operation on the linear part of the 
plot. Consideration of the initial solute concentration (Co) was an important 
experimental consideration to ensure that for a given solid-liquid ratio, the final 
solution concentration was non-zero. Therefore low quantities of adsorbent 
were required to satisfy this criterion. 
Adsorbent r. r. r+ dr 
particle 
r=0 dv 
Figure 3.11. Schematic diagram illustrating a shell balance used for the 
diffusion model. 
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From the basic diffusion equation (Fick's Law): 
_4 
ý2 aäA) 
=D gLp(1-E)+ä CW 
q 
J= -Dý Dr 
DZ a 
rz 
ac 
= Lp(1-e) 
äq 
+e 
q ar är 
For irreversible adsorption: 
=0 for r1: 5 r _R 
äq 
=0 and at 
Therefore :a r2 
aC 
=0 
Integrate once, r2 
aC 
_ A(t) ör 
Atr=R, ac 
ar ar 
r=R 
De 
äý 
r=R 
= k, C - c) 
kf = m/s (film mass transfer coefficient) 
Introduce the following into the above equation 
(Equation 3.2) 
(Equation 3.3) 
(Equation 3.4) 
(Equation 3.5) 
(Equation 3.6) 
(Equation 3.7) 
(Equation 3.8) 
(Equation 3.9) 
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I/3 
rc- co (Equation 3.10) 
R Co - C 
By eliminating C, the following reduction is reached 
- 
dc 
_ 
De Co 1X Bi }{ct+a3J_} 
(Equation 3.11) dt R2 pqo 1+a3 1+Bi(1i(-1) V 
113 
CC- 
Where Bi =K 
xR 
and a= 
. 
Saturation concentration =. Co 
qxM 
v 
(Equation 3.12 
This can then be solved and rearranged to obtain 
-d(D _ 
DeBi JýC 
+ q*MP 
[ý3 
-1} dt R2(1 - e)Lpq * Bi + c(1- Bi) 
°V 
(Equation 3.13) 
A full derivation can be found in appendix 2 
The 1st order differential equation was solved using Matlab software (Version 
7.0). The value of the fitting parameter (the effective diffusivity) was varied 
using the software to minimise the sum of the squares error between the 
experimental data and the model prediction over the first 24h (explanation 
given below) and the resulting effective diffusivity value reported to 2s. f. 
Results reported below are normalised concentration (C(t) / Co) plotted 
against time. 
Experimental data requirements 
The model may be used to predict the effects of changing adsorbent 
parameters e. g. amount of adsorbent, effect of variation of particle size, and 
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external agitation rates etc. The results of the simulation work presented 
below offer insight into the affect of pore structure on the adsorption kinetics of 
both albumin and lysozyme. Before the model was used as a predictive tool, 
preliminary experiments were undertaken to obtain the required parameters 
used in the subsequent simulation work. The protein adsorption capacity 
value (q*) was required along with material characterisation data including 
solid density, porosity and mean particle size. An estimate of the value of D. 
was obtained using the following equation: 
De = ex- (Equation 3.14) 
The value of 4 is a tortuosity factor, as used by Suzuki, (1974) 
3.1.8 Estimation of protein effective diffusivities 
within nanoporous copolymer adsorbents. 
The effective diffusivity is a parameter that is unique to each solute / 
adsorbent pair. Therefore by directly comparing the effective diffusivities for 
each solute within the different materials it was possible to begin to quantify 
the effects of the changing pore structure on the protein adsorption dynamics. 
Equilibrium uptake capacity data was required for the model. Physiological 
concentrations (-. 50 mg/I) of the uraemic toxins were found not to be suitable 
given the slow uptake kinetics experienced (solute diffusion flux is proportional 
to the concentration gradient between the bulk solution and the particle 
interior) in preliminary work resulting in equilibrium not being reached for 
hundreds of hours. Therefore, higher initial solute concentrations were used 
to increase the concentration gradient between the bulk solution and the 
adsorbent interior. The experimental methodology used was the same as 
described previously. The mass of adsorbent used was such that upon 
achieving equilibrium, measurable concentration of residual protein was still 
present in solution. Each experiment was carried out following the 
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methodology described in section 3.1.1 following samples taken within the first 
24h, one sample was subsequently taken every 24 hours until no further 
change in solution concentration was measured over a 24h period. All 
samples were measured using the HPLC method described previously. The 
resulting change in concentration was then converted into a normalised 
concentration (C(t)/Co) and plotted against time. The model predictions were 
overlayed on the experimental data and the best fit value of the effective 
diffusivity (De) was determined. 
Capacity experiments were conducted with XAD4, CW1 and CW4 with both 
lysozyme and albumin in single solute systems. All these experiments were 
carried out at a stirrer speed of (700rpm) to minimise effects of external mass 
transfer resistance. After initial experiments it was clear that protein 
adsorption capacities were considerably higher than those quoted in literature 
by Davankov et al, (2000) and Winchester et al, (2004). Subsequently, 0.5g 
of adsorbent was used and this resulted in an equilibrium uptake value (q*) 
being evaluated where the initial solute concentration, Co was sufficiently 
different from the final solute concentration, Cof to allow quantification of q* 
with confidence. 
3.1.9 Influence of stirrer speed on protein uptake 
kinetics and evaluation of Blot number. 
In order to quantify the effect of external mixing on the convective mass 
transfer of solute from the bulk to the surface of the particle the magnitude of 
the dimensionless Biot number (Bi) was evaluated using an empirical 
correlation from literature to obtain the magnitude of the convective mass 
transfer coefficient. Two experiments were undertaken, one at the low 
agitation speed (84rpm) and the other at the intermediate agitation speed 
(700rpm). 0.5g of XAD4 was contacted with 0.51 of single protein lysozyme in 
0.1 M Hepes buffer solution. 
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The following mass transfer correlation by Kulov et al. (1983) was used to 
evaluate the magnitude of the film mass transfer coefficient: 
A=0.267 x ScO. 25 x Re0.75x N0,25 Xd - (Equation 3.15) °° (V x di )o. zs 
Where: 
Sc -=Schmidt number; Sc =D (Equation 3.16) Pv 
The rotational Reynolds number (Re) for the agitated tank may be defined as 
follows: 
pxNxD, 2 Re = 
p 
(Equation 3.17) 
The dimensionless Sherwood number is a measure of convective mass 
transport to diffusive mass transport. 
Sh =k fd` dv 
(Equation 3.18) 
The film mass transfer coefficient was evaluated by multiplying the Sherwood 
number with the bulk diffusivity of the solute and divided by the tank diameter. 
kf= Sh x 
D° 
(Equation 3.19) 
The film mass transfer coefficient can then be used to evaluate the Biot 
number (Bi) as follows: 
kfR 
Bi = De (Equation 3.20) 
For Biot numbers exceeding 100, the film boundary layer effect may be 
considered negligible (shown in Figure 3. ). Therefore if the Biot number for 
-96- 
Chapter 3 Protein adsorption studies 
each of the adsorption experiments exceeds this value, the external mass 
transfer resistance may be ignored. If the magnitude of the effective diffusivity 
is known, simulations may be undertaken to show the influence of the Bi on 
the uptake kinetics. Bi values of 1,2,5,10,20,50,100 and 1000 were used 
and results are discussed later. 
3.1.10 Mass transfer effects on protein adsorption 
dynamics: modelling influence of particle size. 
In order to use the model to predict the effect of changing particle size, it was 
first necessary to complete experiments using the same adsorbent material 
and protein but varying only the particle size (thus keeping the effective 
diffusivity of the protein unchanged). If the effective diffusivity remains 
constant, any change in kinetics was due to the change in particle size. This 
may be presented by plotting the normalised concentration data for the 
various particle sizes on the same plot using a dimensionless time defined as 
z= 
DZt 
. By plotting the uptake 
data using dimensionless time the effect of 
rP 
particle size is essentially normalised. If the pore structure of the two particle 
sizes is the same, the plots should overlay. 
Two different mean particle sizes (28µm and 49µm) of CW4 were studied 
using an initial concentration of lysozyme of 600 mg/I. The stirrer speed was 
set at 700 rpm for the study to minimise the effect of film mass transfer 
resistance whist not causing excessive foaming. 
In addition to De parameter estimation from the experimental data, simulations 
were undertaken to show the effect of particle size (0.5,10,20,40,80,160, 
320,400 µm beads) on lysozyme uptake kinetics for CW4. 
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Table 3.4. Matrix of experiments undertaken to obtain data for parameter 
estimation. 
Adsorbent Protein 
Mean 
Particle 
Size (gm) 
Adsorbent Mass 
(g) 
Initial Conc 
(mg/I) 
Stirrer 
Speed 
(rpm) 
XAD4 HSA 478 5 3000 700 
XAD4 HSA 70 0.5 400 700 
XAD4 LYZ 165 0.5 400 700 
XAD4 LYZ 478 5 5000 700 
XAD4 LYZ 114 0.5 600 84 
CW1 HSA 197 22 500 700 
CW 1 LYZ 197 0.5 200 700 
CW4 HSA 28 3 600 700 
CW4 LYZ 28 0.5 600 700 
CW4 LYZ 49 0.5 600 700 
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3.2 Results and discussion 
3.2.1 Mass transfer effects on protein adsorption 
dynamics: Influence of film boundary layer. 
The effect of external mass transfer resistance was studied using lysozyme 
and the adsorbent XAD4 (Sauter mean particle size of 478 gm). The 
reduction in bulk solution concentration of lysozyme was used to evaluate the 
adsorption uptake value q(t) at any given time (using the mass balance 
equation 3.21 below) and this was normalised (on the basis of the protein 
uptake after 24h) and plotted against time. Thus data presented here as 
normalised uptake {q(t)/q(f)} represent the uptake of the protein at a given 
time point (q(t) = mg/g) compared with the uptake of the protein after 24h, q(f). 
Due to the low starting protein concentrations mimicking physiological 
concentrations of MMs (see Table 3.3 for details) and the low diffusivity values 
of proteins such as lysozyme (1 x 10"10 m2/s) and albumin (6.1 x 10'11 m2/s) 
the measured protein (lysozyme/albumin) uptake values q(t) after 24h for all 
samples were quite low and nowhere near the saturation uptake values 
(studied in detail and reported later in section 3.2.5. The solution 
concentrations after 24h were all very low (<4mg/I lysozyme for 
XAD4, <10mg/l lysozyme for CW1) showing that near complete removal of 
MM's from solution took place during this time period. 
R(t) _ 
(C -C)XV 
m 
(Equation 3.21) 
Figure 3.12 shows the uptake of lysozyme onto XAD4 in a 24 hour period 
minutes. The plot has reached a plateau due to near complete removal of 
lysozyme from solution. It is difficult to ascertain if any uptake rate changes 
are due to stirrer speed or a slightly different q(f) value. Figure 3.13 shows 
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the same data plotted as normalised q(t)/q(f) against time and the plot shows 
negligible differences. Examining the data over the initial 100 minutes as in 
Figure 3.14 shows little change between the 700rpm and 826rpm speeds. 
The 84rpm stirrer speed appears to demonstrate a slightly slower uptake over 
this time period. 
4- 
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Figure 3.12 Kinetic uptake of lysozyme expressed in terms of q(t)/time onto 
XAD4 (particle size range 500-710 , um); uptake data for different stirrer 
speeds, initial concentration of lysozyme : 100mg/l. 
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Figure 3.13. Kinetic uptake of lysozyme expressed in terms of q(t)/q(f) onto 
XAD4 (particle size range 500-710 , um); uptake data for different stirrer 
speeds, initial concentration of lysozyme : 100mg/l. 
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Figure 3.14 Kinetic uptake of lysozyme expressed in terms of q(t)lq(f) onto 
XAD4 (particle size range 500-710 , um); uptake 
data for different stirrer 
speeds over T= 0-100mins, initial concentration of lysozyme : 100mg/l. 
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Uptake of lysozyme onto CW1 (see Figure 3.15) within the first 400 minutes 
of the experiment, external agitation does appear to influence the uptake 
kinetics. Initial uptake of lysozyme at the two higher speeds seem similar, but 
at the slowest stirrer speed (84 rpm) there is a marked reduction in the 
adsorption rate of lysozyme. After 400 minutes, the two higher stirrer speeds 
exhibit similar values of lysozyme uptake by CW1. 
However, it would be expected that the two high speeds begin to overlap 
suggesting the boundary layer thickness is such that its impact on overall 
mass transfer is negligible. This can be seen in Figure 3.16 where the data is 
again plotted as normalised q(t)/q(f). From 400mins to 24hours the two 
higher stirrer speeds show similar uptake suggesting external mass transfer 
resistance is similar. 
The normalised uptake against time plot for the lowest stirrer speed exhibits a 
lower gradient up to 400 minutes suggesting a reduced uptake per unit time 
(see Figure 3.17). As the particle size and initial concentration are constant, 
the additional resistance to mass transfer could be a result of an increase in 
boundary layer thickness. However, after 400 minutes the kinetic uptake for 
all stirrer speeds is comparable for the two higher speeds and slightly reduced 
on the slowest speed suggesting a small increase in external mass transfer 
resistance. 
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Figure 3.15. Kinetic uptake of lysozyme expressed in terms of q(t)/time onto 
CW1 (particle size range 500-710 µm) at different stirrer speeds, initial 
concentration of lysozyme : 100mg/1. 
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Figure 3.17. Kinetic uptake of lysozyme expressed in terms of q(t)/q(f) onto 
CW1 (particle size range 500-710 pm); uptake data for different stirrer speeds 
over T= 0-400mins, initial concentration of lysozyme : 100mg/1. 
The effect on uptake of albumin onto XAD4 with varying stirrer speeds is 
proved difficult to quantify due to the small uptakes (q(f)= <2). After the 24h 
period, there was still around 150mg/I of albumin present in solution, however 
due to the slower diffusivity of this molecule, little uptake has occurred. 
Figure 3.18 shows q (t) against time over a 24h period. It suggests that there 
is little difference in uptake rates between the various stirrer speeds. The 
normalised data (Figure 3.19) demonstrates that in fact the 700rpm speed 
appears to exhibit the fastest kinetics over a time period of 0-400mins. Figure 
3. is the same data as the previous figure plotted over the time period of 0- 
400mins. Although the 700rpm appears to exhibit a reduction in kinetic 
uptake over this period, it is likely that this is experimental error due to the 
small changes in bulk concentration observed. 
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Figure 3.18. Kinetic uptake of albumin expressed in terms of q(t)/time onto 
XAD4 (particle size range 500-710 , um) at different stirrer speeds. , initial 
concentration of albumin : 200mg/1. 
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Figure 3.19. Kinetic uptake of albumin expressed in terms of q(t)/q(f) onto 
XAD4 (particle size range 500-710 , um); uptake data for different stirrer 
speeds over T= 0-1440mins, initial concentration of albumin : 200mg/1. 
- 105 - 
o  
0 200 400 600 800 1000 1200 1400 
Time (mins) 
Chapter 3 Protein adsorption studies 
1 
0.9 
0.8 
0.7 
a 
0.6 f 
V 0.5- 
Af 
CO 0.4A f  
Efff  
Z 0.3 f 
f. fi   0.2 f! A 
0.1   f 
826rpm   700rpm f 84rpm 
0 
0 50 100 150 200 250 300 350 400 
Time (mins) 
Figure 3.20. Kinetic uptake of albumin expressed in terms of q(t)/q(f) onto 
XAD4 (particle size range 500-710 pm); uptake data for different stirrer 
speeds over T= 0-400mins, initial concentration of albumin 200mg/l. 
Albumin uptake onto CW1 very low (-0.6mg/g after 24 hours) (See Figure 
3.21). Due to such low uptake values over this period, it wasn't possible to 
identify if agitation rates affected uptake kinetics using this methodology. The 
data does suggest that CW1 may be excluding albumin from its internal pore 
structure. 
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Figure 3.21. Kinetic uptake of albumin expressed in terms of q(t)/q(f) onto 
CW1 (particle size range 500-710 pm); uptake data for different stirrer speeds 
over T= 0-400mins, initial concentration of albumin 200mg/1. 
In summary, the influence of external agitation on protein uptake kinetics 
appears to be negligible for XAD4 with both marker proteins. Lysozyme 
uptake onto CW1 showed some differences in terms of uptake rate when 
agitation rate was varied. The particle size of CW1 (Sauter mean 513pm) 
was larger than the XAD4 (Sauter mean 478 pm) and the expected hindrance 
to internal mass transfer of CW1 was likely to be higher the XAD4 (due to the 
pore structure identified in chapter 2). We would expect therefore the 
influence of external mass transfer effects would be less in CW1 than XAD4. 
The result could be due to error associated to the small amount of uptake 
measured over the 24hour period and the fact q(f) may be greatly different 
from q*. At the physiological concentrations used, in conjunction with the low 
diffusivities of the solutes, it may be difficult to identify clearly external mass 
transfer effects. The modelling section (presented later in this chapter) 
approaches the issue of external mass transfer using a modified approach 
and offers additional insight into the influences of boundary layer thickness in 
this system. 
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3.2.2 Mass transfer effects on protein adsorption 
kinetics: influence of particle size. 
The particle size of the adsorbent affects the path length for solute diffusion 
and therefore it is an important parameter that may be varied by the engineer 
in designing a haemoperfusion device. Experiments were undertaken using 
different particle size fractions of the same material in order to identify the 
effect of changing the particle size on the protein adsorption kinetics over a 
clinically relevant time period (typically -6h with a final adsorption data point 
at 24 h). 
Uptake q(t) of lysozyme (initial concentration 100mg/I) over a time scale of 0- 
400 mins with three different particle size fractions is shown in Figure 3.22. 
The q(f) value is not a q* since the amount of adsorbent used in these 
experiments (15g) is such that even if all the protein is removed there is still 
available area for further adsorption. 
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Figure 3.22. Kinetic uptake of lysozyme expressed in terms of q(t) against 
time onto XAD4 (particle size values show are Sauter means, stirrer speed set 
to 826rpm); effects of changing particle size; T= 0- 1440mins, initial 
concentration of lysozyme 100mg/1. 
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Figure 3.23 shows the normalised uptake {q(t)/q(f)} where q(f) is the 
adsorption uptake value after 24 h, of lysozyme onto different size fractions of 
XAD4 (the stirrer speed used was 826 rpm to minimise external mass transfer 
effects). The largest particle size (Sauter mean 716 µm) showed slightly 
slower kinetics when compared with the 478 µm sample. However, there was 
a marked difference in the lysozyme adsorption kinetics (significantly faster) 
displayed by the crushed (Sauter mean 163 gm) sample. The crushed 
sample removed all the lysozyme from the solution in less than 20 minutes, 
whereas the larger sized fractions took in excess of 300 minutes. 
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Figure 3.23. Kinetic uptake of lysozyme expressed in terms of normalised 
q(t)/q(f) onto XAD4 (particle size values show are Sauter means, stirrer speed 
set to 826rpm); effects of changing particle size; T= 0- 400mins, initial 
concentration of lysozyme : 100mg/l. 
The reader is referred to chapter 2 where characterisation of the pore 
structure of the different size fractions of XAD4 showed no real differences. 
The observed differences in the lysozyme adsorption kinetics reported here 
are due exclusively to the increased path length for diffusion in the larger 
particles. This is clearly shown by rescaling the experimental adsorption data 
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by defining a dimensionless time ", r" that accounts for the effect of particle size 
on the observed adsorption kinetics. Since the time for solute diffusion within 
the particle is proportional to the square of the particle radius, time may be 
scaled by the square of the radius of the particle, thus, a dimensionless time 
"i" may be defined as: 
Det 
Vr2 (Equation 3.22) 
Upon rescaling of the XAD4 lysozyme adsorption data to account for the 
increased path length for diffusion in the larger sized particles, all the data fell 
on a single curve (see Figure 3.24) These results support data obtained from 
the nitrogen porosimetry measurements (reported in chapter 2) that indicated 
that XAD4 particles of various sizes had similar internal pore structures. 
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Figure 3.24. Kinetic uptake of lysozyme expressed in terms of normalised 
q(t)/q(f) onto XAD4 plotted against dimensionless time "r "(particle size values 
show are Sauter means, stirrer speed set to 826rpm) , initial concentration of 
lysozyme : 100mg/!. 
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Lysozyme adsorption kinetics on CW1 for different particle sizes (430 µm, 513 
gm and 780 µm, using a high stirrer speed, 826 rpm, to minimise external 
particle film diffusion effects) is show in Figure 3.25. 
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Figure 3.25. Kinetic uptake of lysozyme expressed in terms of q(t) against 
time onto CW1 (particle size values show are Sauter means, stirrer speed set 
to 826rpm); effects of changing particle size; T= 0- 1440mins, initial 
concentration of lysozyme : 100mg/1. 
The largest sized fraction (Sauter mean size 7804m) showed considerably 
slower lysozyme uptake and after 3h was approximately 20% lower in 
comparison with the 430 gm sized fraction. The adsorption kinetics of 
lysozyme onto CW1 was noticeably slower in comparison with XAD4 
(compare data in Figure 3.22 and Figure 3.25). 
Both of these experiments were conducted under the same conditions and it 
is apparent that for similar size fraction e. g. 478µm (XAD4) and 430µm (M) 
after 3h the uptake of lysozyme onto XAD4 is greater than M. This is likely 
to be due to the more open pore structure of XAD4 as reported in chapter 2. 
The normalised uptake of lysozyme onto different size fractions of CW1 is 
shown in Figure 3.26. Again the largest particle size exhibits a noticeable 
difference in uptake kinetics compared to the smaller sizes. The 513p fraction 
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is slightly slower that the 430,1 fraction but the differences are small due to the 
relatively similar sizes. 
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Figure 3.26. Kinetic uptake of lysozyme expressed in terms of normalised 
q(t)/q(f) onto CW1 plotted against time (particle size values show are Sauter 
means, stirrer speed set to 826rpm); effects of changing particle size; T= 0- 
400mins, initial concentration of lysozyme : 100mg/!. 
Upon rescaling of the adsorption data, all the data fell on a single curve. 
Figure 3.27 shows the dimensionless time plot for the uptake of lysozyme on 
CW1 suggesting that the internal pore structure of the adsorbents is the same 
for all particle sizes studied. 
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Figure 3.27. Kinetic uptake of lysozyme expressed in terms of normalised 
q(t)/q(f) onto CW1 plotted against dimensionless time "r "(particle size values 
show are Sauter means, stirrer speed set to 826rpm, initial concentration of 
lysozyme : 100mg/1. 
Comparison of the lysozyme adsorption data for XAD4 and CW1 suggested 
that the uptake kinetics for CW1 appears considerably slower in comparison 
with XAD4. The reduced kinetic uptake may be attributed to the tighter 
mesopore structure of CW 1 manifesting in a reduction in the magnitude of the 
effective diffusivity of the solute within the adsorbent particle (discussed in 
detail later in section 3.2.5. ) 
Albumin adsorption kinetic data for different size fractions of XAD4 (Sauter 
mean values 400 µm and 716 µm using stirrer speed 826 rpm) demonstrated 
notably slower adsorption of albumin (see Figure 3.28) The effect of changing 
particle size was more apparent with albumin than lysozyme because albumin 
has a lower diffusivity in solution due to its larger molecular size. 
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Figure 3.28. Kinetic uptake of albumin expressed in terms of q(t) against time 
onto XAD4 (particle size values show are Sauter means, stirrer speed set to 
826rpm); effects of changing particle size; T=0- 1440mins. q(f) for 400µ 
fraction was 3.17mg/g and 2mg/g for the 716µ fraction. , initial concentration 
of Albumin : 200mg/l. 
When the data is normalised (q(t)/q(f)) and plotted against dimensionless time 
the data begins to fall on a single curve suggesting that again internal pore 
structure appears unaffected by particle size (see Figure 3.29). 
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Figure 3.29. Kinetic uptake of albumin expressed in terms of normalised 
q(t)/q(f) onto Cwi plotted against dimensionless time "z "(particle size values 
show are Sauter means, stirrer speed set to 826rpm), initial concentration of 
Albumin : 200mg/1. 
Albumin adsorption on two different size fractions of CW1 (513µm and 
780µm) was also studied (see Figure 3.30). However, due to the low total 
adsorption capacity for albumin (- 0.5 mg/g over 24h) on this material, any 
differences in uptake kinetics with varying particle size could not be 
distinguished experimentally (possibly due to most of the adsorption taking 
place on the external surface of the adsorbent bead). The adsorption data for 
the first 120 min suggests that initial uptake kinetics is similar for both size 
fractions. After approximately 200 min albumin uptake by the 513µm size 
fraction seemed to be complete, q* - 0.3mg/g. Albumin adsorption on the 
larger size fraction (780µm) continued beyond 2h and the adsorption capacity 
after 24h (q* - 0.5 mg/g). The uptake capacity values measured for albumin 
were over a 24h period were low making it difficult to have confidence in the 
observed measured differences. Capacity calculations obtained from this 
data show a q(f) value after 24h contact of adsorbent with albumin solution of 
around - 0.5mg/g. 
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Figure 3.30. Kinetic uptake of albumin expressed in terms of q(t) against time 
onto CW1 (particle size values show are Sauter means, stirrer speed set to 
826rpm); effects of changing particle size; T=0- 1440mins, initial 
concentration of albumin : 200mg/l. 
3.2.3 Adsorption kinetics in p binary system. 
Figure 3.31 shows adsorption data for lysozyme on CW1 for a number of 
experiments where different concentrations of a competing protein (albumin) 
was present in solution. 15g of the adsorbent was used, with a stirrer speed 
of 826rpm. Adsorption data for lysozyme on CW1 from a single solute in 
buffer overlays on that obtained from two other experiments with 200 mg/I and 
1000 mg/I of albumin present in buffer solution (in addition to 100mg/I of 
lysozyme in solution). The data suggests that the presence of albumin had 
little effect on the uptake kinetics of lysozyme. This may be due to size 
exclusion of albumin from the internal adsorption surface of the adsorbent 
particle. If lysozyme diffuses more quickly into the internal pore structure of 
the adsorbent (due to a larger diffusivity in comparison with albumin), it may 
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irreversibly adsorb on the internal surface of the adsorbent reducing the 
possibility of competition from albumin. As the concentration of albumin in 
solution rises, the driving force for diffusion increases and this may counter 
the smaller diffusivity of albumin. This effect is not noticed for the lysozyme 
adsorption data on CW1 obtained with 1000 mg/I background albumin in 
solution. 
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Figure 3.31. Adsorption uptake of lysozyme onto CW1 with varying 
concentrations of albumin present in a binary system. Stirrer speed 826rpm, 
initial concentration of lysozyme : 100mg/I 
XAD4 however, has demonstrated its ability to allow albumin into its pore 
structure. Therefore when albumin is present in a binary system with 
lysozyme, it is possible the adsorption kinetics and capacity for lysozyme will 
reduce. However the experimental data shows that the presence of albumin 
at 200mg/I appears to have little effect on the uptake of lysozyme similar to 
the effects seen with CW1. When the concentration of albumin increases to 
1 g/l the uptake of lysozyme actually increases (see Figure 3.32). Although 
this is initially counter intuitive, the literature does offer potential explanation. 
Kandori et al (1999) published work concerning cooperative adsorption of 
albumin and lysozyme onto CaHap surfaces. They presented evidence that 
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suggested lysozyme and albumin formed agglomerates in solution, so the free 
lysozyme bound to albumin both in solution and on the CaHap surface. An 
increase in uptake of lysozyme was reported. It is therefore hypothesised that 
adsorbed albumin on XAD4 may offer additional sites for removing lysozyme 
from solution. 
To examine this hypothesis further, a sample of XAD4 was "pre-coated" with 
albumin. The coated XAD4 was then centrifuged to remove extra particle 
liquid and then added to a reactor containing 100mg/I of lysozyme in a single 
solute system. If the adsorbed albumin is offering additional sites for 
lysozyme adsorption, it may be possible the precoated resin would augment 
the uptake of the lysozyme. Figure 3.33 shows plots of lysozyme uptake from 
a single solute system, a binary system containing 1 g/I of albumin and the 
pre-coated XAD4 sample in a single solute solution. Lysozyme uptake onto 
the pre-coated adsorbent is notably faster than the virgin material suggesting 
the lysozyme molecules are attracted to the albumin adsorbed to the surface. 
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Figure 3.32. Adsorption uptake of lysozyme on XAD4 (15g) with varying 
background concentrations of a competing protein albumin present in solution 
(particle size 478 µm; stirrer speed 826rpm. Initial concentration of lysozyme : 
100mg/I. 
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Figure 3.33. Adsorption of lysozyme on XAD4, lysozyme present as a single 
protein with varying background concentrations of a competing protein 
albumin present in solution, and with a pre-coat of albumin on the adsorbent 
(particle size 478 pm; stirrer speed 826 rpm. 
This data suggest that the Vroman effect does not appear to be occurring 
between lysozyme and albumin because uptake of lysozyme is consistent 
with single solute systems in CW1 and actually increased in XAD4. If the 
Vroman effect was occurring in this system, a decrease in lysozyme uptake 
would occur due to the displacement of the lysozyme molecules by albumin. 
3.2.4 Competitive adsorption using a clinically 
relevant peritoneal dialysis fluid. 
The adsorption performance of the adsorbent CW4 (as a potential middle 
molecule size selective adsorbent) was compared with XAD4 using peritoneal 
dialysis (PD) fluid. The PD fluid had been concentrated using ultrafiltration 
(method described previously) so as to contain -50 mg/I ß2"M and -40 g/I 
albumin. Both materials were tested under identical conditions, The CW4 
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material showed fast adsorption kinetics for ß2-M with the concentration of the 
ß2-M falling below the detectable limit (measured by ELISA) within 3 hours 
whilst the XAD4 sample showed comparatively slower rate of removal of 02-M 
from solution within the 7 hour period over which the adsorption experiment 
was conducted (data presented in Figure 3.34). The particle sizes of the two 
materials were slightly different, CW4 mean size 4,8 p. m whereas XAD4 mean 
size 114 µm meant, the effect of particle size on ß2-M removal would need to 
be taken into account. When the experimental data is plotted against 
dimensionless time. (see Figure 3.35) the plot is essentially normalised 
against the particle size and the true effects of the differing pore structures 
become apparent. In order to non dimensionalise the time effective 
diffusivities for lysozyme in CW4 (6.5x10.12m2s'1) and XAD4 (3.4x10'12 m2s') 
were used as an estimate. These values were obtained in the modelling 
section of this thesis (see section 3.2.5 below) 
The data suggest that the kinetic uptake of ß2-M onto both materials is very 
similar even though the internal pore structure of the two materials are 
different. Due to the noise in the data it is not possible to quantify the 
differences in kinetics. Therefore from this data the influence of albumin 
adsorption on the uptake kinetics of ß2-M appears minimal assuming the 
effective diffusivity values for ß2-M is similar to lysozyme for both materials. 
However, it is likely that the capacity for ß2-M will have reduced due to some 
of the sites being occupied by albumin molecules on XAD4. Therefore it is 
clear that the size excluding principle results in extra capacity for MM's due to 
reduced loss of this area because of albumin accessibility. In addition any 
issues relating to the effects of albumin reduction in the patient will be reduced 
in CW4 over XAD4 based on the data presented in the modelling section and 
the chapter 2. The data also suggest there is no augmentation of ß2-M 
removal due to the presence of albumin on the materials surface as seen with 
lysozyme. 
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Figure 3.34. Kinetic uptake of ß2-M expressed in terms of q(t) against time 
onto CW4 (mean size 48 pm) and XAD4 (mean size 114 pm) from a 
multicomponent system. Stirrer speed : 826rpm. Initial concentration of ß2- 
M-50 mg/l. 
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Figure 3.35. Uptake of /32-M on CW4 (mean size 48 , um) and XAD4 (mean 
size 114 pm) plotted against dimensionless time obtained by estimation of ß2- 
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M effective diffusivities. Stirrer speed : 826rpm, Initial concentration of /32- 
M-50 mg/l. 
3.2.5 Estimation of lysozyme and HSA effective 
diffusivities in nanoporous polymeric adsorbents. 
The effective diffusivities for lysozyme and human serum albumin in single 
solute systems were obtained for each of the adsorbent materials XAD4, CW1 
and CW4. 
Experimental uptake of lysozyme on XAD4 (mean size 165 µm) was used to 
estimate the magnitude of the effective diffusivity of lysozyme within XAD4 
using the mass transfer model (developed earlier) incorporating the 
irreversible adsorption isotherm (see Figure 3.1) The value of the effective 
diffusivity De of lysozyme obtained from best fit of the model prediction to the 
experimental adsorption data was De = 3.1 x 10-12 m2/s. (see Figure 3.36). 
The effective diffusivity value was used to predict the adsorption dynamics of 
lysozyme within larger particles of XAD4 (mean size 476 µm). The model 
prediction for the initial rate of change of concentration (over a period of 12 h 
following adsorbent-solution contact) matches up with the adsorption data 
quite well (see Figure 3.37). However, at long times, the experimental data 
and the model prediction are less well matched. There may be a number of 
explanations for such an observation including denaturing of the protein 
leading to lower confidence in the correct measurement of the solute 
concentration in solution at long time intervals (this was quite a common 
occurrence for experiments that were run over several days). 
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Figure 3.36. Adsorption uptake of lysozyme on XAD4 (mean size 165, um; 
stirrer speed 700rpm, effective diffusivity used for model prediction D. = 3.1 x 
10"12 m2/s, initial lysozyme concentration : 400mg/1, adsorbent mass : 0.5g 
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Figure 3.37. Adsorption uptake of lysozyme on XAD4 (mean size 478 , um; 
stirrer speed 700 rpm), effective diffusivity used for model prediction D. = 3.4 
x 10-12 m2/s. initial lysozyme concentration 5g/l, adsorbent mass : 5g. 
- 123 - 
Chapter 3 Protein adsorption studies 
The value of the effective diffusivity De of albumin obtained from best fit of the 
model prediction to the experimental adsorption data of human serum albumin 
on XAD4 (mean size 165 µm) resulted in estimation of the value of De = 1.6 x 
10.13 m2/s. The model prediction and experimental data were in good 
agreement for data obtained over 3 days however, data obtained thereafter 
showed a sudden observed decrease in the protein solution concentration 
(see Figure 3.38). This reduction in protein solution concentration may arise 
due to protein denaturing over long periods of time. It is also possible that 
bacterial growth could occur in solution. The bacteria could then feed on the 
proteins and reduce their concentration in the bulk. 
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Figure 3.38. Adsorption uptake of albumin on XAD4 (mean size 165 pm; 
stirrer speed 700 rpm, effective diffusivity used for model prediction D. = 1.6 x 
10"13 e/s, initial albumin concentration : 200mg/!, adsorbent mass 0.5g 
In a similar manner, the value of the effective diffusivity D. of albumin 
obtained from best fit of the model prediction to the experimental adsorption 
data of human serum albumin on XAD4 (mean size 70 µm) resulted in 
estimation of the value of D. = 1.9 x 10.13 m2/s. The model prediction and 
experimental data were in good agreement (see Figure 3.39). 
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Figure 3.39. Adsorption uptake of albumin on crushed sample of XAD4 
(mean size 70 pm; stirrer speed 700 rpm), effective diffusivity used for model 
prediction De = 1.9 x 10"13 n2/s, initial concentration of albumin : 400mg/l, 
mass of adsorbent : 0.5g. 
The value of the effective diffusivity De of lysozyme obtained from best fit of 
the model prediction to the experimental adsorption data of lysozyme on CW 1 
(mean size 197 µm) resulted in estimation of the value of D8 = 3.6 x 10-13 
m2/s. The model prediction and experimental data were in good agreement 
for the first 24 h (see Figure 3.40). The estimated effective diffusivity for 
lysozyme in the CW 1 is considerably lower than that on XAD4 
(De = 3.5 x 10.13 m2/s) with the same molecule. This suggests the different 
pore structure is affecting the rate of adsorption. 
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Figure 3.40. Adsorption uptake of lysozyme on CW1 (mean size 197 , um; 
stirrer speed 700 rpm), effective diffusivity used for model prediction De = 3.6 
x 10.13 rn2/s. initial concentration of lysozyme : 400 mg/l, mass of adsorbent : 
2.5g 
The value of the effective diffusivity De of albumin obtained from best fit of the 
model prediction to the experimental adsorption data of albumin on CW1 
(mean size 197 µm) resulted in estimation of the value of D. =4x 10-13 m2/s. 
The model prediction and experimental data were in good agreement (see 
Figure 3.41). 
I 
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Figure 3.41. Adsorption uptake of albumin on CW1 (mean size 197 , um; 
stirrer speed 700rpm, effective diffusivity used for model prediction Da = 3.5 x 
10.13 n2/s, initial albumin concentration 200mg/l, mass of adsorbent 22g. 
The value of the effective diffusivity Do of lysozyme obtained from best fit of 
the model prediction to the experimental adsorption data of albumin on CW4 
(mean size 49 µm) resulted in estimation of the value of D. = 6.5 x 10-12 m/s. 
The model prediction and experimental data were in good agreement (see 
Figure 2.42). 
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Figure 3.42. Adsorption uptake of lysozyme on CW4 (mean size 49 pm; 
stirrer speed 700 rpm, effective diffusivity used for model prediction De = 6.5 x 
10"12 rrr2/s. initial lysozyme concentration 600mg/l, mass of adsorbent 0.5g. 
The value of the effective diffusivity De of lysozyme obtained from best fit of 
the model prediction to the experimental adsorption data of albumin on CW4 
(mean size 28 µm) resulted in estimation of the value of De = 2.3 x 10-12 m2/s. 
The model prediction and experimental data were in good agreement (see 
Figure 3.43). 
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Figure 3.43. Adsorption uptake of lysozyme on CW4 (mean size 28 , um; 
stirrer speed 700rpm), effective diffusivity used for model prediction D. = 2.3 x 
10.12 m2/s.. initial lysozyme concentration 600mg/l, mass of adsorbent 0.5g. 
The value of the effective diffusivity De of albumin obtained from best fit of the 
model prediction to the experimental adsorption data of albumin on CW4 
(mean size 28 pm) resulted in estimation of the value of D. = 3.6 x 10-14 m2/s. 
The model prediction and experimental data were in good agreement (see 
Figure 3.44). 
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Figure 3.44. Adsorption uptake of albumin on CW4 (mean size 28, um; stirrer 
speed 700 rpm), effective diffusivity used for model prediction D. = 3.6 x 10-14 
m2/s. initial albumin concentration 600mg/l, mass of adsorbent 3g. 
Table 3.5 summarises the results of the estimated effective diffusivities (De) 
for lysozyme and human serum albumin in each of the materials XAD4, CW 1 
and CW4. The estimated effective diffusivity values for albumin were an order 
of magnitude smaller than for lysozyme in both XAD4 and CW4. This 
indicated hindered diffusion of albumin within the adsorbent particles. The 
effective diffusivity of lysozyme in CW1 was found to be smaller than that for 
XAD4. This may be attributed to the tighter mesopore structure of CW1. The 
magnitude of the lysozyme effective diffusivity in CW4 was comparable to that 
of lysozyme effective diffusivity in XAD4 suggesting that although the pore 
cut-off values were similar for CW1 and CW4, CW4 may possess a more 
open pore structure. 
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Table 3.5. Summary of parameters used for modelling studies and evaluated 
effective diffusivities. 
Material Solute 
Particle 
Diameter 
(µm) 
Mass 
(g) 
Stirrer 
Speed 
(rpm) 
Effective 
Diffusivity 
(De x 10-13) 
(m2 s") Re x 107 
Bi x 
105 
q* 
(mg g") 
XAD4 LYZ 478 5 700 34 7 6.9 419 
XA D 44 LYZ 165 0.5 700 31 7 78.5 410 
XAD4 LYZ 114 0.5 84 34 0.7 1.08 415 
XAD4 HSA 73 0.5 700 1.9 7 60.0 105 
XAD4 HSA 165 0.5 700 1.6 7 1360 95 
CW 1 LYZ 197 0.5 700 3.6 7 4.7 59 
CW 1 HSA 197 22 700 3.5 7 
--- 
8.1 
-------- 
2 
CW4 LYZ 28 0.5 700 23 7 
----- 
22 
--- --- 
567 
- CW4 LYZ 49 0.5 700 65 7 2.7 577 
CW4 HSA 28 3 700 0.36 7 4.61 51 
Table 3.6 summarises the saturation uptake data of lysozyme and albumin 
onto each of the adsorbent materials. Protein surface coverage values were 
evaluated using a theoretical monolayer coverage per square meter based on 
the area footprint of each of the molecules (-9 nm`' for lysozyme and -49 nm' 
for albumin). The surface area accessible to each molecule was based on the 
nitrogen porosimetry data (see Chapter 2). The theoretical calculations 
correlated well with measured experimental protein adsorption values for both 
CW1 and XAD4. Measured lysozyme adsorption on CW4 suggested a higher 
capacity indicating greater available surface area compared with measured 
surface area from nitrogen porosimetery data. CW4 also displayed a 
significantly higher adsorption capacity for albumin compared with CW 1, 
around half that observed for XAD4. CW4 displayed adsorption capacity for 
lysozyme greater than that measured for XAD4. The lack of correlation of 
protein surface coverage for CW4 (with the dry surface area values reported 
in chapter 2) suggested that perhaps the adsorbent material porn stiuctr, ro 
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may change when exposed to the buffer solution e. g. due to polymer segment 
swelling. 
Table 3.6. Estimation of protein surface coverage based on experimental 
adsorption data and available surface area measurements. 
Material 
Particle 
size 
(µm) 
Protein 
adsorption 
capacity 
(mg g-) 
Accessible 
surface 
area for 
LYZ 
(m2 g-') 
Accessible 
surface 
area 
available 
for HSA 
(m2 g-) 
Protein 
surface 
coverage 
(mg m-2) 
*Monolayer 
coverage 
(mg m-2) 
XAD4 165 LYZ 410 103 - 3.9 2.7 
XAD4 430 LYZ = 415 125 - 3.3 2.7 
XAD4 780 LYZ = 419 128 - 3.3 2.7 
XAD4 165 HSA - 95 - 21 4.5 2.4 
CW 1 197 LYZ = 59 24 - 2.5 2.7 
CW 1 197 HSA =2 - 1 2 2.4 
CW4 28 LYZ = 567 31 - 18 2.7 
CW4 28 HSA = 51 - 1 51 2.4 
CW4 49-- LYZ === 577 37 - 15.6 2.7 
theoretical coverage based upon tootprint sizes of -. 9 nm` for lysozyme 
(LYZ) and - 49 nm`' for albumin (HSA). 
The observed adsorption data allows rational assessment of tho suitability of 
each of the adsorbent materials in terms of potential use in a blood purification 
device. Whilst CW1 showed good size exclusion properties, effectively 
eliminating albumin, the measured adsorption capacity for lysozyme was 
considerably lower than the other materials. Therefore, a larger quantity of 
CW1 would be required in order to reduce the concentration of MMs from 
blood in comparison with the other adsorbents studied here. This implies 
making the device larger (to accommodate more of the adsorbent) with the 
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consequence that the extracorporeal blood volume is increased. Also, the 
increased external bead surface area per unit volume may affect the 
biocompatibility of the device e. g. a larger bed height resulting in a greater 
overall pressure drop across the column, thus shear damage to blood cells 
may arise (explained further in chapter 4). In order to remove the same 
quantity of MM's as CW4,10 times more CW1 adsorbent material would be 
required. For example to cleanse 51 of blood, typical blood concentration of 
P2-M- 35 mg/I, -3 g of CW 1 would be required whereas less than -0.5 g of 
CW4 would be required for the same task. The higher albumin adsorption 
capacity displayed by CW4 would still only result in less than 25mg of human 
serum albumin which would not be clinically relevant given HSA blood 
concentration -- 40 g/l. 
The considerably higher lysozyme adsorption capacity coupled with superior 
adsorption kinetics displayed by CW4 makes it a suitable adsorbent material 
for further clinical testing in a haemoperfusion device. To illustrate the effects 
of available surface area the model was used to compare the three materials 
(CW1, CW4 and XAD4). The mass of each adsorbent was selected to give a 
saturation uptake of 572mg. The particle size of each material was fixed at 
400 µm, solution volume 0.51, stirrer speed set to 826rpm (negligible external 
mass transfer effects) and the initial concentration of lysozyme fixed at 
700mg/I. The effective diffusivities for lysozyme uptake and saturation 
capacities were taken as the average values for each material reported in 
Table 3.5. Figure 3.45 shows the model prediction for 24h of adsorbent- 
solution contact. The results clearly showed that despite XAD4 and CW4 
having slightly different effective diffusivities, the uptake profile when the 
saturation uptake values were normalised were virtually identical. Despite a 
large quantity of the adsorbent CW1, the resulting uptake was still slower due 
to slower intraparticle solute diffusion. This data highlights the suitability of 
CW4 as a potential adsorbent material for use in blood purification. The 
adsorbent selectively removed MMs (similar D. as XAD4) whist removing less 
human serum albumin and required a lower adsorbent mass for the task. 
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Figure 3.45. Comparison of adsorption uptake of lysozyme on XAD4, CW1 
and CW4 (initial concentration of lysozyme 700mg/l; mean size 400 , um) in a 
well mixed system. 
3.2.6 Influence of external agitation on the 
adsorption kinetics 
As described previously, the magnitude of the Biot number was evaluated for 
each of the adsorption experiments undertaken. Table 3.5 summarises the 
data for each of the experiments conducted. The experiment conducted at 84 
rpm had a Biot number an order of magnitude less than the experiments 
conducted at the maximum stirrer rate. As all of the experiments were 
conducted using a Biot number greater than 100 the external mass transfer 
resistance was negligible. To demonstrate the effect of external agitation 
(magnitude of Biot number) the mass transfer model was used to conduct 
simulations using different magnitudes of Biot number. Adsorption uptake of 
albumin onto CW4 was used to study the effect of external agitation on the 
resulting mass transfer rate (using an initial solute concentration of 600mg/I, 
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adsorbent mass 0.5g). When the Biot number was greater than 
approximately - 20 the plots virtually overlay on one another (see Figure 3.46) 
Therefore the predominant resistance to mass transfer under these conditions 
was within the adsorbent bead itself and not due to film boundary layer 
resistance. 
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Figure 3.46. Influence of Blot number on uptake kinetics of albumin on CW4 
(mean size 28 um, initial concentration of albumin : 600mg/l; ), effective 
diffusivity used for model prediction D. 3.6 x10.14 m2/s. 
3.2.7 Mass transfer effects on protein adsorption 
dynamics: modelling the effect of particle size. 
By undertaking experiments using the same adsorbent material and solute 
molecule but with different particles size fractions, the effective diffusivity (DB) 
of the solute in the particle would remain the same, hence it would be possible 
to investigate the effect of changing the particle size on protein adsorption 
dynamics. By using the previously estimated value of the effective diffusivity 
of the protein in a given adsorbent material, it was possible to change other 
parameters e. g. the particle size and observe the resulting solute adsorption 
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dynamics simply by using the model and undertaking simulations of such an 
exercise. However, in order to ensure the effective diffusivity was 
independent of the particle size it was first necessary to obtain experimental 
data for differing particle size fractions, fitting the D parameter and ensuring 
that its magnitude did not vary with particle size for the given solute-sorbent 
system. Results of nitrogen porosimetry (see Chapter 2) supported the 
assumption that pore structure remained unaffected as a consequence of a 
change in the particle size. The De values were fitted to a number of 
experiments and the results are tabulated in Table 3.7. The fitted D, for 
lysozyme adsorption using two different particle sizes of CW4 showed similar 
orders of magnitude, the variability likely to be due to the fact the two size 
fractions were from different batches. The effective diffusivity values for 
XAD4, Sauter mean 165 µm and 478 pm were similar suggesting that the 
intraparticle diffusivity may be taken to be particle size independent. 
Table 3.7. Fitted De values to CW4 and XAD4 adsorption data for different 
particle sizes. 
Material Solute 
Mean particle 
diameter (µm) 
Effective 
diffusivity 
(De x 1012) 
(m2 s-) 
CW4 LYZ 28 2.3 
CW4 LYZ 49 6.5 
XAD4 LYZ 478 3.4 
XAD4 LYZ 165 3.1 
Figure 3.47 shows a plot of the two size fractions of CW4 with respect to 
adsorption of lysozyme (initial concentration of 600mg/I, stirrer speed 
826rpm). The x-axis is dimensionless time effectively normalising for the 
effect of particle size on diffusion time. The data appears to overlap 
suggesting the longer adsorption times for diffusion are simply due to the 
longer diffusion path length. The data suggests that once an effective 
diffusivity value has been obtained for a given adsorbent / solute combination, 
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the model may be used to simulate the dynamics of adsorption with respect to 
changing particle size. This is of particular importance when considering the 
design of a haemoperfusion device where the particle size is an engineering 
parameter. Although it is intuitive that a small particle size will result in faster 
adsorption kinetics (and so highly desirable) any proposed blood purification 
device imposes limitation on the actual particle size range that may be used 
due to consideration of blood pressure drop across the packed bed which 
increases as the particle size decreases. High shear may damage the blood 
cells and needs to be avoided. Therefore, this scenario leads to an 
optimisation problem, where the particle size may be minimised to maximise 
uptake kinetics, whist not causing damage to the cells (this problem will be 
discussed in more detail in chapter 4). The discussion does however highlight 
the need for a predictive model to help quantify the effects of changing the 
adsorbents physical characteristics. Figure 3.48 shows a theoretical plot of 
adsorption uptake of lysozyme on CW4 and the effect of changing the 
adsorbent particle size. Clearly, the particle size has a significant effect on 
the adsorption kinetics particularly over a clinically relevant time period 
typically between 3-5h. For an initial solute concentration of 600mg/I, the 
particles with a diameter larger than 300 µm showed a fractional uptake of 
less than 0.1 (adsorption time - 400m), whilst an adsorbent with a diameter 
40 µm, reduced the concentration of the MM marker to less than half the initial 
concentration in the same time period. 
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Figure 3.47. Modelled adsorption uptake of lysozyme on to different particle 
size of CW4 fractions (49p and 28 , u) plotted against dimensionless time 
stirrer speed : 700rpm. Initial concentration of lysozyme : 600mg/1. 
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Figure 3.48. Modelled adsorption uptake of lysozyme onto CW4 at various 
particle sizes. stirrer speed : 700rpm, initial concentration 600mg/1. 
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3.3 Conclusions 
In this chapter three copolymer adsorbents have been characterised in terms 
of their adsorption capacity and kinetics. The effect of tailoring adsorbent 
pore structure on human serum albumin accessibility has been studied using 
simple binary systems as well as adsorption studies using clinically relevant 
peritoneal dialysis fluid. Experiments in combination with a theoretical model 
have allowed assessment of the effect of pore structure, particle size and 
external fluid mixing conditions on the adsorption dynamics. The lysozyme 
adsorption capacity of CW1 and XAD4 correlate well with the measured 
surface area values. The lysozyme and albumin adsorption capacity values of 
CW4 appear greater than those suggested from material surface area 
characterisation. 
Albumin adsorption capacity values measured with CW1 suggested that the 
adsorbent pore structure effectively size excluded albumin (q* -2 mg/g) whilst 
XAD4 pore structure was accessible to albumin (q* - 100 mg/g). The 
differences in the measured effective diffusivity values for lysozyme in CW1 
and XAD4 highlights the effect of a tightly regulated mesopore structure 
(pores < 10nm) on the hindered diffusion of MMs in the adsorbent particle. 
Lysozyme diffusion in CW4 was considerably faster than in CW1 suggesting a 
more open mesopore structure accessible to MMs. Human serum albumin 
adsorption on CW4 was noticeable. CW4 had a greater adsorption capacity 
for lysozyme than the XAD4 material. The adsorption data using peritoneal 
dialysis fluid with CW4 and XAD4 suggested similar uptake rates for ß2-M. 
The adsorption model allowed comparison of the MM adsorption dynamics for 
the three adsorbent materials. When the adsorption data was normalised for 
capacity, the MM uptake performance of XAD4 and CW4 were comparable. 
As CW4 demonstrated a reduced capacity for albumin and showed a higher 
saturation capacity (on a mg/g basis) than XAD4 it seems to offer potential as 
an adsorbent for use in a haemoperfusion device. The high adsorption 
capacity should result in a reduction in the required quantity of adsorbent 
material required to remove clinical quantities of MM's. Therefore, the 
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adsorption device may be made more compact with a lower pressure drop 
and less potential damage to blood cells. A reduction in the external 
adsorbent surface area coming into contact with blood components could 
benefit biocompatibility of the device. 
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Chapter 4 
Dynamic scaling down of a fixed-bed 
haemoperfusion column 
This chapter introduces the importance of considering the design of a 
haemoperfusion device for both its ability to adsorb MM's and any potential 
damage it could have on the cells as a result of the flow regime present. 
Models are developed to help understand the effects of changing key design 
parameters on the flow conditions. The principle of dynamically scalling down 
a commercial column is included and its potential use as a means to study 
biocompatibility of adsorbents is discussed. Uptake of lysozyme onto two 
adsorbents is conducted on a dynamically scaled down system. 
4.1 Introduction to haemoperfusion column 
design. 
Chapter 3 highlighted the importance of pore structure (solute size exclusion 
and intraparticle diffusion) and mixing (external mass transfer) on the uptake 
of uremic toxins. However, for nanostructured polymeric adsorbents to be 
successfully used as a treatment, the contacting system needs to be 
considered. Extracorporeal blood volume has to be minimised, shear damage 
to the blood cells is a concern as well as bioincompatible blood-surface 
interactions. A fixed-bed adsorber is a column packed with a bed of 
adsorbent material through which the fluid flows in a downward direction, 
usually with the aid of a pump. Often a diffuser is placed at the inlet of the 
column to promote good flow distribution and minimise flow channelling 
effects. 
The flow dynamics within the clinical column may have a pronounced effect 
not only on the dynamics of solute removal but also the biocompatibility of the 
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device. The focus of this chapter is the examination of the flow conditions 
found in a clinical haemoperfusion device. Subsequently, a dimensional 
analysis to dynamically scale-down the experimental evaluation of adsorbents 
using a small-scale mini-column device is made. The use of such an 
approach has the potential of reducing the cost of testing adsorbent materials 
(using limited quantities of available donor blood) without compromising the 
validity of the testing protocols. Studies of both adsorption performance and 
biocompatibility may be possible. 
4.1.1 Introduction to Biocompatibility 
An important development in modern medicine is the introduction of foreign 
materials to replace biological matter or to aid the body's natural functions. In 
addition to using materials in intimate contact with the body, many 
extracorporeal devices have been developed to assist in surgical procedures, 
and sustain life when natural organs begin to fail. 
The term biocompatibility refers to what effect a foreign material has on the 
body when it comes into contact with living tissue and body fluids. Perhaps 
the biggest influences on this reaction involve the specific material, the 
amount of trauma caused during its implantation, the host, and the location of 
the material. Normally, the body's immune response is directed at rejecting 
foreign bodies. There are many ways in which biocompatibility can be 
measured, and these will be discussed later in this chapter. 
Early biomaterials tended to focus on methods of repairing failed mechanical 
structure within the body such as bone fractures and displacements. Early 
practice included use of metal screws and plates to assist in fracture fixation. 
Such methods date back to the late 1800's. It wasn't until the 1940's when 
materials were used for applications beyond mechanical support. Coinciding 
with the introduction of acrylics, scientists were beginning to develop materials 
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specifically designed to be biocompatible, and looked at furthering their use in 
biological systems. 
Literature suggests that it is prudent to categorise "biomaterials" depending on 
whether their contact with blood will be long term (e. g. a joint implant) or short 
term (e. g. an extracorpeal device used as a life saving measure infrequently 
or for a short duration). Although haemodialysis may be viewed as short term 
exposure (typically a haemodialysis session last around 3-5 hr) of blood to the 
dialysis membrane, due to its repetitive nature (typically three times per week, 
potentially for several years) current clinical thinking is that blood-dialyser 
interactions should be viewed as though the device were permanent when 
evaluating biocompatibility. 
The ISO standard 10993 helps to categorise the type of testing required of a 
biomaterial depending on its end use. Although the standard doesn't offer 
any specific protocols for biomaterial evaluation, it does offer a structured test 
simulation system. In addition, the standard cites various references with 
details of appropriate test methodologies. 
This standard is concerned with all medical devices that come into contact 
with blood. Although much of it is generic in nature, section 4, `selection of 
tests for interactions with blood (ISO 10993-4: 2002) offers useful guidelines 
for the design of testing protocols, Any biocompatibility testing must adhere to 
the guidelines set out in this standard. 
Biomaterial engineering aims to replicate biological functionality whilst 
minimising adverse side reactions. The reader is referred to a review article by 
Michanetzis et al. (2002) that further elaborates on the use of ISO standard 
10993 for biocompatibility evaluation of biomedical devices. The review also 
discusses a number of biocompatibility testing protocols and evaluates them 
against both cost and efficiency. The multi-centre work highlighted the need 
for continuity in biocompatibility testing and commented on the potential for 
multifactorial influences of the effects demonstrated in each of the protocols. 
It was highlighted that the equipment used in the testing (e. g. piping and 
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tubing used for haemodialysis) could itself be responsible for a adverse 
biocompatibility response. 
Michanetzis et at. (2002) used assays for platelet adhesion, activation, 
aggregability and activation of the coagulation system. This paper highlights 
the lack of well defined protocols in the field of biocompatibility testing. In 
addition to the plethora of potential experimental methods and their 
associated errors, the variability of blood sources may also impact on the data 
gathered. It is therefore prudent to focus initial biocompatible investigations 
on global responses such as changes in platelet counts and damange to red 
blood cells (e. g. due to shear damage), and then choose more subtle tests 
(e. g. release of cytokines) to undertake more detailed studies of suitable 
adsorbent materials that have undergone preliminary screening. 
4.1.2 Measuring biocompatibility 
Due to the chronic nature of renal disease, long term effects of haemodialysis 
treatment manifest in elevated immune response of patients due to the blood 
routinely coming in contact with artificial surfaces (haemodialysis membrane 
etc). Development of polymeric adsorbents for use in haemoperfusion 
requires evaluation of biocompatibility reactions. One approach is to look at 
the two predominant effects a foreign material (e. g. the adsorbents) may have 
on the blood post contact. These effects may be compartmentalised as 
affecting the complement and coagulation systems. The two systems also 
have the potential to interact once activated (i. e. the complement system can 
be activated due to thrombus production. ) 
There are a number of adverse biological responses when blood comes into 
contact with a foreign material. Protein pathways such as activation of the 
complement system are established ways to identify a response between the 
blood and artificial surface. Although complement activation is know to act via 
two pathways (classical and alternative) it is the alternative pathway which is 
- 144 - 
Chapter 4 Dynamic scaling down of a fixed-bed haemoperfusion column. 
almost exclusively involved in contact with biomaterials. Each of the 
pathways involves different entities in the activation process, although they do 
share a terminal pathway. The propagation of the system involves a cascade 
not unlike that of the coagulation system. Each of the propagation steps are 
controlled by regulatory proteins and are either inhibitory or amplifying in 
nature. The alternative pathway can operate without antibody participation. 6 
proteins (C3, B, D, H, I& P) are involved and these are able to initiate and 
control the response of the pathway. The result of the initiation is the 
formation of activator bound C3/C5 convertase (Pangburn et al, 1986). 
After initiation, the propagation of the alternative pathway is continuous and 
begins with a spontaneous hydrolysis of the thioster in the native C3. C3 is 
then cleaved by C3 convertase. This process creates C3b, which is then free 
to attach to either host or non-host particles. 
The initiation of many of these interactions (immune response, coagulation 
etc) is due to interactions at the material surface / blood interf ace (Turbill et al, 
1996). It is therefore not surprising to find that a huge amount of research has 
been undertaken to study the behaviour of blood at the solid-liquid interface. 
Of particular relevance, is the Vroman effect which is the sequential 
displacement of proteins present in blood serum that adsorb to the material 
surface. It is these sequential events taking place at the interface that have 
been identified as the starting blocks of the coagulation cascade, and also 
contribute to the body's immune response. The reader is referred to the paper 
by Brash et al, (1984) for more details on this. The possibility of engineering 
surfaces that retard such events may hold the key to improved biocompatible 
surfaces. Since albumin is said to be the first protein to adsorb onto the 
material surface, research has focused on limiting its adsorption to the 
surface. 
The reader is referred to a paper by Mao et al. (2004) who have summarised 
key factors involved in the propagation of a biocompatibility response. The 
paper divides two major approaches to engineering biomaterials. The first 
deals with the development of a material that prevents or in some way 
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suppresses the reactions with blood (an approach was that of interfering with 
the coagulation cascade). The second approach was to prepare polymers 
that were inert to the blood interaction. The former strategy has been argued 
to be the most important due to the knowledge that the resulting reactions 
from contact with an artificial material are associated with the materials 
surface and not its bulk characteristics (Sun et at, 2003). The secondary 
advantage of taking this approach is that the surface of materials can be 
modified in order to improve their properties, whilst the bulk material remains 
unchanged *giving greater flexibility in controlling mechanical as well as 
biological characteristics. This approach may be appropriate for the polymeric 
adsorbents studied here where the functionality (size exclusion due to pore 
size control and surface area for adsorption) lies within the bead whereas the 
contact of blood cellular components is on the outside of the bead surface that 
may be modified post adsorbent synthesis. 
4.1.3 Experimental design consideration for the study 
of biocompatibility. 
What becomes apparent after reviewing relevant literature is the need to 
identify not only the correct markers to identify bio-incompatible responses but 
also minimising any effects associated with the experimental design. The 
concurrent analysis of a 'control' sample is a useful way to evaluate some of 
these issues, but concerns have been raised concerning the sensitivity of 
each method. Much work in current literature (eg Sandeman et al (2005) 
contacts the adsorbent with a stagnant pool of blood. The results of such 
work are then extrapolated to predict the behaviour in flow systems. 
Therefore, the design and use of a dynamic system for evaluating bio- 
incompatibility responses could offer additional insight. In addition, 
technologies employed to evaluate specific parameters (such as platelet 
activation) may require much validation to ensure any effects observed are 
due to the biomaterial being investigated. Therefore by identifying a robust 
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scale down system, all the relevant factors can be studied in 'real' flow 
conditions, ensuring accurate reproducible results with the clinical system 
whilst using small blood volumes. 
4.1.4 Characterisation of column haemodynamics 
Damage to cells 
Chapter 3 showed that high shear rates are effective in reducing external 
mass transfer resistance, thus high blood flow rate though the packed-bed 
may be desirable. In addition, reduced particle size was shown to have a 
dramatic effect on the uptake kinetics of the target molecules. However, if a 
haemoperfusion device contains a packed-bed of particles, as the particle 
sizes decreases, the pressure drop across the bed increases. To achieve 
high blood flow rates, the increased shear in the system may damage blood 
cells. Figure 4.1 depicts potential effects of shear stress on blood cell 
damage. It is therefore important to consider the potential damage to cells 
that may occur as a result of high blood flow rates in a haemoperfusion 
device. 
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Figure 4.1. Effect of shear rate on platelets and red blood cells. Adapted from 
Deutch et al (2006) 
The combination of shear stress experienced by blood cells and exposure 
time to the stress within the column requires some consideration. The 
retention time of blood within the column may be evaluated from the column 
volume, bed porosity and flow rate quite easily. However, the fact that blood 
is re-circulated and each parcel of blood may make multiple passes makes 
analysis of the effect of exposure time vs shear stress more complicated. 
One way would be to multiply the contact time per pass by the number of 
passes per treatment to obtain the overall contact time. 
4.1.5 Determining a blood analogue suitable for column 
studies 
In order to be able to experimentally analyse the hydrodynamic effects within 
a haemoperfusion device, the selection of a blood analogue (in terms of 
rheological properties) was considered. For the work carried out here, use of 
whole blood was not possible due to unavailability of sufficient quantities of 
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donor blood, handling issues due to risk of infection transmission, blood 
coagulation etc. Since the main objective was to investigate the dynamic 
scaling of the fluid dynamics from a clinical-sized column to a small-scale 
column, the use of a blood analogue mimicking the rheological behaviour of 
blood as found in clinical systems was acceptable. 
Blood is a complex multicomponent two phase mixture of salts, water, 
proteins and cells. Blood rheology shows considerable dependence on its 
many components, in particular, red cell and protein concentrations. The flow 
characteristics of blood at high shear rates (typically greater than 20 s'i such 
as in arterial flow) can be considered as Newtonian. However at lower shear 
rates (less than 20 s''), blood exhibits non-Newtonian characteristics. 
Blood exhibits shear thinning behaviour mainly due to the presence of red 
blood cells. These are bi-concaved discs approximately 8, um in diameter but 
are capable of severe deformation. Typically, these cells make up about 40% 
of the total blood volume. Variation in red cell count (often referred to as 
haematocrit) has a pronounced effect on the blood viscosity. When blood is 
at rest, the red cells tend to aggregate together to form a structure resembling 
rouleaux. At low shear rates, the aggregates begin to break-up. During this 
phase, the viscoelasticity of blood is determined primarily by the aggregation 
tendency of the red cells only. The forces that are required to break-up the 
rouleaux bring about orientation changes resulting in elastic energy being 
stored within the blood. Any additional flow requires the sliding of the cellular 
structure, the energy from which is dissipated as viscous friction. As the 
shear rate is increased further, the cells de-aggregate and the resulting forces 
act to orientate the cells in the direction of flow. At higher rates of shear the 
cells deform and will form layers between plasma. 
Platelets (typical size 2.5 µm) are smaller than the red blood cells and have 
little effect on blood rheology, however they are important In clot formation. 
The fluid dynamics in the column may influence mass transfer of platelets to 
the surface of the adsorbent which subsequently influence the coagulation 
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cascade. Therefore, the fluid dynamics within the column could have a role to 
play with the resulting biocompatibility response. 
It is also well documented in literature (Chien et al. (1977)) that changes in 
plasma protein concentrations have major effects on blood rheology. The 
protein content also influences the behaviour of the red cells (aggregation) 
and hence also influence its rheology via this mechanism. The three main 
serum proteins that affect blood viscosity are human serum albumin, 
fibrinogen and globulins. Large blood protein e. g. globulins appear to have 
more of an effect than both albumin and fibrinogen weight for weight, although 
the effects is disproportionately high at low shear rates (less than 30 s'1). 
From a hydrodynamic perspective, the key characteristics of blood are its 
apparent viscosity and the sedimentation rates of the red cells. Once blood is 
removed from the vascular system it quickly coagulates unless it is chemically 
altered by the addition of an anticoagulant. 
Blood plasma exhibits a viscosity of around 18 mPa. s and the final 
characteristics of whole blood are defined by a number of other factors 
including cell and protein concentration. Shear rate also effects the viscosity 
of blood as it exhibits shear thinning characteristics at low shear rates. Figure 
4.2 shows a plot of apparent viscosity against shear rate for whole blood 
(hematocrit 35-45%) The plot demonstrates that blood essentially behaves as 
a Newtonian fluid at shear rates above 20 s" with an apparent viscosity of 
8mPa. s. Therefore at shear rates likely to be found in a haemoperfusion 
device, blood flow behaviour may be described as Newtonian. It follows that 
any blood analogue designed for study of flow conditions in a haemoperfusion 
device may be Newtonian with a viscosity of 8mPa. s. The blood analogue 
must not demonstrate any hysteresis else the changes in the viscosity will 
change the behaviour exhibited in the column during experiments where the 
blood analogue volume is re-circulated through the adsorber bed. 
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Figure 4.2. Effects of shear rate on viscosity of whole blood. Adapted from 
O'Callaghan (2005) 
After consulting literature, it was found that blood analogues may be produced 
by mixing glycol with water at various concentrations. In order to obtain an 
analogue with a viscosity of 8mPa. s solutions of different concentrations of 
glycol in ultrapure water (10 - 90 wt. % ) were prepared. In addition to the 
glycol mixtures, a sample of the Hepes buffer solution (not containing any 
protein) was also made and analysed to identify its rheology. 
Once the relevant concentration of glycol/water giving a viscosity of 8mPa. s 
was identified, additional testing was carried out to ensure its properties 
remain constant during studies of flow through a packed bed. If the solution 
displayed a hysteresis curve when the shear rate was progressively increased 
to a maximum and then decreased along the same range of values then, the 
solution would not be appropriate for the study. In addition, in order to identify 
if there was any plastic behaviour of the blood analogue, a step change 
analysis was undertaken. Thus, the shear rate was increased linearly to a 
maximum value (1400s'1) and then suddenly reduced to zero following which 
immediately the linear increase in shear rate was repeated. If the gradient 
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(shear stress (i) versus shear rate (y)) were found to remain unchanged 
following each of the step changes then the solution was found not to exhibit 
plastic behaviour. The range of shear rates used depended on the expected 
viscosity but values used were in the range of 0- 2500 s''. 
Effects of temperature 
The effect of temperature on fluid rheology was studied by measuring the 
viscosity of each of the solutions at three temperatures (18°C (room 
temperature), 25°C, and 37°C). Any fluid dynamics work subsequently carried 
out was undertaken at a fixed temperature. 
Hepes buffer evaluation 
In order to understand the flow characteristics of Hepes buffer solution 
through a packed column, the viscosity of the solution was measured. 
Measurement of viscosity 
In order to characterise the blood analogue a concentric cylinder viscometer 
was used (A Haake, VT 550). A bob and cup arrangement was used where 
the cup was stationary and the bob was rotated. A force transducer 
measured the torque required to maintain a constant rotational speed of the 
bob. Resistance to the rotation of the bob was caused by the fluid. The 
instrument was capable of varying shear rate and the resulting shear stress 
was measured. Shear stress was plotted against shear rate, the gradient of 
the resulting trend line (if the data showed a linear correlation) provided a 
measure of the viscosity of the fluid. A linear relationship indicated that the 
sample was Newtonian in nature. A non-linear profile would suggest that the 
fluid flow characteristics were non-Newtonian with the gradient at a particular 
shear rate corresponding to the apparent viscosity at the measured 
conditions. A number of different sensor (bob) and cup arrangements were 
available and the expected properties of the sample (range of viscosities) 
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dictated the selection of the appropriate sensor. For the study of the 
Newtonian glycol-water blood analogues, the "NV" sensor was selected 
(sensor details provided in Table 4.1. ) 
Table 4.1. Properties of NV sensor. 
Geometry 
Viscosity (mPas) 2-2000 
Recommended Viscosity Range 
(m Pas) 
5-300 
Shear Rate (s-) 27-27,000 
Sample Volume (cm) 9 
Gap (mm) 0.35 
Radius; Length (mm) 20.1/60 
........................ . Reproducibility (±%) 3 
A number of assumptions are inherent in the mathematical relationships 
describing flow within the instrument: 
0 Steady state flow 
" Laminar flow 
" No end effects 
" Fluid is incompressible. 
" Constant temperature 
In order to obtain the viscosity of the various concentrations of glycol in water 
and a hepes buffer sample, the NV geometry was utilised and a shear rate 
range of between 0- 2500 s1 was used. 
- 153 - 
Chapter 4 Dynamic scaling down of a fixed-bed haemoperfusion column. 
4.1.6 Scale-down of haemoperfusion column design 
scale down. 
A scaled-down system has the potential benefit that it may be used to 
undertake in vitro biocompatibility studies and/or for studying adsorption 
performance of MMs during fluid flow through a packed bed. The advantage 
of scaling down is the reduction in the required volume of donor blood whilst 
still exposing both the blood and adsorbent to clinically relevant flow 
conditions. The success of any small scale experiments relies on the dynamic 
scaling down of the system. Therefore, a thorough investigation into the 
validity of the proposed scale down system should be undertaken before any 
biocompatibility / adsorption studies commence. 
Before discussion of how the scale down parameters were obtained, a 
discussion of the key hydrodynamic characteristics of flow through a packed 
bed will be presented. 
A packed-bed contains both the packing material and voids created in the 
area between the packing material. The bed void fraction is the term used to 
describe the relative amount of voids a particular packing material creates 
within a particular packed bed. The volume fraction of voids is also known as 
the bed porosity (c). Sc) represents the specific surface area per unit volume 
of the solid particles in the bed. The total surface area per unit volume of 
packed bed is given by the following equation: 
Total area =(I - e)sp (Equation 4.1) 
The particles used as packing material were assumed to be spherical (refer to 
Chapter 2 showing optical photographs of spherical adsorbent beads), 
therefore So is given by: 
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4r(dp /2)2 
_ 
)rdp2 
= 
'rd p2 =6 4/3r(dp /2)3 4/6n(do /8)3 2r(dp /6)3 dp 
(Equation 4.2) 
so = 6/(d) (Equation 4.3) 
In order to develop a Reynolds number for flow through a packed bed, it is 
necessary to obtain an equivalent diameter available for flow in the packed 
bed. For random packing, this can be defined as follows: 
d_ 4E 
e (1- e)So 
(Equation 4.4) 
In addition to the above parameter, the fluid velocity in the bed was also 
required. This can be obtained by using the volumetric flow rate and dividing 
it by the empty cross sectional area of the bed. This is known as the 
superficial velocity (u). The mean velocity within the interstices of the bed can 
be calculated by the following equation. 
__ 
u 
Ub 
Ex A 
(Equation 4.5) 
From this, a Reynolds number for a fixed bed can be derived. 
Reb 
d 
=e (Equation 4.6) 
p 
For Reb s 2, flow is said to be laminar. 
Resistance to fluid flowing through a packed bed, e. g. due to frictional drag 
results in pressure drop along the length of the bed. The resistance to flow is 
related to the properties of the packed-bed, e. g. particle diameter, bed 
porosity, bed-length etc. 
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Force balance across a pipe 
For a capillary, radius r; and length L, a force balance yields: 
PI 
( -7) 
Pz 
(P, -PZ)x(; zr,. 2)= r 11 
x(2nr, L) (Equation 4.7) 
Therefore: 
zwall =yr (Equation 4.8) 
Since, 
Zwal! 
,u= (Equation 4.9) I 
wall 
Therefore: 
Ywnfl - 
ýwnll 
_ 
API r (Equation 4.10) 
,u2, uL 
The equivalent capillary model of a porous medium 
The bed is considered to be composed of single-sized spheres of diameter dp, 
and the bed packing is taken to be random, rather than ordered. The specific 
surface of the particle is therefore defined as: 
26= 
-Td 
pý dN 
6 
(Equation 4.11) 
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An element of fluid takes a convoluted path as it moves through a packed bed 
(hence we introduce the concept of an equivalent capillary). The equivalent 
diameter of such a capillary will be based on the "hydraulic radius" concept. If 
we assume that the characteristics of the packed bed are such that the wetted 
perimeter and the fraction of the cross section of the bed that is open to flow 
are uniform along the length of the bed (in a statistical sense) then it follows 
that we may write the hydraulic radius (rh) as: 
cross section open to flow 
rh . (Equation 4.12) 
wetted perimeter 
Thus, the hydraulic radius takes the form: 
r- 
cd P (Equation 4.13) 
I-C 
Detailed derivations may be found in fluid mechanics text books such as 
Middleman (1998). 
We define the friction factor (f) for flow in a packed bed as: 
f1Z 
2 
(Equation 4.14) 
Taking the relation of shear stress (i) for a capillary and using the definition of 
the hydraulic radius (derived above), the friction factor, f may be defined as: 
IAý Zd 
f=J=l (Equation 4.15) 
Pýs2 3Puö(1-e) 
Where: 
uo = ue (Equation 4.16) 
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and u is the average velocity (which we don't know) whereas the superficial 
velocity (u0=Q/Ac) we can measure. Q is the volumetric flow rate and Ac is the 
cross-sectional area of the empty column. 
Equation 15 is simply a definition of fin terms of bed characteristics. To relate 
pressure drop in the packed bed to flow rate we assume that in laminar flow 
the friction factor for flow through a packed bed will be similar to that given by 
the Hagen-Poiseuille law (we simply replace the pipe diameter with 4rh). The 
Hagen poieuille law may be written in the following way: 
f_ 
16 (Equation 4.17) 
Re 
For a packed bed, the modified Reynolds number is: 
u(4rh)p Reb = (Equation 4.18) 
p 
Using the Hagen-Poiseuille relationship (above), we get the following 
correlation: 
16 
eReb 
(Equation 4.19) 
The above equation doesn't fit available data for slow (laminar) flow of viscous 
fluids through packed beds however a simple empirical correction of the 
numerical coefficient results in the model fitting the data extremely well. This 
leads to the Carman-Kozeny equation (Carman 1938) which is often used to 
correlate pressure drop in packed beds for low flows, Reb < 2. 
OPf 1 83 
u= 
LK ö 
(Equation 4.20) 
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Which can be rearranged to yield: 
u A Pf = (K1, uL) 63 
(Equation 4.21) 
As the adsorbent particles within the haemoperfusion column may be 
assumed to be spherical, the value of Kc =5 therefore, the equation may be 
written as: 
ýzu Apf = (180 LL) 
(63d 
n 
(Equation 4.22) 
Kc is a constant, the magnitude of which depends on the particle shape, the 
bed porosity and particle size range. This value is usually in the region of 3.5 
- 5.5, but often a value of 5 is used when the particles are spherical. 
Calculation of wall shear 
yw =8 
ä (Equation 4.23) 
f 
Where :- 
d, = 
4e 
d (Equation 4.24) 
(1-s) 
6 
and 
U=Q (Equation 4.25) 
exA, 
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4.1.7 Experimental design. 
Once a column design is obtained, effects of packing with different material, 
size fractions and varying bed porosities can be evaluated in terms of wall 
shear, Reynolds number or pressure drop, with a blood substitute fluid. In 
order to validate the scale down column design initial studies using water will 
be undertaken. For scale-down of the clinical system the following factors 
were considered: - 
" Wall effects (ratio of column diameter and particle size) 
" Magnitude of Re 
" Magnitude of Wall shear rate 
" Contact area (adsorbent to fluid ratio) 
For scaling down the column, the average particle size should be decreased 
by the same factor as the reduction in the column diameter. The flow rate 
through the column needs to be changed to keep the flow regime similar. 
This may be done by keeping the magnitude of the Reynolds number the 
same, or attempting to keep the wall shear rate similar. Geometric scaling of 
the aspect ratio (column diameter : particle size) results in an increase in the 
external surface area to blood volume in column due to the reduced particle 
size. The scaled down system then offers a worse case scenario in terms of 
biocompatibility of blood surface response due to the higher surface area 
contact with blood. However, due to the porous structure of the adsorbents 
the external surface area is negligible when compared with the internal 
structure therefore the effects of scale down on adsorption capacity is likely to 
be low. The volume of blood can be scaled in accordance with the reduction 
of column volume and the flow rate will dictate the time required to ensure the 
same number of passes each unit of blood through the column. 
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4.1.8 Scale down rig design. 
A commercial haemoperfusion column (Medasorb device by Renaltech) was 
not available for flow characterisation experiments. Therefore, recourse to 
literature provided information on typical particle sizes, bed lengths (25cm), 
column diameters (5cm) and typical range of flow rates used in clinical 
haemoperfusion columns. This information was used to calculate typical 
Reynolds numbers found in clinical haemoperfusion columns. An adjustable 
(bed height) 26mm (ID) x 500mm (length) column was purchased from Sigma 
(hence forth called pilot-scale system). The flow dynamics found in a clinical 
sized column was replicated in the pilot scale system. Subsequently, a scaled- 
down mini-column (0.5cm X 4cm) was used to validate the scale down 
methodology. See Figure 4.4 for schematic of this approach. 
The base of the columns contain a frit to prevent loss of particles. After some 
validation work using mechanical pressure gages, the final rig was designed 
using an electronic pressure transducer purchased from RS capable of 
pressure measurements from 0-l bar. This was linked to a digital display 
unit purchased from Digitron, UK. The bottom of the column was open to 
atmosphere and the pressure recorded is therefore gauge pressure. A 
peristaltic pump capable of supplying flow rates between 50mllmin and 
400ml/min was used. Initial studies highlighted the pulsing created from the 
peristaltic pump resulted in difficulties in accurately recording the pressure 
drop across the packed-bed for a given flow rate. A length of large bore 
tubing was added to the outlet of the pump which reduced these effects. In 
addition, a snubber was attached to the pressure transducer, which further 
reduced the pulsing effects (Figure 4.3 shows a schematic diagram of the rig). 
The pilot-scale column was used to study the effect of flow conditions on 
pressure drop and ascertain whether reduction in bed height resulted in 
increasing wall effects. Results from the experimental set-up were then used 
in conjunction with the equations above to identify flow conditions for the 
scaled-down mini-column. Once the Reynolds number or shear rate for the 
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commercial system are obtained at a given flow rate (range 200 - 450ml/min), 
by knowing the particle size and bed porosity for the other systems in addition 
to the column geometry, an estimate of the required flow rate can easily be 
obtained using the models described above. Table 4.2 shows an example of 
how scale down of the commercial column is possible based (in this case) on 
wall shear rate. The models were inputted into Excel and the various 
parameters of each system added. Then, the flow rate of the pilot study and 
micro columns was adjusted until the resulting wall shear rate was 
approximately equal to the commercial column. 
Adjustable 
4 fixed bed 
column 0- 
25 
3 
X6 
Figure 4.3 Schematic of Rig design. (1) fluid reservoir (2) peristaltic pump (3) 
large bore tubing to help reduce effects of pulsing (4) Pressure transducer (5) 
Diffuser to dissipate flow evenly over bed (6) frit at bottom of column to 
prevent loss of adsorbent. 
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Calculate wall shear based 
Calculate on values calculated on 
commercial column. wall shear 
5 2.5cm H 
0.5cm 
ý001- - 10.10 
4cm 
25cm 0-40cm 
Commercial Pilot-scale Mini-column 
column column (small-scale) 
Figure 4.4. Schematic of scale down strategy from commercial column to mini 
column. 
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Chapter 4 Dynamic scaling down of a fixed-bed haemoperfusion column. 
The bed packing material used for the large column experiments was a 
styrene-DVB copolymer MN200 (provided courtesy of Purolite International 
(UK) Limited). The polymeric material was available in a large quantity (for 
use in the pilot scale system). The adsorbent pore structure is unsuitable for 
use in the removal of middle molecules from blood, however, the material 
possesses similar packing properties to the materials characterised in this 
work. The material was used "as received". It was characterised using the 
methods developed in chapter 2 and a summary of the important properties is 
presented in Table 4.3 
Table 4.3 Particle size data for materials used in packed-column experiments 
Material Sauter 
mean 
(µm) 
Medium 
(µm) 
Mode 
(µm) 
Span 
MN200 550 575 601 0.5 
XAD4 130 231 250 0.6 
CW4 49 66 72 1.4 
The pilot-scale system was first characterised in terms of pressure drop 
versus flow rate using the 8mPa. s blood analogue to acquire the relevant flow 
characteristic data within the system. The particle size was reduced by the 
same factor as the reduction in column diameter as close as possible (x5). 
Table 4.3 highlights the larger span of the CW4 material compared to the 
other materials. Considerable effort was spent to obtain a tight particle size 
distribution but for the smaller sized particles (--50 pm) the larger span was 
the best that could be achieved using the sieve fractions available. The CW4 
material was used for the initial studies into the validity of the scale down 
procedure. 
Pre Testing validation 
The bed was packed by free settling of a slurry. Upon commencement of flow 
the bed height reduced resulting in compression of the bed and changes in 
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the bed porosity. In order to ensure reproducibility of results taken for the pilot- 
scale system, measurements were taken once the bed had settled. A simple 
experimental procedure was established by undertaking experiments to 
evaluate the time taken for a freshly packed bed to settle. Figure 4.5 shows 
data for a 44cm bed height with a fluid (viscosity 8mPa. s) pumped through the 
bed at a flow rate of 400mlImin. The data suggests that 30 min was required 
for the bed to settle under the conditions of the experiment. For all column 
flow experiments, 30 min time was allowed to elapse before experimental data 
on pressure drop at a particular flow rate was recorded. 
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Figure 4.5 Pressure drop across a 30cm bed in the pilot scale column with 
respect to time. 
Calculation of bed porosity (c) 
In order to obtain the bed porosity (e), the following procedure was followed. 
A bed of adsorbent particles was packed into the pilot scale column as a 
slurry. The 8mPa. s fluid was pumped through the bed using a peristaltic pump 
and the system was allowed to reach steady state by leaving it running for 30 
mins. After this time, the flow was stopped and the valve at the base of the 
column was shut. The valve was opened to allow liquid to drain until the top 
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of the liquid was level with the top of the adsorbent bed, at this point the valve 
was closed. In order to collect the liquid between the particles, the bed 
contents were centrifuged and the mass of the liquid collected was converted 
into volume to give the porosity (e) of the packed bed using the following 
equation: 
e_` imerstiti al 
Vbed 
(Equation 4.26) 
The values of c were obtained for bed heights of 10cm using the pilot-scale 
column. The measurements were repeated 3 times for each packing material 
and an average value of c was obtained. The method was repeated using the 
small scale mini-column with materials XAD4 and CW4. 
Pressure drop measurements 
The pressure drop across the entire system comprises of frictional drag in the 
pipe work and fittings as well as across the bed itself. To minimise the 
pressure drop of the fittings etc., the pipe length between the pump discharge 
and the entrance to the column was kept as short as possible. The pressure 
drop associated with the adapter connecting the feed pipe to the column via 
the fluid distributor had to be modified resulting in virtually no detectable 
pressure drop across the empty column (filled with fluid) when the system was 
operated at clinically relevant flow rates (250-400 ml/min). 
4.1.9 Validation of wall effects 
Fluid flow through a packed bed follows the path of least resistance, e. g. in 
channels and along the walls of the column where the local porosity is high. 
This may be minimised by using a high column diameter to particle size 
aspect ratio (usually around 50) so for the pilot scale column (i. d. 25mm), the 
particle size would need to be around 500pm. For a given column diameter, 
accurate measurement of flow characteristics through the bed i. e. pressure 
drop versus flow rate data requires high bed height to column diameter ratios 
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(greater than -10). In this study, the pressure transducer provided a 
linear 
response between 0-1 bar(g) with accuracy of ±0.01 bar(g). 
To evaluate when (with the smallest bed height) wall effects became dominant 
in the pilot-scale system (ixP/L) vs Q (flow rate) data was obtained at different 
bed heights. Deviation of the plotted data from the universal trend line 
suggests domination of wall effects as the bed height was reduced. The 
experiments were conducted at clinically relevant flow rates (150 - 450ml/m). 
The column was carefully filled with adsorbent material (MN200) and pressure 
drop measurements taken as described previously. Once measurements 
over the desired flow rates were completed, the bed was emptied and 
additional material was added to increase the bed height and the method 
repeated. 
For the small scale mini-column system, experiments of pressure drop across 
the column were conducted and compared with the pilot-scale column system. 
To maintain dynamic similarity, reduced flow rates were required and these 
were provided by employing a Masterflex type peristaltic pump. As the 
measured pressure drops were also considerably smaller (around 0.01 Bar) a 
U-tube manometer was used to accurately obtain the pressure drop values. 
This method was employed using the small scale mini-column system at two 
packed bed heights (2cm & 4cm). The result were plotted as friction factor (f) 
versus modified Reynolds number (Reb). In the case of effective dynamic 
scaling, the data for the pilot-scale and mini-column systems should lie on one 
universal curve. 
4.1.10 Modelling of adsorber column 
parameters 
Once an adsorbent material has been selected on the basis of middle 
molecule adsorption capacity and size exclusion characteristics, there are still 
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a number of parameters that may be changed in order to optimise the 
haemoperfusion treatment. By changing the size & quantity of the adsorbent, 
and the packing density the resulting flow conditions vary greatly. In order to 
study the effect of these parameters on the adsorption performance of the 
device and to ensure that any proposed device is unlikely to cause shear 
damage to the blood cells, analysis of the effect of these parameters was 
undertaken. 
4.1.11 Effects of changing bed porosity 
The porosity of the bed affects shear within the packed-bed of a commercially 
sized coulmn. The porosity of the bed is a parameter that can be changed for 
a given particle size by adjusting the span of the particle size distribution. If 
monosized particles are manufactured (e. g. using the membrane 
emulsification system) the resulting bed porosity may be much higher than for 
a bed packed with particles having the same mean size but a wider size 
distribution. The increase in porosity may result in lower shear facilitating the 
use of higher flow rates and/or a reduction in particle size for the same wall 
shear. In Chapter 2, it was shown that using the membrane emulsification 
technique polymeric adsorbents with a tight particle size distribution may be 
synthesised with no apparent change in internal pore structure. This would be 
of considerable benefit for use in a packed-bed haemoperfusion column. 
In order to identify the effect of changing bed porosity for a given particle size 
some simulations were carried out. The flow rate was varied within the clinical 
range (200 - 450ml/min) and the resulting wall shear experienced by blood 
cells was calculated for values of bed porosity ranging from 0.2 - 0.6. 
Calculation of the resulting wall shear was done using the following equation :- 
wall shear rate =8 x" d, (Equation 4.27) 
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Where :- 
4xe 
dr = 
(1- E) x 
6v 
(Equation 4.28) 
flow rate and it = (Equation 4.29) 
ex area of column 
4.1.12 Effects of changing particle size 
In order to quantify the effects of different particles sizes, a set of simulations 
were conducted for a bed with porosity set to 0.4 and changing the flow rates 
within the clinical range. This is of some importance because minimising the 
particle size, greatly enhances the kinetic uptake of MM molecules. The 
effects were modelled by calculating the wall shear for a fixed bed porosity 
and varying only the particle size. The commercial sized column was used for 
this evaluation. Minimum and maximum flow rates (200ml/m & 450mVm) 
were used for these calculations. 
4.1.13 Scale down column evaluation of uptake 
kinetics of lysozyme by XAD4 and CW4 
Chapter 3 contained a number of empirical and theoretical approaches to 
characterise the adsorption characteristics of polymer nanoporous adsorbents 
at removing MM's and size excluding albumin. This section discusses how a 
suitable scaled down haemoperfusion column may be used for evaluating 
adsorbent biocompatibility as well as studying the adsorption kinetics from 
clinical fluids including blood. In order to validate the system and highlight any 
changes in adsorption capacity due to the fixed bed system preliminary 
adsorption studies were completed. 
-170- 
Chapter 4 Dynamic scaling down of a fixed-bed haemoperfusion column. 
The system was scaled down based upon the Reynolds number to ensure the 
flow dynamics in the small-scale column mimicked those in a commercial 
system. The Reynolds number for the commercial column was calculated and 
the flow rate adjusted for the scaled down column system so that the Re was 
similar in magnitude. 
The scaled down system may be used' for the concurrent study of 
biocompatibility and adsorption. Experiments were conducted using CW4 and 
XAD4 and the uptake kinetics of lysozyme was evaluated under dynamically 
scaled flow conditions. Both these materials had been previously 
characterised (using well mixed batch adsorption experiments in chapter 3) . 
The use of a fixed-bed contacting arrangement instead of the well-mixed 
stirred reactor system would provide insight into the effect of the contacting 
arrangement on external mass transfer and hence kinetics of the adsorption 
process. 
Bed height was fixed at 4cm and the amount of adsorbent required for the 
packing of the column was carefully weighed to allow calculation of uptake 
capacity. Reynolds values were obtained by calculation for the commercial 
column and then the flow rate for the scale down calculated based upon the 
particle size of the adsorbent (measured using the Malvern mastersizer as 
described in Chapter 2) and the geometry of the mini-column. Initial 
concentration of the lysozyme in Hepes buffer was 1 g/I and the volume of the 
fluid reactor was 0.51. 
The stock solution was contained in a1L stirred vessel placed in a 
thermostated water bath (temperature maintained at 37'C). A short length of 
insulated piping was run through the peristaltic pump and into the adsorber 
column which was allowed to flow back into the reservoir. See Figure 4.6 
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Insulated piping 
pump column 
1L reactor 
Max buffer level 
Water bath 
Figure 4.6 Schematic diagram of scale-down adsorber rig for adsorption 
studies 
In order to obtain low flow rates (0.48 -1.09ml/min) required to obtain the 
required Re number, a smaller capacity peristaltic pump was used. The pump 
was equipped with 12 rollers to minimise pulsing. The desired flow rate was 
set by calibrating the pump speed and measuring the volumetric output. The 
flow rate was checked once the column was connected to the rig as the 
additional resistance created by the packed bed affects the resulting 
volumetric flow rate. The Re of the commercial column was obtained using 
the following equation : 
a(bd, Reb = (Equation 4.30) 
and, 
U 
ub =ExA (Equation 4.31) 
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Samples from the bulk solution (in the reactor) were taken and the resulting 
concentrations measured using the HPLC method outlined previously (see 
chapter 3). An initial sample was taken (t = 0) before the pump was started 
and then subsequent samples were taken at regular intervals to follow the 
concentration change in the bulk. 
4.2 Results and discussion 
4.2.1. Blood analogue 
The glycol water mixtures were analysed using the method described above 
and the resulting viscosities plotted as in Figure 4.7. It is apparent that the 
fluid viscosity changes with increasing concentration of glycol and the change 
is non-linear. Therefore an exponential form of the equation was fitted to the 
data and is included in the figure 4.7. 
From the figure, a glycol concentration of 41% should give a solution with a 
viscosity of 8 mPa. s at room temperature. This solution was prepared and 
analysed to ensure it did exhibit the required viscosity of 8 mPa. s. (see Figure 
4.8) 
The rheology of the solution was then measured to see if the solution 
exhibited any hysteresis effects when sheared. To further validate its 
suitability for use as a blood analogue in packed bed experiments, a number 
of shear rate step changes were made to see if the solution exhibited any 
plastic behaviour. The results (see figure 4.9) clearly show that no hysteresis 
was observed therefore the analogue appeared suitable for use in the study. 
2L of solution was used for the packed bed experiments to reduce the 
potential effect of temperature increase caused by prolonged flow through the 
pump during experimentation. 
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4.2.2 Effects of temperature change on blood 
analogue. 
Each of the samples were run at 3 differing temperatures to identify any 
change in viscosity that may occur. The temperature of the fluid was 
maintained by circulating pre-heated water around the jacket of the concentric 
cylinder viscometer and an internal probe recorded the actual temperature 
during analysis . Again, exponential 
fits were used to describe the 
relationship between solution viscosity and the concentration of glycol in 
water. 
Figure 4.7 shows that solution viscosity increased as the temperature 
decreases. The effect of temperature was more apparent as the 
concentration of glycol increased. Therefore, during experiments the 
temperature was controlled to minimise changes in solution viscosity. 
Figure 4.8 shows that at room temperature, a 41% glycol solution had a 
viscosity of 8 mPa. s. In order to ensure this value was correct, 2L of the 
sample was prepared and viscosity measured. Figure 4.8 shows 
considerable scatter, however, the gradient suggests that the fluid viscosity is 
8 mPa. s. Figure 4.9 highlight that no hysteresis was shown by the fluid as the 
shear rate was increased and decreased. 
Hepes buffer 
Hepes buffer was found to exhibit Newtonian behaviour and had a viscosity of 
1.6 mPa. s at 37'C. 
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4.2.3 Validation of wall effects 
1200 1400 1600 
The packed bed height in the pilot scale column was varied and the pressure 
drop across each bed height at a range of clinically relevant flow rates was 
measured. Figure 4.10 shows results of pressure drop per unit length of bed 
against flow rate. The data falls on a straight line suggesting that the packing 
characteristics of the bed don't particularly change as the bed height is varied 
between 10-30cm. 
When the same data is plotted as frictional factor against the Reynolds 
number (Re), again, the data appears to fall on a universal line. Figure 4.11 
shows this data in addition to data obtained for the small scale mini-column 
with bed height 2 cm and 4cm over a range of flow rates. The plot shows that 
the fluid dynamics in the mini-column system and the pilot scale system are 
similar for the same Reb. Data for the mini-column system at the two bed 
heights suggests wall effects may be ignored. 
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The Carman-Kozeny equation can be used to correlate pressure drop in 
packed columns 
The experimentally obtained pressure drop measurements across the packed 
bed of the pilot-scale column were compared with those predicted by the 
Carman-Kozeny equation. The following equation was used and various 
values of K substituted to fit the model to the experimental data. 
APf =(36KPL) 
ýe3d22 
0 
(Equation 4.32) 
Expected values of K are normally in the region of 3-5.5. The pressure drop 
across each of the bed heights was obtained at different flow rates and 
compared with the predicted values obtained when using the Carman-Kozeny 
equation. As the bed height increased the accuracy of the equation 
increased. However, there was still a fair discrepancy between the empirical 
data and the estimated values (with K in the region of 3-5.5). Much of this 
error could be associated with difficulties encountered in experimentally 
obtaining the bed porosity values. The Carman-Kozeny equation is sensitive 
to the magnitude of c. The values for the mini-column system did not 
correlate well with the equation. Accurate measurement of the bed porosity 
was difficult for the mini-column system which is a likely source of error. 
4.2.4 Effects of changing packing porosity on wall 
shear. 
It is known that bed porosity influences the resulting shear stress experienced 
by blood cells during haemoperfusion. Although this value is linked directly to 
the particle size, it is also effected by the particle size distribution. Therefore, 
by being able to quantify the effects of changing the bed porosity on pressure 
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drop, it is possible to predict the effects of both the particle size and 
distribution. As expected the results of the calculation (see Figure 4.12) 
demonstrate that at the higher flow rate the effects of changing porosity are 
more apparent. As any inline treatment requires the haemoperfusion column 
to cope with the dialyser flow rates, the final column design must ensure that 
the shear rates at the upper clinical flow rates are acceptable. 
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Figure 4.12 Effects of changing packing porosity on wall shear rate 
4.2.5 Effect of changing particle size on pressure drop 
In order to optimise kinetic uptake of MM's, chapter 3 demonstrated the 
dramatic effect of particle size on solute diffusion time. However, it is also 
clear that as particle size decreases, pressure drop and wall shear increase. 
Therefore. there is benefit in being able to determine the minimum particle 
size that may be successfully used in a haemoperfusion device. Calculations 
were made to look at the effects of varying particle size with a constant bed 
porosity of 0.4 and flow rates of 250ml/min and 450m1/min (see Figure 4.13). 
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It is interesting to note that'as the particle size increases, the effects on wall 
shear become less apparent. 
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Figure 4.13. Effect of changing particle size on the wall shear rate (Porosity 
of bed 0.4) 
4.2.6 Potential optimisation of a commercially sized 
haemoperfusion device in terms of particle size. 
Although there are several parameters that have the capacity to be 
simultaneously changed, it is possible to make an attempt to optimise the 
haemoperfusion column. The particle size distribution is the primary 
parameter effecting packing porosity. By selecting a number of porosity 
values, a minimum particle size can be obtained for each porosity value using 
the equations described previously. 
As an estimate of exposure time, the contact time of each parcel of blood 
through the column can be multiplied by the total number of passes during a6 
hour dialysis session. It is assumed the blood volume is 5L. Blood flow rate 
was set at the max value of 450m1/m. The commercial column dimensions 
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are 5cm x 25cm. The contact time can be obtained by dividing the volumo of 
blood in the column by the blood flow rate (450ml/m). The volume of blood in 
the column will vary depending on the porosity. In order to obtain the 
maximum shear rate, the total exposure time was estimated at each porosity 
value and then multiplied by 4 to provide a safety factor. Total exposure time 
Te was calculated by 
V 
i' _ -- i 
(Equation 4.33) 
Where V, is the volume of blood in the column, F, is the system flow rate and 
C is the amount of times each parcel of blood will pass through the column in 
the treatment time (T). Hence the C value can be obtained : 
F xT (' _- (Equation 4.34) Vi, 
Where Vb is the blood volume of the patient (assumed to be 5L). 
The results of these calculations over a range of bed porosity values is shown 
in Table 4.4. 
Table 4.4. Effects of changing porosity on the potential minimum particle size 
based on the criteria suggested by Deutch et al (2006). 
Porosity Volume of 
blood in 
column (cm3) 
Contact 
time for 6 
hour 
treatment 
(sec) 
Estimate of 
max shear 
rate 
permissible 
(s"') 
Min Particle 
size (pm) 
0.2 98 416 
- ---- 
600 
-- 
1500 
0.3 147 640 ---------- - 560 --- - 630 
0.4 196 832 500 345 
0.5 245 1024 490 185 
0.6 295 1248 480 105 
0.7 343 1472 420 65 
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By using a Micropore Technologies Ltd dispersion cell system, it is possible to 
produce particles of a tight size distribution as discussed in chapter 2. The 
resulting particles have the potential to have a packing porosity of around 0.6 - 
0.7. As discussed in chapter 3, the smaller particle size will offer substantial 
benefits in terms of uptake kinetics. Therefore by utilising such a technique 
for the production of the adsorbent beads, it may be possible to use particle 
sizes in the region of 60 - 100Nm in a commercially sized column. In addition, 
by using a material similar to CW4, it has been demonstrated that a 
considerably smaller amount of material is required. Therefore, the pressure 
drop across the bed will likely to be considerably smaller than current devices. 
4.2.7 Uptake in mini-column system. 
The Sauter mean value for the XAD4 particle size used in this study was 
130/im. The CW4 adsorbent had a mean particle size of 481um. Calculations 
for flow rates of 325ml/min (mid-point of clinical blood flow rate range of 200 - 
450 ml/min) suggests Re - 0.21. In order to obtain a Re of 0.21 a flow rate of 
1.2 ml/min was required for the XAD4 packed column and 3.1 ml/min for the 
CW4 system. The pump speed was adjusted to produce these flow rates. 
Figure 4.14 shows the resulting decrease in concentration with respect to time 
for the XAD4 system. A final saturation uptake value of 358mg/g was 
observed. This value is of similar magnitude to saturation values reported in 
chapter 3 (410mg/I) for the idealised well-mixed system. Figure 4.15 shows 
the reduction in lysozyme concentration due to adsorption onto CW4 using the 
scaled down mini-column system. The final saturation uptake was 492mg/g, 
again similar in magnitude to the data reported in chapter 3 (577mg/g). Slight 
differences may be attributed to batch-to-batch variability. 
During a3 hour dialysis session with the commercial sized column, each 
parcel of blood will pass through the column around 12 times. Based on the 
volume of fluid used for this experiment (0.51) and the flow rates used, it was 
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calculated that it would take 3.4 days for 12 passes of each parcel of blood to 
pass through the XAD4 mini-column and 1.3 days in the CW4 system. 
Looking at both the plots it is clear that the material has been saturated by this 
time. The efficacy of the CW4 material does however suggest that there is no 
need to use a column with the quantity of adsorbent used in the current 
commercial columns. However, much of the uptake rate is due to the small 
particle size and it is likely that an excess of material would be required to 
reduce the concentration of toxins to a sufficient level within a normal dialysis 
treatment time if a larger particle size was used. However this may be a 
reasonable approach to use for studies of biocompatibility. 
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Figure 4.14. Uptake of lysozyme onto XAD4 (1301im), 1 gIl initial 
concentration in a dynamically scaled down micro column, 
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Figure 4.15. Uptake of lysozyme onto CW4, particle size 48pm, 1.6 g/l initial 
concentration in a dynamically scaled down micro column. 
4.3. Conclusions 
This chapter has outlined an approach for the dynamic scaling down of a 
clinical-sized haemoperfusion column to that of a small scale mini-column 
system that may be used for investigations of biocompatibility and adsorption 
performance. The chapter outlined the lack of continuity in current 
biocompatibility studies and therefore provides a case for standardisation. 
Much of the current biocompatibility work is carried out under flow conditions 
too dissimilar to how the device is likely to be used and the scale down 
approach hopes to negate much of this disparity, It is possible to scale down 
based on an important flow parameter such as the Reynolds number or wall 
shear rate. By ensuring such parameters are constant, the performance of 
the device may be studied under "clinically relevant" flow conditions without 
the need for large quantities of donor blood. The scale down procedure 
inevitably results in some compromises. This study used a scaled down 
particle size which resulted in an increase in the external surface area to 
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column volume ratio. Therefore a "worse case" situation arises in terms of 
biocompatibility response. 
This chapter highlights the important role that flow has on any proposed 
haemoperfusion device. The effects of changing critical parameters such as 
particle size and packing porosity have been quantified and related to the 
potential damage they could have on cells. The resulting understanding 
provides a vital platform to inform a commercial column design and for 
fundamental studies into biocompatibility. 
By using a Micropore Technologies Ltd dispersion cell system it could be 
possible to use a particle size approximately 4 times smaller than those used 
in some existing commercial columns. 
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Chapter 5 
Conclusions and future work 
The objectives of this research were to select divinylbenzene polymer 
adsorbents based upon pore structure so that an evaluation of their suitability 
for blood purification could be assessed. Initial investigation highlighted a 
group of middle molecular sized molecules that literature suggested would 
benefit patient health if they were removed. A surrogate marker (lysozyme) 
was then selected to study the efficacy of different adsorbents. A potential 
strategy of size excluding human serum albumin molecules to allow access to 
the internal pore structure to MM size molecules was considered. An attempt 
at understanding the fundamental influences of pore structure, particle size 
and external mixing conditions on uptake of lysozyme (MM surrogate marker) 
and human serum albumin (large blood protein) was made. The effects of 
competitive adsorption on uptake of MM markers was also studied in both 
simple and clinically relevant multi-component solutions (PD fluid). A model 
was obtained to help predict adsorbent performance once an effective 
diffusivity value for a particular molecule / adsorbent pair had been obtained 
experimentally. Finally an insight into the flow conditions within a 
heamoperfusion device were obtained using a scale down system having the 
potential to be used as a method of studying biocompatibility responses. A 
model was used to help predict the influence of particle size, flow rate and 
bed porosity on shear rate. 
The work contained within this thesis has contributed to original knowledge. 
By applying engineering principles new knowledge of the structure-properties 
relationship in porous material in liquid phase adsorption has been 
demonstrated. This knowledge can be applied to the design of an augmented 
haemoperfusion device which could have important application in clinical 
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renal care. In addition, an original approach to the design of a scaled down 
haemoperfusion column based upon dimensions from an existing commercial 
device was completed. This technique has provided a means of evaluating 
biocompatibility of haemoadsorbents in realistic flow conditions. 
5.1 Selection and characterisation of materials 
Various styrene divinylbenzene polymer adsorbents were obtained and 
characterised using a number of techniques. Nitrogen porosimetry was 
carried out to obtain estimates of the pore structure for each of the selected 
adsorbents. Materials were selected based upon their structures. Adsorbents 
allowing access to larger blood proteins such as albumin (XAD4) in addition to 
materials that were unlikely to allow passage of these larger molecules (CW1 
& CW4) were chosen. 
Micrograph and SEM images demonstrated all particles were spherical and 
had a cauliflower type internal pore structure. 
The nitrogen porosimetry date suggested likely surface areas available for 
adsorption of lysozyme and albumin. From this data XAD4 appeared to have 
the highest capacity for lysozyme adsorption, followed by CW4 and CW1. 
However, XAD4 had a pore structure that based upon the porosimetry data 
was likely to allow access to albumin, whilst the other two adsorbents were 
likely to size exclude it. 
Particle size distributions were obtained for each of the sieved size fractions. 
This data suggested that even when carefully sieved, fines were still present 
and it was difficult to obtain tight particle size distributions using this method. 
A novel membrane based system capable of producing particles with a tight 
particle size distribution was also investigated to see if the process affected 
the resulting pore structure. The particle size analysis confirmed that' the 
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resulting span was tight and the porosimetry data suggest little change in the 
pore structure when compared to suspension polymerisation produced 
adsorbents. 
5.1.1 Influence of pore structure and mixing 
conditions on mass transfer of MM's 
Each of the adsorbents were evaluated using a batch reactor for uptake 
kinetics and capacity of lysozyme and human serum albumin. Adsorption 
capacity correlated well with pore distributions obtained from nitrogen 
porosimetry with the exception of CW4 which demonstrated a slightly greater 
capacity for adsorption then the porisimetry data suggested. Internal mass 
transfer resistance appeared predominant and external mass transfer 
resistance appeared negligible. Particle size influenced kinetic uptake of 
lysozyme and albumin greatly and it is clear this is a vital parameter to 
consider in the design of a hemoperfusion column. 
CW1 effectively size excluded albumin, whist both CW4 and XAD4 allowed it 
access to some of their internal pore structure. XAD4 had a capacity for 
albumin around double that of CW4 although CW4 exhibited a greater 
capacity for lysozyme molecules. 
A model was used to predict behaviour of adsorbents once a small number of 
batch experiments had been completed to obtain vital parameters. By using a 
fitting parameter (the effective diffusivity) the. model can also be used to 
identify the possible effects of pore structure on uptake kinetics. The model 
demonstrated that pore size distributions did influence the resulting effective 
diffusivities for Lysozyme and albumin. CW1, which effectively size excluded 
albumin possessed a lysozyme effective diffusivity an order of magnitude 
smaller than that of XAD4. CW4 appeared to have the highest effective 
-188- 
Chapter 5 Conclusion and future work 
diffusivity for lysozyme. Clearly a more open pore structure results in 
improved uptake kinetics for the molecules able to access the internal 
structure. 
In addition to single solute systems, binary solutions were also prepared and 
studied using the batch reactor methodology on XAD4 and CW1. Binary 
systems containing albumin and lysozyme demonstrated an augmentation of 
lysozyme uptake on XAD4 thought to be due to cooperative adsorption. 
Therefore this offered limited insight into the effects of competitive adsorption. 
However, experiments conducted at Leicester General hospital using 
concentrated peritoneal dialysis fluid (a complex fluid containing both MM's 
and albumin at clinical concentrations) offered additional insight into effects of 
competitive adsorption. XAD4 and CW4 were compared for their ability to 
remove ß2-M in a batch reactor from the concentrated PD fluid. XAD4 
demonstrated that the kinetic uptake of 02-M did not vary significantly from 
CW4, which possesses a pore structure that allows much less albumin into its 
internal structure. Therefore, it is likely that MM capacity will be higher on 
CW4 as less of its surface area can be swamped by albumin. 
5.1.2 Potential influence of column design on 
flow conditions 
From the literature it became apparent that there is a need for a standardised 
procedure for the evaluation of biocompatibility in blood purification devices. 
Not only does there appear to be a lack of continuity but also biocompatibility 
appears to be rarely studied under clinical flow conditions, It is believed that 
flow is an important consideration for the biocompatibility performance of any 
device and could be an important component of its evaluation. 
- 189 - 
Chapter 5 Conclusion and future work 
Study of a proposed scaled down hemoperfusion system was presented, thus 
allowing study of adsorbents in clinically relevant flow conditions without the 
necessity for large volumes of donor blood. The scale down procedure was 
based upon dimensionless parameters obtained from an existing clinical 
device. It was demonstrated that wall effects were negligible and that 
dynamic scale down of a commercial sized column is possible. However, it 
was noted that the ratio of surface area of the adsorbent to column size in the 
scale down column was greater than in the full size column. Therefore, it 
represents a `worse case' scenario in terms of biocompatibility. 
The scale down parameters were then used as a predicative tool to model 
effects of changing some key engineering parameters (particle size, packing 
porosity, flow rate). It was shown that changing particle size had the greatest 
effect on the resulting wall shear rate (within the clinical flow rate range of 200 
- 450ml/m). Changing packing porosity also made substantial differences to 
the wall shear rate. As particle size has been shown to have a great influence 
on uptake kinetics of MM's, the flow model was used to try to identify the 
smallest possible particle size whist not creating conditions likely to damage 
the cells. By using a Micropores Technologies dispersion cell it is possible to 
create adsorbents with a tight particle size distribution. The nitrogen porosity 
data suggests use of such a method has little effect on the resulting pore 
structure. Therefore by utilising such a technology it has been shown that 
high bed porosities can be obtained, allowing the use of adsorbents around 5 
times smaller than those currently employed in commercial columns. The 
capacity data would suggest that a material like CW4 could be used in smaller 
quantities than current commercial adsorbents duo to its high capacity. 
Therefore it may be possible to use a much smaller device still capable of out 
performing current technologies. This offers a clinical advantage in terms of 
minimising extracorporeal blood volume and reducing the cost of the device. 
This may also present an advantage in terms of biocompatibility duo to the 
reduced quantity of adsorbent. 
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5.2 Future work. 
Insight has been gained concerning the influence of particle size, pore 
structure and mixing conditions on the performance of a blood purification 
adsorbent. With the exception of preliminary batch reactor studies using PD 
fluid, the majority of this work has been done using simple solutions. 
Therefore further investigation into more complex solutions may offer 
additional insight into how MM's may interact with other molecules within the 
blood and effect uptake. 
An obvious next step would be to evaluate the uptake kinetics and capacity of 
other MM's (as documented in chapter 1) from a complex clinical fluid such as 
concentrated PD fluid. Following such an exercise the scale down column 
could be used to measure uptake of the same markers from whole blood. 
Perhaps the biggest area requiring further study is the biocompatibility of the 
selected adsorbents. Although it has been shown that a smaller quantity of 
adsorbent than current commercial columns may be required it has not been 
demonstrated if this result in an acceptably biocompatible device. The use of 
the scale down column proposed in this work would prove useful in this 
evaluation. Initial studies should be concerned with global markers such as 
platelet counts, in addition to more specific investigations into things like 
concentration of M. 
The adsorbent CW4 may be suitable for use in a device to augment current 
heamodialysis. However, a study of other application such as sepsis may 
provide further applications and therefore increase the likelihood of 
commercialisation. If the device was to be used as a stand alone treatment, 
it may also be desirable to study the potential of use in conjunction with a 
plasma separation module. It the plasma could be separated, and the cells 
bypass the adsorbent device, the biocompatibility of the device may be 
irrelevant. 
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Appendix 1 
IUPAC Classification of adsorption isotherms 
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Figure 1. Types of physisorption isotherms (adapted from Sing et at, 1985) 
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Figure 2. Types of hysterisis loops (adapted from Sing et al, 1985) 
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Appendix 2 
Derivation of irreversible adsorption model by 
Suzuki et al (1973) 
The usual shell balance for mass transfer within the adsorbent particle: 
aq(1-e)ps4nr2ör 
+aceps4nr2Sr JAIr - Jlr+Br at at 
Applying Fick's Law: 
J= -De är 
For irreversible adsorption, the solute uptake at equilibrium, q*, is independent 
of the solute solution concentration c, i. e. if there is solute in solution, 
adsorption will continue until the solute runs out or the adsorbent gets 
saturated. 
Between r; <_ r: 5 R: 
aq` 
at 
Ignoring solute hold-up in the adsorbent pores, eq. 1 simplifies to: 
a [r2 ac 
^ Tr ar 
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Integrating eq. 2 once gives: 
r2 
är 
= A(t) (3) 
A boundary condition may be as follows: 
At r=R; 
ac ac 
Dr ar 
r=R 
Where: 
D 
är =kf `C--cR) 
c5) 
r-R 
Therefore: 
ac kf (c_CR) 
Dr De 
I=R 
And hence: 
2 
A(r) 
DL (C 
- cR) (6) 
Integrating eq. 3 requires a second boundary condition which is as follows: 
At r=r,, c= 0, thus: 
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_fdc=rI ---dr 
(7) 
c=0 r=rj r 
Yielding: 
A(t) 
[r- r] (8) 
Therefore, combing the results in [6] and [8]: 
-R2kf- IC 
- cR 
r-r; (9a) c= De rr 
Hence at r=R: 
Rk f- [C-CRR - r; CR = (9b) 
De rr 
Define the following variables: 
O=L and Bi= 
pR; 
Do 
Therefore, [9b] may be represented as: 
CR =Bi{C-CR 
1-o (10) 
Express CR in terms of C: 
CR =C 
Bi(1-O) (11) 
Bi + O(1- Bi) 
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Applying a mass balance on the solute in the stirred vessel: 
-V 
dc 
=d qp, (l-s 
47IR3 Nv =A,, kf(C -cR) (12) dt dt 3 
The average solute composition in the adsorbent is: 
- 
ß'[R3 - i3 
a 
zR3 3 
And: 
(Co - Cinf )y (14a) 
flip 
q= 
(C°-C 
(14b) 
MP 
Dividing eq. 14b by eq. 14a and using the result in eq. 13: 
q= C° -C =-o3 (15) 
q* Co -Cllr 
Thus: 
C=Co 
-{(i--03 
Xco 
-l"inf 
)} ý1V) 
From eq. 14a: 
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*mý, 
Co - C; a =g y 
(17) 
Replacing eq. 17 in eq. 16: 
C. =co- 
(1-o3 qV ° (18) 
Combining [11], [12], [13] and [18] yields a first order ordinary differential 
equation: 
do D. Bi I)q ml, 
dt ps(1-. F)o q*RZ 
[C" 
+ 
(01 
V ßi+O(1-13i) 
The o. d. e. in eq. 19 was solved numerically using an explicit 4`h order Runge- 
Kutta method in Matlab (release 2007b) using the initial condition: 
Att=0; 4=1 
The value of the film mass transfer coefficient was evaluated using the 
correlation in Middleman (1998): 
1 
4q 
Sh = 0.418Sc°"25 Re 0.75 
D (20) 
V0; 
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